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ABSTRACT 
 
The middle T-antigen (MT) encoded by polyomavirus induces tumours by mimicking an 
activated cell surface receptor. A hydrophobic region close to the C-terminus locates MT to 
the plasma membrane where it initiates oncogenic signalling. HA or FLAG tags added to the 
C-terminus of MT could be detected on the outside of cells, demonstrating that MT is a 
transmembrane protein. Addition of a KDEL sequence retained MT in the endoplasmic 
reticulum, where it failed to transform cells as a consequence of its lack of binding to ShcA, 
PI3K, and PLC-γ1 despite the phosphorylation of the appropriate binding sites. Additional 
studies show that MT binding to PP2A is probably required in addition to the TMD for MT to 
exit the ER and migrate to the plasma membrane. MT on the cell surface is present in discrete 
clusters that contain phosphorylated ShcA and so represent active signalling complexes. New 
mutations in the hydrophobic region prevented MT clustering, and also inhibited cell 
transformation without altering the association of MT with its known binding proteins. 
Overall, these data, together with previous publications, illustrate that MT associates with 
signalling proteins at discrete subcellular membrane sites in its maturation pathway. MT 
binds to PP2A in the cytoplasm, to c-Src at the ER, and to ShcA, PI3K, and PLC-γ1 at 
subsequent locations en route to the plasma membrane. Formation of a large macromolecular 
complex in the plasma membrane is probably required for MT signalling. Similar cell surface 
complexes are observed with activated growth factor receptors, so it is possible that normal 
and oncogenic signalling from receptors is also dependent upon the assembly of large 
macromolecular complexes at the cell surface membrane. There was no obvious association 
of MT clusters with lipid rafts but there was colocalisation with the actin cytoskeleton.  
  
3 
 
DECLARATION OF ORIGINALITY 
Unless otherwise stated, all experiments were performed by me, Yunsi Zhou, the author of 
this thesis. 
 
COPYRIGHT DECLARATION 
The copyright of this thesis rests with the author and is made available under a Creative 
Commons Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, 
distribute or transmit the thesis on the condition that they attribute it, that they do not use it 
for commercial purposes and that they do not alter, transform or build upon it. For any reuse 
or redistribution, researchers must make clear to others the licence terms of this work. 
 
  
4 
 
ACKNOWLEDGEMENTS 
I would like to thank my supervisors Professor Steve Dilworth and Dr Nick Dibb for their 
guidance throughout my project and their advice on my thesis.  
 
Many thanks to Dr Natalia Ichaso, who generated many of the plasmids that forms the basis 
of my project; our collaborators Dr Jitka Forstova and Dr Vojtech Zila at Charles University 
in Prague, who generated IEM images for our paper; Dr Nicola Brownlow at London 
Research Institute for her advice on experiment designs; Dr Rupa Sarkar for her help with 
RNA extraction and all the colleagues at the IRDB for their support. 
 
I would like to thank my father, Mingxuan Zhou, for moral support. With loving memories, I 
would like to give thanks to my mother, Yanfen Lu, for being a great role model in my life. I 
would also like to thank my grandma and the rest of my family as well as friends far and near 
for their continuous encouragement. 
  
Finally, I would like to give special thanks to Mark Refermat for all his patience, 
encouragement and support throughout my study, especially during my final year. 
 
  
5 
 
PUBLICATIONS 
 
Zhou AY, Ichaso N, Adamarek A, Zila V, Forstova J, Dibb NJ, Dilworth SM. Polyomavirus 
middle T-antigen is a transmembrane protein that binds signalling proteins in discrete 
subcellular membrane sites. J Virol. 2011 Apr;85(7):3046-54. Epub 2011 Jan 12. 
 
Zhou AY, Ichaso N, Shah K, Zila V, Forstova J, Dibb NJ, Gullick WJ, Dilworth SM. 
Oncogenic signalling by polyoma virus MT occurs in discrete membrane complexes. Manual 
script completed. 
  
6 
 
Table of Contents 
FIGURE AND TABLE LIST ........................................................................................................................ 10 
ABBREVIATIONS .................................................................................................................................... 15 
LIST OF MT MUTANTS ........................................................................................................................... 18 
CHAPTER 1 – INTRODUCTION ....................................................................................................... 20 
1.1 Overview ..................................................................................................................................... 20 
1.2 Small DNA Tumour Viruses ......................................................................................................... 20 
1.3 MPyV Genome ............................................................................................................................ 22 
1.4 T-antigens .................................................................................................................................... 23 
1.4.1 Large T-antigen .................................................................................................................... 25 
1.4.2 Middle T-antigen .................................................................................................................. 25 
1.4.3 Small T-antigen .................................................................................................................... 29 
1.5 Late Replication Cycle Proteins ................................................................................................... 29 
1.6 Cooperation of MPyV T-antigens induces tumour formation .................................................... 30 
1.7 Transcription Factors in MT-induced Transformation ................................................................ 31 
1.8 MT in Other Polyomaviruses ....................................................................................................... 32 
1.8.1 Hamster Polyomavirus ......................................................................................................... 32 
1.8.2 Human Merkel Cell Polyomavirus ........................................................................................ 32 
1.9 MT Oncogenic Mouse Models .................................................................................................... 33 
1.10 MT Binding Proteins .................................................................................................................. 34 
1.10.1 PP2A ................................................................................................................................... 34 
1.10.2 Src Family Tyrosine Kinase ................................................................................................. 36 
1.10.3 PI3 Kinase ........................................................................................................................... 38 
1.10.4 Shc ...................................................................................................................................... 40 
1.10.5 PLC-γ1 ................................................................................................................................. 42 
1.10.6 Regulatory Protein 14-3-3 .................................................................................................. 43 
1.11 Proline –rich Region .................................................................................................................. 44 
1.12 Additional Tyrosine Phosphorylation ........................................................................................ 44 
1.13 Subcellular Localisation of MT .................................................................................................. 45 
1.14 Cytoskeletons and Focal Adhesion Complexes ......................................................................... 47 
1.14.1 Focal Adhesion Kinase ........................................................................................................ 48 
1.14.2 Vinculin............................................................................................................................... 50 
1.14.3 Integrin ............................................................................................................................... 51 
1.15 Lipid Rafts .................................................................................................................................. 51 
7 
 
1.16 Membrane Localisation Region ................................................................................................ 53 
1.17 Aims: ......................................................................................................................................... 57 
CHAPTER 2 - MATERIAL AND METHODS ............................................................................................... 58 
2.1 Cell Culture .................................................................................................................................. 58 
2.2 Plasmids ...................................................................................................................................... 58 
2.3 Mutant Generation ..................................................................................................................... 59 
2.4 Agarose Gel Electrophoresis ....................................................................................................... 59 
2.5 Ethanol Precipitation of DNA ...................................................................................................... 60 
2.6 Foci Formation Assay and Stable Cell Line Isolation ................................................................... 60 
2.7Attractene Transfection and Transient Expression...................................................................... 61 
2.8 Cell Lysis, SDS-PAGE and Western Blotting ................................................................................. 61 
2.9 Co-immunoprecipitation (IP) and in vitro Kinase Assay .............................................................. 62 
2.10 Antibodies ................................................................................................................................. 63 
2.10.1 In-house Antibodies: .......................................................................................................... 63 
2.10.2 Commercial Antibodies: ..................................................................................................... 63 
2.11 In Vitro Translation.................................................................................................................... 64 
2.12 Detergent Resistance Membrane Fractionation ...................................................................... 64 
2.13 Immunofluorescent (IF) Staining .............................................................................................. 65 
2.13.1 Total MT ............................................................................................................................. 65 
2.13.2 Surface MT ......................................................................................................................... 66 
2.13.3 IF Labelling of Actin ............................................................................................................ 67 
2.13.4 Vybrant® Lipid Raft Labelling ............................................................................................. 67 
2.13.5 Plasma Membrane Labelling .............................................................................................. 67 
2.14 Image Analysis with FIJI ImageJ Software ................................................................................. 67 
2.15 Receptor Expression Level Analysis .......................................................................................... 68 
2.15.1 RNA Extraction and Conversion into cDNA ........................................................................ 68 
2.15.2 Primer Design and Expression Assay for Growth Factor Receptors .................................. 69 
CHAPTER 3 – MPyV MT BINDS SIGNALLING PROTEINS AT DISCRETE SUBCELLULAR MEMBRANE SITES
 .............................................................................................................................................................. 71 
3.1 INTRODUCTION: .......................................................................................................................... 71 
3.2 RESULTS: ..................................................................................................................................... 73 
3.2.1 MT is a tail-anchored transmembrane protein .................................................................... 73 
3.2.2 MT localised in the Endoplasmic Reticulum failed to transform ......................................... 75 
3.2.3 Association with PP2A is required for MT to migrate out of the ER .................................... 83 
8 
 
3.2.4 MTKDEL and Src Tyrosine Kinase Association ...................................................................... 90 
3.2.5 MT Membrane Insertion Mechanism .................................................................................. 95 
3.2.6 The C-terminal hexapeptide has a functional role ............................................................. 101 
3.3 DISCUSSION: .............................................................................................................................. 108 
3.3.1 Summary ............................................................................................................................ 108 
3.3.2 MT is an integral transmembrane protein that is first inserted in the ER ......................... 110 
3.3.3 MTKDEL redistributes pp60c-src but not pp62c-yes .......................................................... 111 
3.3.4 PP2A plays a role in MT migration to higher membrane sites .......................................... 112 
3.3.5 Membrane Targeting and Insertion Mechanism for Tail-Anchored Proteins .................... 114 
3.3.6 Residues KRS adjacent to the hydrophobic sequence are important for MT function ..... 115 
CHAPTER 4 – ONCOGENIC SIGNALLING BY MPyV MT OCCURS IN DISCRETE MEMBRANE COMPLEXES
 ............................................................................................................................................................ 117 
4.1 INTRODUCTION: ........................................................................................................................ 117 
4.2 RESULTS: ................................................................................................................................... 119 
4.2.1 MT forms large complexes on cell surface ........................................................................ 119 
4.2.2 Surface MT complexes contain signalling molecules ......................................................... 127 
4.2.3 New non-transforming mutants of MT TMD isolated ....................................................... 133 
4.2.4 Subcellular location and distribution of MT hydrophobic domain mutants...................... 137 
4.2.5 Characterisation of Other Hydrophobic Domain Mutants ................................................ 151 
4.2.6 Evaluating the amount of actively signalling MT ............................................................... 155 
4.2.7 Measuring the sizes of MT complexes on the cell surface ................................................ 156 
4.3 DISCUSSION: .............................................................................................................................. 164 
4.3.1 Summary ............................................................................................................................ 164 
4.3.2 MT transformation signal is generated at the plasma membrane .................................... 165 
4.3.3 Macromolecular complexes of MT on the cell surface is required for transformation .... 167 
4.3.4 Estimating the proportion of active MT molecules ........................................................... 177 
4.3.5 TMD targets MT from the Golgi to the plasma membrane ............................................... 178 
CHAPTER 5 - MECHANISM OF MPyV MT MACRO-COMPLEX FORMATION ........................................ 180 
5.1 INTRODUCTION: ........................................................................................................................ 180 
5.2 RESULTS: ................................................................................................................................... 182 
5.2.1 Membrane Micro-domains ................................................................................................ 182 
5.2.3 Focal Adhesion Associated Proteins .................................................................................. 201 
5.2.4 EGFR1 and PDGFRβ ............................................................................................................ 210 
5.3 DISCUSSION: .............................................................................................................................. 219 
9 
 
5.3.1 Summary ............................................................................................................................ 219 
5.3.2 Lipid rafts do not play a role in MT cluster formation ....................................................... 220 
5.3.3 MT and Cytoskeleton ......................................................................................................... 221 
5.3.4 Lack of PDGFRβ and reduced EGFR expression in MT-transformed cells .......................... 225 
CHAPTER 6 – GENERAL DISCUSSION ................................................................................................... 228 
6.1 Overall Summery ....................................................................................................................... 228 
6.2 Macro-complex Formation in GFR Activation ........................................................................... 230 
6.2.1 Receptor Clusters ............................................................................................................... 230 
6.2.2 Inhibiting GFR oligomerisation ........................................................................................... 231 
6.2.3 Mixed clusters: do they exist? ........................................................................................... 232 
6.2.4 Mechanism of Macro-complex Formation ........................................................................ 234 
6.2.5 Additional components in MT clusters require further investigation ............................... 234 
6.3 Changes in PDGFRβ in cells transformed by MT ....................................................................... 235 
6.4 A Story Unfinished .................................................................................................................... 236 
6.5 Future Projects: ......................................................................................................................... 237 
SUPPLEMENTARY MATERIAL .............................................................................................................. 239 
REFERENCE .......................................................................................................................................... 242 
 
  
10 
 
FIGURE AND TABLE LIST 
Figure # Figure Title Page 
Figure 1.1 MPyV genome structure and the T-antigens encoded  23 
Figure 1.2 Mouse Polyomavirus MT Anatomy 26 
Figure 1.3 Transmembrane domain sequence of MT 53 
Table T2.1 Reagents used for making cDNA from extracted RNA 68 
Table T2.2 PCR mix preparation for receptor expression analysis 69 
Figure 3.1 MT C-terminus is translocated across to the cell surface 74 
Figure 3.2 ER-retention sequence abolishes MT transformation of 
fibroblast monolayer  
76 
Figure 3.3 MTKDEL is localised to the ER membrane  78 
Figure 3.4 MTKDEL is absent from the Golgi apparatus  79 
Figure 3.5 Analysis of MTKDEL location and association with known 
MT-binding proteins 
81 
Figure 3.6 Kinase activity associated with MTKDEL  82 
Figure 3.7 MT mutant 180∆10 lacking PP2A binding is localised to ER 
region 
85 
Figure 3.8 Schematic representations of the MT mutations and 
antibodies used in Chapter 3.2.3 studies  
87 
Figure 3.9 Mutants lacking PP2A binding failed to reach the plasma 
membrane  
88 
Table T3.1 Summary of MT distribution in chapter 3.2.3 
immunofluorescence staining analysis  
89 
Figure 3.10 MTKDEL failed to associate with pp62c-yes 91 
Figure 3.11 MTKDEL redistributes pp60c-src 93 
Figure 3.12 Single-cell images showing pp60c-src and MT distribution 
in cell lines 
94 
Figure 3.13 pp62c-yes distribution is not affected by the MT expressed 
in cells 
95 
11 
 
Table T3.2 Kyte and Doolittle’s hydrophobicity scale  96 
Figure 3.14 Analysis of MT and ASNA1 association by 
immunoprecipitation 
97 
Figure 3.15 In vitro co-translated MT and ASNA1 failed to associate 100 
Figure 3.16 Loss of hexapeptide is inhibitory in HA-tagged MT 102 
Figure 3.17 Immunofluorescence and immunoprecipitation analysis of 
∆416-421MTHA+ 
103 
Figure 3.18 Loss of C-terminal hexapeptide reduced the ability of MT to 
transform fibroblasts  
105 
Figure 3.19 Six-Glycine substitution of the C-terminal hexapeptide 
inhibited transformation 
106 
Figure 3.20 Expression levels of hexapeptide region mutants  107 
Figure 3.21 A schematic representation of the sequence of events 
during the maturation of a transforming MT complex  
109 
Figure 4.1 Surface MT is found in discrete focal patches over the whole 
surface of the cell 
120 
Figure 4.2 Large complexes of MT on the cell surface membrane 121 
Figure 4.3 Permeabilisation of plasma membrane does not enhance 
the fluorescence signals of externally labelled HA-tags 
122 
Figure 4.4 Surface MT does not colocalise with endosome markers 122 
Figure 4.5 MTFLAG clusters on the cell surface can be labelled at 4˚C  123 
Figure 4.6 MT clusters labelled from the cell exterior correlate with 
MT molecules labelled from the inside of cells 
125 
Figure 4.7 Colocalisation level between activated ShcA and surface MT 
complexes in cells expressing wild type or the non-
transforming mutant 200∆10 MTHA+  
128 
Figure 4.8 Dasatinib reduces colocalisation level between activated 
Shc and surface MT complexes  
131 
Figure 4.9 Growth inhibition of MT-expressing cells by dasatinib 132 
Figure 4.10 Mutagenesis of MT hydrophobic sequence and their effects 
on MT transformation 
135 
12 
 
Figure 4.11 Characterisation of non-transforming TMD mutants L405E 
and neu-mutant 
136 
Figure 4.12 L405E C-terminus failed to translocate to the outer cell 
surface 
138 
Figure 4.13 Hydrophobic domain mutants with FLAG-tag  140 
Figure 4.14 Mutant L405E MT is stable 142 
Figure 4.15 Analysis of downstream signalling effectors in cells 
expressing mutant L405E  
142 
Figure 4.16 Characterisation of L405E KDEL 144 
Figure 4.17 Measuring surface HA fluorescence signals 146 
Figure 4.18 Measuring surface fluorescent complexes 148 
Figure 4.19 IEM analysis of wild type and L405E MT at the plasma 
membrane  
150 
Figure 4.20 Hydrophobic sequences from FGFR3 receptors localise MT 
to intracellular membranes 
151 
Figure 4.21 MT localised to the Golgi apparatus associates with all 
signalling molecules 
154 
Figure 4.22 Immunoprecipitation of MT from the cell surface 156 
Figure 4.23 Analysis of MT complexes on the cell surface 158 
Figure 4.24 Dasatinib inhibits MT association with signalling molecules 160 
Figure 4.25 Analysis of MT distribution after dasatinib treatment 161 
Figure 4.26 Distribution of MT after treatment with okadaic acid 163 
Figure 4.27 A schematic representation of  the final step in the assembly 
of a transforming MT complex 
165 
Table T4.1 Subcellular location of MT mutants and their ability to 
transform as well as their ability to associate with MT-
binding partners 
167 
Figure 4.28 Mutant 200∆10 reduces the foci formation induced by wild 
type MT plasmid 
172 
Figure 4.29 Colocalisation between MTFLAG and 200∆10 MTHA on the 
cell surface 
173 
13 
 
Figure 4.30 Colocalisation between MTFLAG and MTHA complexes on 
the cell surface 
174 
Figure 4.31 Colocalisation analysis between MTFLAG and MTHA 
complexes on the cell surface 
175 
Figure 5.1 Little colocalisation between surface MTHA and raft marker 
at 37°C in cells expressing wild type or non-transforming 
mutant 
183 
Figure 5.2 Level of surface MT fluorescent signals inversely correlates 
with lipid raft staining  
184 
Figure 5.3 Cells with stronger surface MTHA signals have lower levels 
of the raft marker 
185 
Figure 5.4 Little colocalisation between surface MTFLAG and raft 
marker at 4°C 
186 
Figure 5.5 Very little colocalisation between surface MT complexes 
and intracellular H-RasG12V-Myc 
188 
Figure 5.6 Co-immunoprecipitation between MT and H-RasG12V-Myc 189 
Figure 5.7 Time course for MβCD treatment 190 
Figure 5.8 Methyl-β-cyclodextrin increases surface and overall MT 
staining 
191 
Figure 5.9 Detergent resistance fractionation of cell membrane in cell 
lines expressing wild type or non-transforming MT mutant 
194 
Figure 5.10 Surface MT complexes colocalise with actin cytoskeleton  196 
Figure 5.11 Additional support images for surface MT complexes co-
stained with actin-cytoskeleton 
197 
Figure 5.12 Cytochalasin D does not disrupt surface MT complex 
formation 
199 
Figure 5.13 Surface MT complexes colocalise with micro-tubules inside 
cells 
200 
Figure 5.14 Dual labelling surface MT complexes and intracellular 
vinculin 
202 
Figure 5.15 Little colocalisation between surface MT complexes and 
vinculin at the basement membrane 
203 
Figure 5.16 Surface MT complexes and activated focal adhesion kinase 205 
14 
 
Figure 5.17 Additional frames for surface MT complexes co-staining 
with activated FAK 
206 
Figure 5.18 Partial colocalisation between surface MT and integrin 
αVβ5 
208 
Figure 5.19 Zoom-in images of Figure 5.18 209 
Figure 5.20 Antibody-induced endocytosis of integrin αVβ5 210 
Figure 5.21 Slow EGFR internalisation in fibroblasts expressing wild 
type MT 
211 
Figure 5.22 Analysis of EGFR1 and PDGFRβ protein levels in Rat-2 
fibroblast cell lines  
212 
Figure 5.23 Changes in expression levels of various growth factor 
receptors in Rat-2 fibroblasts transformed by MT 
213 
Figure 5.24 Level of mRNA for EGFR family receptors and PDGFRβ in 
cell lines expressing MT 
214 
Figure 5.25 Dasatinib up-regulates PDGFRβ in cells expressing wild 
type MT 
216 
Figure 6.1 A schematic representation of the maturation of a 
transforming MT complex 
229 
 Supplementary Figures  
Figure S2.1 Complete amino acid sequence of MPyV MT 239 
Table ST2.1 Primers for MT Mutagenesis 240 
Table ST2.2 Primers for Receptor Transcription Detection 240 
Table ST2.3 Oligonucleotides for Sequencing MT Plasmids 240 
Table ST2.4 Inhibitor and Compound List 241 
 
  
15 
 
ABBREVIATIONS 
 
BCA bicinchoninic acid assay 
bp base pair 
BPV bovine papillomavirus 
CCD cytochalasin D  
cDNA complementary deoxyribonucleic acid 
CHX cycloheximide 
CT-B cholera toxin subunit-B 
Cytb5 cytochrome b5 
DIF detergent-insoluble faction 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
DPBS Dulbecco’s phosphate-buffered saline, PBS supplemented with CaCl2 and MgCl2 
dsDNA double-stranded DNA 
DSF detergent-soluble faction 
EGFR epidermal growth factor receptor 
EphA Ephrin type-A receptor 
ER endoplasmic reticulum 
FAK focal adhesion kinase 
FBS foetal bovine serum  
FCS fetal calf serum 
FGFR fibroblast growth factor receptor 
c-FMS colony stimulating factor 1 or macrophage colony-stimulating factor receptor  
GFR Growth Factor Receptor 
GM1 monosialotetrahexosyl ganglioside 
HaPyV hamster polyomavirus  
HER2/Neu/ErbB2 human epidermal growth factor receptor 2 
HPV human papillomavirus 
IB immuno-binding 
IEM immuno-electron microscopy 
IF immunofluorescence staining/labelling 
16 
 
IGF-IR Insulin-like Growth Factor I Receptor 
IRβ insulin receptor subunit β 
IP immunoprecipitation 
kDa Kilo Daltons 
LB lysogeny broth 
LT Large T-antigen 
MβCD Methyl-β-cyclodextrin  
MC PyV Merkel Cell polyomavirus  
MF membrane fraction 
MMTV mouse mammary tumour virus 
MPyV murine Polyomavirus 
MSC mesenchymal stem cell  
MT Middle T-antigen 
NMF non-membrane fraction 
NSCLC non-small cell lung cancer 
OA okadaic acid 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffer saline 
PCR polymerase chain reaction 
PDGFRβ platelet-derived growth factor receptor β isoform 
PLC-γ1 phospholipase Cγ1 
PM plasma membrane 
PP2A protein phosphatase 2A 
Pr Pearson’s coefficient 
PTK protein tyrosine kinase 
PyV polyomavirus 
Rb retinoblastoma protein 
RNA ribonucleic acid 
RT room temperature 
RTK Receptor Tyrosine Kinase 
SDS sodium dodecyl sulphate 
SFK Src Family Tyrosine Kinase 
SH Src-homology domains 
siRNA small interfering RNA 
SRP signal recognition particles  
17 
 
ST Small T-antigen 
SV40 simian virus 40 
TA tail-anchored 
TBE Tri-borate/EDTA 
TBS-T Tris-Buffered Saline and Tween-20 
TMD transmembrane domain 
TRC transmembrane-domain recognition complex 
VSV G vesicular stomatitis virus G protein 
WB Western blotting 
WCL whole cell lysates 
wt wild type 
w/w weight to weight 
Φ diameter 
  
18 
 
LIST OF MT MUTANTS 
 
Mutant Name Mutation and Phenotype Reference and Figure 
MTHA+ Extended HA-tag added to the C-terminus. 
Strongly transforms 
Zhou et al. 2011; 
Figure 3.1 
MTFLAG FLAG-tag added to the C-terminus. Strongly 
transforms 
Figure 3.1 
MTKDEL ER retention sequence KDEL added to the C-
terminus. Binds PP2A and pp60c-src only. Non-
transforming 
Zhou et al. 2011; 
Figure 3.2-3.4 
MTGGDV Sequence GGDV added to the C-terminus, a 
control for MTKDEL. Strongly transforms 
Zhou et al. 2011; 
Figure 3.2-3.5 
MTSec61β Hydrophobic sequence substituted with that of 
ER-resident tail-anchored protein Sec61β. 
Weakly transforming  
Zhou et al. 2011; 
Figure 3.2 and 3.5 
180∆10 Lacks both PP2A and Src binding sites. Non-
transforming 
Brewster et al. 1997; 
Figure 3.7 
200∆10 Lacks Src binding site only. PP2A binding site 
intact. Non-transforming 
Brewster et al. 1997; 
Figure 3.7 
∆419-421 Deletion of final 3 amino acids at the C-terminus. 
Strongly transforms 
Figure 3.16 
∆416-421 Deletion of final 6 amino acids at the C-terminus. 
weakly transforms 
Figure 3.18 
416G6 Glycine substitution of the final 6 amino acids at 
the C-terminus. Very weakly transforms 
Figure 3.19 
L405E Mutation of Leucine 405 to Glutamate in the 
hydrophobic sequence. Binds to all known MT-
binding proteins associated with transformation 
but cannot transform. C-terminus is not exposed 
on cell surface 
Figure 4.10 – 4.13 
L405E KDEL L405E mutation with ER-retention sequence 
KDEL added to the C-terminus. Escaped 
entrapment in the ER but unstable. Non-
transforming 
Figure 4.16 
G406L Mutation of Glycine 406 to Leucine in the 
hydrophobic sequence. Transforms 
Figure 4.10 – 4.13 
neu-wt MT Hydrophobic sequence substituted with that of 
wild type ErbB2/neu receptor. Strongly 
transforms 
Figure 4.10 and 4.11  
neu-mutant MT Hydrophobic sequence substituted with that of Hynes and Stern. 
19 
 
ErbB2/neu receptor carrying the activating 
mutation of Valine to Glutamate (V664E). Binds 
to all known MT-binding proteins associated 
with transformation but cannot transform. C-
terminus not exposed on cell surface 
1994; Figure 4.10 
and 4.11 
FGFR3-wt MT Hydrophobic sequence substituted with that of 
FGFR3 receptor. Trapped in the ER and Golgi. 
Non-transforming 
Figure 4.10 and 4.20 
FGFR3-mutant 
MT 
Hydrophobic sequence substituted with that of 
FGFR3 receptor with the activating mutation of 
Glycine to Arginine (G380R).  Trapped in the ER 
and Golgi. Non-transforming 
Figure 4.10 and 4.20 
∆402-406 Deletion of 5 amino acids in the middle of the 
hydrophobic region. Trapped in the Golgi. Non-
transforming 
Figure 4.21 
dl1015 Deletion between amino acid residues 339-347. 
Intact binding sites for PP2A, Src, Shc, PI3K and 
PLC-γ1 but unable to transform. Defect 
unknown. 
Magnusson and Berg. 
1979; Magnusson et 
al, 1981; Figure 4.17 
NS2/DC1/DC2 PP2A binding disrupted. Non-transforming Dilworth et al. 1994; 
Zhou et al. 2011; 
Figure 3.8, 3.9, Table 
T3.1 
∆J-DC1 DC1 mutation combined with the deletion in the 
dnaJ domain. Lacks binding to Hsc70and PP2A. 
Non-transforming 
Dilworth et al. 1994; 
Whalen et al. 2005; 
Zhou et al. 2011; 
Figure 3.8, 3.9, Table 
T3.1 
 
 
 
  
20 
 
CHAPTER 1 – INTRODUCTION 
 
1.1 Overview 
Over the past fifty years, research on polyomaviruses had contributed substantially to the 
understanding of basic cell biology, oncogenic signalling and transcription control.  Studies 
of murine (mouse and rat) polyomavirus were particularly prolific from the late 1970s to 
early 1990s (Dilworth 2002). During that time, research on the mouse polyomavirus 
oncogene, Middle Tumour-antigen (MT), led to the discovery of cellular tyrosine kinases 
(Eckhart, Hutchinson et al. 1979) and  PI3 Kinase activity was also first reported during the 
studies of MT associated oncogenic signalling (Whitman, Kaplan et al. 1985). Although 
many years have passed since MT was first discovered, it remains a useful tool for studying 
the events underlying cancer formation and metastasis in animal models.  
 
1.2 Small DNA Tumour Viruses 
Polyomaviruses (PyV) belong to the small DNA virus class, which are also known as DNA 
tumour viruses. These are non-enveloped, capsid-only viruses containing a circular double-
stranded DNA (dsDNA) genome of about 5,000 bp in size. Murine polyomavirus (MPyV) 
was the first of its kind discovered by Ludvik Gross in 1953 (Gross 1953), when working on 
the cell free transmission of leukaemia in mice. Inoculation of filtered leukemic mice cell 
extracts into new-born mice induces tumour formation in a range of tissues. Other members 
of PyV family include simian virus 40 (SV40), murine polyomavirus (MPyV), avian 
polyomavirus, hamster polyomavirus (HaPyV), JC virus, BK virus, SA12 virus, 
lymphotropic polyomavirus, K virus, and the recently discovered, Human Merkel Cell 
polyomavirus (MC PyV) (Pipas 1992, Jiang and Imperiale 2012).  
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Other examples of small DNA virus family include adenoviruses, papillomaviruses, 
and parvoviruses. The genome of a small DNA virus is divided into early and late 
transcriptional regions where different sets of viral proteins are made using the host 
machinery, depending on the virus life cycle. The early transcription regions of 
polyomavirus, papillomavirus and adenovirus genomes all encodes viral proteins with 
oncogenic potential, termed tumour-antigens (T-antigens), probably developed through 
evolution as a means to promote the replication of both host and virus genomes (Dilworth 
1995). Therefore these viruses are also known as small DNA tumour viruses (Jiang and 
Imperiale 2012).  
 A common strategy used by DNA tumour viruses is the inactivation of tumour 
suppressors such as p53 and the retinoblastoma protein (Rb) family members. In fact, many 
of the known tumour repressors were first discovered as cellular proteins associated with T-
antigens (Lane and Crawford 1979, Linzer and Levine 1979). SV40 LT, adenovirus E1B and 
HPV E6 all target p53 tumour suppressor, although the mechanisms of p53 inactivation are 
different (reviewed by O'Shea and Fried 2005, Atkin, Griffin et al. 2009). Other tumour 
antigens, such as E6 and E7 from papillomavirus, bind and activate cyclins, cdks and other 
transcriptional factors that promote cell cycle entry. Some tumour antigens, such as MT, are 
able to activate multiple mitogenic signalling pathways by mimicking an activated growth 
factor receptor. Others bind and activate a growth factor receptor, as in the case of the E5 
oncoprotein encoded by the bovine papillomavirus (BPV) which can bind and activate 
PDGFRβ (Sparkowski, Anders et al. 1995).  
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1.3 MPyV Genome  
All polyomavirus genomes encode a large and a small size tumour-antigen, abbreviated as LT 
and ST, respectively. In addition, murine and hamster PyV genome also encoded an 
intermediate-sized tumour-antigen, MT (Pipas 1992). The recently discovered human MC 
PyV also has an early transcription region that encodes an additional polypeptide of a similar 
size to that of the murine PyV MT but has not yet been fully characterised.   
Once inside the cell, the virus is transported into the nucleus (Kasamatsu and 
Nakanishi 1998), where the genome is uncoated and RNA transcription of the early region on 
the genome begins. The early transcription region encodes three tumour-antigens. These are 
large T (LT), middle T (MT) and small T (ST), with molecular weight of 100, 55 and 22 kDa, 
respectively (Ito, Spurr et al. 1977, Hutchinson, Hunter et al. 1978, Schaffhausen, Silver et al. 
1978, Simmons, Chang et al. 1979). The tumorigenic effect of MPyV in vivo is attributed 
these three T-antigens working together. The late and early transcription regions are 
separated by a regulatory region that contains the viral origin of DNA replication (ori), the 
promoters for both early and late regions, transcriptional enhancers and binding sites for LT, 
which promotes virus DNA replication (Pipas 1992). LT binding to multiple sites around the 
origin of replication causes a switch of RNA transcription from the early region to the ‘late 
phase’, DNA strand, which encodes three viral capsid proteins, VP1, VP2 and VP3, for virion 
assembly during the lytic phase of the virus life cycle (Pipas 1992). Although virion proteins 
are essential for mature virion production, they are not required for transformation (Fried 
1965).  
 All three tumour antigens (LT, MT and ST) are encoded by the same stretch of viral 
DNA sequence. Using separate reading frames after the common region (Figure 1.1A), two 
immature mRNAs can be translated. One produces LT. The other is spliced to remove 
introns, resulting in two different mature mRNAs, which give rise to MT and ST. Therefore 
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two T-antigens with completely different C-terminal sequence are made, LT and MT, while 
the bulk of ST is essentially the N-terminus of MT (Figure 1.1 B) (Smart and Ito 1978, 
Dilworth 2002). LT, ST and MT all share the same J domain at their N-termini J domain, 
which is highly conserved across all PyV T-antigens, including SV40.After this point, the C-
terminal coding sequence of the MPyV genome is unique and does not share any DNA 
sequence homology with other polyomaviruses (unique region, Figure 1.1 A). And this 
results in the production of three T-antigens, each with a unique C-terminal amino acid 
sequence and function (Pipas 1992). 
 
1.4 T-antigens 
When expressed individually, LT can immortalise primary cells but cannot transform and is 
therefore not required for tumorigenesis (Moore, Chowdhury et al. 1980, Rassoulzadegan, 
Binetruy et al. 1982). ST can promote cell cycle progression but does not have any 
transforming property (Mullane, Ratnofsky et al. 1998). Only MT can transform established 
cell lines into to a fully tumorigenic phenotype when expressed alone (Hassell, Topp et al. 
1980, Novak, Dilworth et al. 1980, Treisman, Novak et al. 1981). Together, these tumour-
antigens are responsible for the effective tumorigenic properties of the MPyV. The 
expression of the three viral oncoproteins leads to dramatic changes in cell morphology such 
as decreased cell-substratum adhesion, stress fibre remodelling with increased cell motility, 
lack of contact inhibition and anchorage independent growth. 
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Figure 1.1 MPyV genome structure and the T-antigens encoded  
A. MPyV genome is divided into early and late regions and marked at 1kb intervals. The coding 
regions in mature mRNA are indicated by solid coloured boxes outside of the circular genome. 
The non-coding mRNA regions are designated by solid lines, and the sequences removed by 
splicing in dotted lines. Unique region of MPyV has no sequence similarity to SV40 or other 
polyomavirus. The coding regions with base-pair numbers corresponding to their positions in 
the genome are indicated in each box. Adapted from a review by Dilworth, 1995. 
B. Translated T-antigens share common sequence at the N-terminal region. All three T-antigens 
encoded by MPyV share the first 79 amino acid sequence that is the J domain (orange). MT and 
ST also share an additional 112 amino acids, which make up the PP2A binding region. The 
unique regions of LT, MT and ST are represented with lilac, red and green, respectively. 
Approximate positions of functional domains are indicated by boxes: Rb binding regions (Rb), 
DNA-binding domain (DBD), helicase domain (Helicase), Src-binding region (Src) and 
transmembrane domain (TMD). Adapted from a review by Cheng et al., 2009. 
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1.4.1 Large T-antigen 
The 100 kDa LT was first identified as a major phosphorylated protein in vivo amongst the T 
antigens of MPyV (Schaffhausen and Benjamin 1979). LT is localised exclusively in the 
nucleus but not the nucleolus (Dilworth, Hansson et al. 1986). The J domain is a highly 
conserved structural domain found in dnaJ/Hsp40 family of molecular chaperones including 
Hsc70. Binding of PyV T-antigens to Hsc70 requires the HDPK residues in the viral protein 
N-terminus and subsequently activates the ATPase activity of the chaperone protein, which is 
thought to facilitate proper folding and maintaining structural integrity of the T-antigens 
(Cheng, DeCaprio et al. 2009).  
Early knowledge in MPyV LT function was based on the studies of SV40 LT. The 
conserved LXCXE motif makes direct contact with a highly conserved ridge in the B domain 
of Rb family proteins, which inactivates the tumour suppressor (Cheng, DeCaprio et al. 
2009). Like SV40 LT, MPyV LT contains a DNA binding domain (DBD), which allows LT 
to bind to the origin of replication on the viral genome, and a helicase domain in the C-
terminal unique region, which plays an essential role in viral genome replication. However, 
unlike SV40 LT, MPyV LT does not target p53 directly and does not transform cells 
(reviewed by O'Shea and Fried 2005). Although PyV LT can immortalise primary cells, 
including human fibroblasts when the expression was driven by a heterologous promoter, it 
does not transform cells into a tumorigenic state (Strauss, Hering et al. 1990).  
 
1.4.2 Middle T-antigen 
Unlike LT and ST, which are cytoplasmic, MT is found in membranes, which can only be 
extracted in the presence of detergents (Ito, Brocklehurst et al. 1977). MPyV MT is a 55 kDa 
polypeptide comprised of 421 amino acid residues and associates with the plasma membrane 
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via a hydrophobic sequence very close to the C-terminus (Figure 1.2). Inducible MT 
expression in rat fibroblasts was accompanied with increase in transformed cell growth and 
kinase activity (Heiser and Eckhart 1985). By studying non-transforming strains of MPyV 
which express truncated MT, it was established that MT is tightly associated with the 
transforming properties of the virus and is associated with strong tyrosine kinase activity 
(Schaffhausen, Silver et al. 1978, Ito, Spurr et al. 1980, Dilworth 2002). However, like many 
viral oncogenic proteins, MT does not have any intrinsic enzymatic activity. MT translated in 
vitro or expressed in bacterial system does not possess any kinase activity. The kinase 
activity associate with MT come from the Src family tyrosine kinase bound to the virus 
protein (Courtneidge and Smith 1983). MT provides binding sites to bring cellular signalling 
molecules to the membrane and propagate mitogenic signals, which is similar to an activated 
Growth Factor Receptor (GFR) (Dilworth 1995, Dilworth 2002).  
The N-terminal region of MT binds to the PP2A core dimer A and C (Glenn and 
Eckhart 1993). PP2A in complex with MT provides a structural platform for Src family 
tyrosine kinases to bind. These include pp60c-src, pp62c-yes and pp59c-fyn. Upon binding to 
MT, Src tyrosine kinase activity is activated, which phosphorylates MT at three major 
tyrosine residues: Y250, Y315 and Y322 (Figure 1.2).These phosphorylated tyrosine residues 
act as docking sites to recruit Src homology 2 (SH2) domain- or phospho-tyrosine binding 
(PTB) domain-containing proteins such as ShcA (to Y250), PI3K p85 subunit (to Y315) and 
PLC-γ1 (to Y322) (see Figure 1.2). 
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Figure 1.2 Mouse Polyomavirus MT Anatomy 
MT is represented linearly and outlined in black. Important phosphorylation sites in MT are 
written in bold together in line with numbers indicating the positions in MT amino acid 
sequence. Sequence 111 to 185 represents PP2A binding region. The CXCXXC motifs required 
for PP2A binding are depicted as C3. Sequence 185to 210 represents the unique binding site for 
Src. PPP represents the Proline-rich region. PyV MT is bound to membranes via C-terminus 
hydrophobic region. It mimics an activated RTK by recruiting members of the Src family 
tyrosine kinases which in turn modify the viral molecule on tyrosine residues to create 
additional binding sites to recruit more signalling proteins as mentioned above. In the end, 
proliferative signals are propagated via the MAPK signalling pathway together with survival 
signals via the activation of AKT signalling pathway. 
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Activated Src can also phosphorylate these signalling molecules and adaptor proteins 
recruited to MT, which in turn alters their activities or creates further docking sites for signal 
transduction. A docking protein ShcA, recruited to the PP2A/MT/Src complex become 
phosphorylated on multiple tyrosine residues, which creates a binding site for the adaptor 
protein Grb2, which then in turn recruits guanine nucleotide exchange factor, Son of 
Sevenless 1 (Sos1), and adaptor, Gabl, to the MT signalling complex. Sos1 subsequently 
activates the Raf-MEK-ERK MAPK signalling cascade and leads to activation of 
transcription factors such as Elk, c-jun, that promote cell proliferation. PI3K p85 recruits the 
catalytic subunit of PI3K, p110, to the plasma membrane, where it converts phosphoinositide 
to PIP3. An increase in PIP3 activates PDPK1, a known activator of AKT serine/threonine 
kinase. AKT itself can also bind to PI3K p110 at the plasma membrane via its pleckstrin 
homology domain and becomes activated. Direct and indirect activation of AKT promotes 
DNA synthesis and inhibits apoptosis. PI3K p110 also activates the small GTP binding 
protein Rac, of which activation is necessary for MT to promote migratory signals and to 
activate c-fos. PLC-γ1 binds to MT p-Y322 via its SH2 domains (Su, Liu et al. 1995) where it 
catalyses the conversion of PIP2 to DAG and IP3. This leads to an increase of Ca
2+
 level 
inside the cell, which can activate the PKC family of phospholipid-dependent Ser/Thr kinases 
that regulate a wide range of protein targets involved in cell signalling. In the end, 
proliferative signals are propagated via the MAPK signalling cascade, together with pro-
survival signals via activation of AKT. A comprehensive report on our current understanding 
on cancer-formation gained from the studies on MPyV MT is compiled by Fluck and 
Schaffhausen (Fluck and Schaffhausen 2009). The mechanism of MT interaction with 
binding partners and signal transduction will be discussed in detail in Section 1.10. Overall, 
the multi-complex MT signalosome depicted in Figure 1.2 resembles the events happening 
during GFR activation (Dilworth 1995). Therefore MT can be considered as a permanently 
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active analogue of a GFR (Ichaso and Dilworth 2001) and has been instrumental in our 
understanding of the molecular events governing GFR signalling. 
 
1.4.3 Small T-antigen 
Since the amino acid sequence of ST is mostly identical to the N-terminal region of MT in 
MPyV, both T-antigens are capable of binding to PP2A, a cellular serine/threonine-specific 
phosphatase (Pallas, Shahrik et al. 1990). The mechanism of PP2A – ST/MT interaction is 
discussed in more details on Section 1.10.1. While SV40 ST can transform cells, MPyV ST 
does not possess such a property. SV40 ST binds only PP2A Aα, while MPyV ST binds both 
Aα and Aβ isoform of PP2A scaffold subunits, therefore probably target different substrates 
(Andrabi, Hwang et al. 2011). Interestingly, PyV ST can block differentiation in multiple cell 
lines. MPyV ST seems to stabilise PP2A Aβ/AKT interaction, which leads to reduced 
phosphorylation of S473 on AKT therefore negatively regulates AKT (Hwang, Jiang et al. 
2013). MPyV ST is likely to play a role in augmenting LT and MT in the immortalisation and 
transformation of primary cells (see 1.6).  
 
1.5 Late Replication Cycle Proteins 
At the late lytic cycle phase, three virion proteins, VP1, VP2 and VP3, are transcribed. VP1 is 
the major virion protein which makes up as much as three quarters of the total virion protein 
content (Atkin, Griffin et al. 2009). Immunofluorescence analysis of individually expressed 
MPyV virion proteins showed VP2 is localised to the perinuclear region of the cells and VP3 
is found in the cytoplasm(Forstova, Krauzewicz et al. 1993).VP1 is localised to the nucleus 
(Stamatos, Chakrabarti et al. 1987) and only in the presence of VP1 can VP2 and VP3 be 
efficiently transported into the nucleus where new virus particles can be assembled (Delos, 
30 
 
Montross et al. 1993, Forstova, Krauzewicz et al. 1993). Recently it has been shown that VP2 
and VP3 can activate caspases, which results in host cell destruction at the end of the virus 
replication cycle (Huerfano, Zila et al. 2010). 
 
1.6 Cooperation of MPyV T-antigens induces tumour formation 
MT is responsible for inducing cellular changes that leads to malignant transformation of 
established fibroblasts. These are post-crisis cell lines capable of indefinite growth. But 
expression of MT alone cannot immortalise primary rodent cells (Rassoulzadegan, Cowie et 
al. 1982). A second oncogene from the early transcription region is needed for the 
transformation of newly isolated primary cells (Schaffhausen and Benjamin 1981, 
Rassoulzadegan, Cowie et al. 1982). The inability of MT to immortalise primary cells is 
probably due to functional tumour suppressor p53 present in most primary tissues (Lomax 
and Fried 2001, Moule, Collins et al. 2004). It has been shown that mitogenic signals induced 
by MPyV MT activates ARF, an activator of p53, therefore induces p53-mediated blockage 
to cell division. In contrast, ST disrupts ARF-p53 signalling pathway, thus alleviating the 
p53-mediated cell arrest (Lomax and Fried 2001). The inability of MT to transform primary 
rodent cells can be overcome by co-expression of mutant p53 as well as the other two T-
antigens (Rassoulzadegan, Cowie et al. 1982, Reihsaus, Kraiss et al. 1992, Lomax and Fried 
2001). Therefore, transformation of primary cells requires cooperation of multiple oncogenes. 
The Ras oncogene and MPyV MT can only transform fibroblasts when cells are immortalised 
prior to transfection, for example, by cellular myc gene, PyV LT or adenovirus E1A (Land, 
Parada et al. 1983, Ruley 1983). Expression of PyV MT alone in most cultured cell lines is 
sufficient to induce full malignant transformation in a single step and does not require 
cooperating oncogenes (Mann, Stevenson et al. 1991). The resulting transformed cells are 
capable of forming invasive cancerous growth when injected into nude mice.  
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1.7 Transcription Factors in MT-induced Transformation 
Early studies of lytically infected cells have demonstrated that transcription factor PEA1 (a 
homologue of AP-1 and c-Jun) and PEA3 (mouse homologous to Ets family transcription 
factors) are key targets for MPyV MT. These transcription factors bind to specific sequences 
in the MPyV enhancer region in the polyoma promoter. Both are highly active in fibroblast 
cell lines infected with MPyV and lead to altered transcription of transformation-related 
genes (Wasylyk, Imler et al. 1988). Both PEA1/AP-1and PEA3/ets are heavily implicated in 
breast cancer. Over-expression of the Est family members are associated with poor prognosis 
(Kurpios, Sabolic et al. 2003). In many breast tumour cells, expression of dominant negative 
AP-1 and Ets reverses the transformed phenotype (Galang, Garcia-Ramirez et al. 1996, 
Shepherd and Hassell 2001). Genes up-regulated by PEA1/AP-1 and PEA3/ets includes 
cyclin D1, matrix metalloproteases, plasminogen activator, EGF and VEGF (Fluck and 
Schaffhausen 2009). PEA1 can also be activated by other transforming oncogenes such as v-
src and c-fos but not the immortalising oncogenes such as MPyV and SV40 LTs (Wasylyk, 
Imler et al. 1988). This suggests distinct targets and pathways exist between immortalising 
oncogenes and transforming oncogenes, and that PEA1/AP-1 mediates at least some of the 
events associated with transformation.  
Other transcription factors whose activity is altered by MT-induced transformation 
include NF-κB (Nabel and Baltimore 1987) and PEA2/RUNX family core binding factor 
(Chiu, Imagawa et al. 1987, Gottlieb and Villarreal 2001). Transcriptional activation 
stimulated by MT is reviewed in detail by reviews by Flucks and Schauffhausen, Gottlieb and 
Villarreal (Gottlieb and Villarreal 2001, Fluck and Schaffhausen 2009). 
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1.8 MT in Other Polyomaviruses 
1.8.1 Hamster Polyomavirus 
The Hamster polyomavirus (HaPyV) is a virus closely related to murine polyomavirus and is 
the only other polyomavirus known to express MT (Delmas, Bastien et al. 1985). Naturally-
occurring HaPyV was found to cause hair follicle epitheliomas. But the malignancies caused 
by inoculation of purified virus into new born hamsters were limited to lymphoma and 
leukaemia instead of the wide spectrum of tumours caused by inoculation with mouse 
polyomavirus (Delmas, Bastien et al. 1985) (Scherneck, Delmas et al. 1987). The HaPyV MT 
shares sequence homology with MPyV at the N-terminal region, required for PP2A and Src 
family tyrosine kinase binding, and at the C-terminal hydrophobic region required for 
membrane anchoring. The intervening sequence is unique to each MT (Delmas, Bastien et al. 
1985) (Goutebroze, Dunant et al. 1997). Unlike MPyV MT, which binds and activates pp60c-
src, pp62c-yes and pp59c-fyn, HaPyV MT only binds pp59c-fyn (Courtneidge, Goutebroze et 
al. 1991), a Src family tyrosine kinase expressed mostly in hematopoietic cells (Cooke, 
Abraham et al. 1991). This is likely to account for the ability of HaPyV MT to induce 
lymphoma and leukaemia (Courtneidge, Goutebroze et al. 1991, Brizuela, Ulug et al. 1995). 
The intervening sequence of HaPyV MT associate with PI3K and PLC-γ1 but not ShcA. The 
divergence at the intervening stretch may also modulate specificity activation of different 
SFK members (Goutebroze, Dunant et al. 1997). 
 
1.8.2 Human Merkel Cell Polyomavirus 
In recent years, the field of research on polyomavirus has been re-ignited following the 
discovery of a human polyomavirus in patients with Merkel Cell Carcinoma, an aggressive 
form of skin cancer associated with immuno-suppression and the elderly, hence the name 
33 
 
Merkel Cell Polyomavirus (MC PyV) (Engels, Frisch et al. 2002, Feng, Shuda et al. 2008). 
From 2007 to present, 9 different human polyomaviruses had been discovered (DeCaprio and 
Garcea 2013). The MC PyV and murine PyV genomes are very similar. Recently, Galloway 
and co-workers discovered an overprinting gene (ALTO, Alternate frame of the Large T 
Open reading frame) can be expressed as an alternative reading frame from the LT gene 
region of MC PyV (Carter, Daugherty et al. 2013). Intriguingly, ALTO is evolutionarily 
related to the MT of MPyV (Carter, Daugherty et al. 2013). A hydrophobic sequence was 
observed in the translated product of ALTO despite having almost no sequence similarity 
with MT and was found to associate with intracellular membranes. However, unlike MPyV 
MT, ALTO product seems to inhibit transformation by inducing apoptosis. Characterisation 
of this previously missed viral gene product is underway and will rely heavily on the 
knowledge gained from MPyV MT. DNA analysis by Galloway et al provided insight into de 
novo protein evolution as a means by which viruses overcome constraints of small genome 
size (Carter, Daugherty et al. 2013). 
MC PyV has been detected in some non-small cell lung cancer patient samples, 
raising the possibility that MC PyV may be associated with the pathogenesis of NSCLC 
(Hashida, Imajoh et al. 2013). Human Polyomavirus may be more prevalent in pathogenesis 
than previously thought. Studies from MPyV will provide crucial insights into the cellular 
and molecular biology of the many recently discovered human PyVs (DeCaprio and Garcea 
2013).  
 
1.9 MT Oncogenic Mouse Models 
In order to study the MT-driven tumorigenesis in specific tissues in vivo, Guy and co-workers 
constructed a PyV MT expression plasmid under the control of a mouse mammary tumour 
34 
 
virus (MMTV) promoter sequence (MMTV-PyV MT). Transgenic mice carrying the 
MMTV-PyV MT sequence express this oncoprotein in the mammary gland, which result in 
widespread spontaneous transformation of the mammary epithelium and rapid production of 
multifocal mammary adenocarcinomas (Guy, Cardiff et al. 1992). This is accompanied by 
strong metastasis potential to the lung of the majority of transgenic mice, which is a feature 
specific to breast cancer metastasis in human but rarely observed in other MMTV-oncogene 
based models, including MMTV-neu. Therefore MMTV-MT is a good model for human 
mammary cancer (Lin, Jones et al. 2003). Crossing MMTV-MT mice with transgenic mice 
lacking certain MT binding proteins allows the study of genetic requirement of MT-induced 
tumorigenesis. For example, crossing MMTV-MT mice with pp60c-src knockout mice 
demonstrated pp60c-src is an important target for mammary tumour formation in vivo. Mice 
lacking pp60c-src expression rarely developed mammary tumour while mice deficient in 
pp62c-yes developed tumours comparable rate to wild type when crossed with MMTV-MT 
mice (Guy, Muthuswamy et al. 1994). Transgenic mice with inducible MT expression using 
Cre-mediated recombination have also been achieved (Cecena, Wen et al. 2006). This allows 
localised, tissue-specific expressing of MT and has been a useful model for studying 
tumorigenesis in a broad range of tissues.  
 
1.10 MT Binding Proteins 
1.10.1 PP2A 
The N-terminus of MT contains the binding region for protein phosphatase 2A core dimer, 
which is made up of a catalytic subunit C or PR35 and a regulatory subunit A or PR65 
(Pallas, Shahrik et al. 1990). Cellular PP2A is a hetero-trimeric complex consist of a catalytic 
subunit C, a scaffolding subunit A and a regulatory subunit B (55 kDa). It is a major cellular 
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Ser/Thr protein phosphatase in eukaryotic cells and is involved in regulating a wide range of 
cellular function including transcription, replication, and can function as a tumour suppressor 
(Janssens and Goris 2001, Cheng, DeCaprio et al. 2009). The catalytic subunit C and 
regulatory subunit A each has two isoforms (α and β) while the other regulatory subunit come 
from a large family of B subunits (B, B’, B’’ and B’’’ family) therefore resulting in at least 
80 possible combinations.  
Binding to PP2A core dimer requires MT N-terminal region 110 – 190 (Martens, 
Nilsson et al. 1989, Glenn and Eckhart 1993, Campbell, Auger et al. 1995, Brewster, Glover 
et al. 1997). The two repeats of highly conserved Cysteine-rich motif (CXCXXC) in the 
region 80 – 191 on MPyV ST and MT are important for the binding to PP2A (Campbell, 
Auger et al. 1995). PP2A regulatory subunit B requires regions of the scaffold subunit A and 
the highly conserved carboxyl terminus of the catalytic subunit C. MT binding to PP2A core 
dimers is mediated through subunit A only and does not require regions in the C subunit 
(Ogris, Gibson et al. 1997). It is still not clear whether phosphatase activity is required for 
MT function. The N-terminal region required for PP2A binding is also required for 
association with the Src family of tyrosine kinases and transformation (Friedmann, Doolittle 
et al. 1978, Markland and Smith 1987). Glover et al., have identified a Serine (S195) and 
Threonine (T203) residue preceded by basic Arginine residues in the region 191 – 210 of 
MT, which is required for the association  of pp60c-src but not PP2A (Brewster, Glover et al. 
1997). Both S195 and T203 are de-phosphorylated in the complex with pp60c-src. It was 
suggested that PP2A may play a role in maintaining these residues in a de-phosphorylated 
state (Glover, Brewster et al. 1999). To support this, an inhibitor of the phosphatase reduced 
the amount of pp60c-src and the PP2A bound to MT. However, the PP2A core dimer 
containing inactive catalytic subunits can still associate with MT and form stable MT-PP2A- 
36 
 
p60c-src complexes in cells (Ogris, Mudrak et al. 1999). Therefore PP2A is more likely to 
provide a structural change for the recruitment of pp60c-src. 
It has been reported that MT-PP2A association changes the substrate specificity of the 
phosphatase, which become sensitive to phosphatase inhibitor, okadaic acid (OA), but 
insensitive to other PP2A-specific phosphatase inhibitor, inhibitor-1 and -2 (Cayla, Ballmer-
Hofer et al. 1993). PP2A subunits can be regulated through post-translational modifications 
such as phosphorylation (Chen, Martin et al. 1992), methylation of the C subunit (Bryant, 
Westphal et al. 1999) and ubiquitination (Trockenbacher, Suckow et al. 2001). Recently, it 
was observed that PP2A scaffolding subunit A forms a complex with de-ubiquitination 
protein USP28 in normal rat fibroblasts. Down-regulation of USP28 in MT-transformed cells 
resulted in raised level of mono-ubiquitinated PP2A without affecting the stability of the 
phosphatase (unpublished data). There may be many ways in which MT interaction changes 
substrate specificity of the PP2A core dimer. 
 
1.10.2 Src Family Tyrosine Kinase 
The potent transforming ability of MT is attributed to its association with Src family non-
receptor tyrosine kinases. Association with Src requires the N-terminal region of MT, which 
overlap largely with PP2A binding region. In addition to PP2A binding region, association 
with Src also requires residues 185 to 210 (Brewster, Glover et al. 1997, Glover, Brewster et 
al. 1999). In vitro translation of the first 220 amino acids of MT N-terminus was enough to 
form a complex containing PP2A and pp60c-src complex (unpublished data). However, the 
mechanism behind MT induced activation of Src tyrosine kinase is still not fully understood.  
 The src gene family has nine known members (blk, c-fgr, fyn, hck, lck, lyn, c-src, c-
yes and yrk), each encoding a cytoplasmic protein-tyrosine kinase involved in signal 
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transduction (reviewed by (Brickell 1992, Kefalas, Brown et al. 1995). Src is the most studied 
prototype of the family of 8 other closely related protein tyrosine kinases. The amino acid 
sequence of SFKs can be divided into four domains. The N-terminal sequence of pp60c-src 
contains a single myristoylation site that localise the protein tyrosine kinase to cell 
membranes. Some SFKs, like c pp62c-yes and pp59c-fyn are also palmitoylated in this 
region. Next to the N-terminal lipid modification domain is the unique domain, followed by a 
Src homology (SH) 3 domain, which recognises and binds specifically to Proline rich motifs 
with consensus sequence, PXXP; and then a SH2 domain that interacts with phospho-tyrosine 
motifs such as the consensus sequence pYEEI (Koch, Anderson et al. 1991). This is followed 
by the catalytic domain with C-terminal tail that contains a negative regulatory 
phosphorylation site at Y527. The SH2 domain of Src binding to its own phospho-tyrosine 
site prevents substrate access, thus locks the kinase in a closed conformation (Ingley 2008). 
The catalytic domain contains a kinase activation loop (A-loop) with an auto-activating 
Y416. Most of the Src tyrosine kinases in normal cells are phosphorylated on Y527, and are 
therefore inactive. pp60c-src association with MT requires the kinase domain and part of its 
C-terminal regulatory tail sequence around Y527, but the tyrosine kinase activity is not 
required (Cartwright, Eckhart et al. 1987, Dunant, Senften et al. 1996). As a result, v-Src, 
which lacks the regulatory tail region, cannot bind to MT (Cheng, Harvey et al. 1988). 
Despite being closely related, only selective members of the SFK associate with MT. MT 
encoded by MPyV preferentially associates with pp60c-src (Courtneidge and Smith 1983), 
pp62c-yes (Kornbluth, Sudol et al. 1987), and, to a lesser extent, pp59c-fyn (Cheng, Harvey et 
al. 1988, Kypta, Hemming et al. 1988) but not pp56c-lck (Louie, 1998) nor pp59/61hck 
(Dunant, Senften et al. 1996). However, HaPyV MT can only bind pp59c-fyn despite a high 
level of sequence homology in the N-terminal regions of the two MTs (Courtneidge, 
Goutebroze et al. 1991). This suggests different mechanisms are employed by the mouse and 
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hamster PyVMTs for their association with particular SFKs. Indeed, HaPyV MT binds to 
pp59c-fyn via the SH2 domain of the kinase and a phospho-tyrosine 324 in the unique region 
of HaPyV MT (Dunant, Senften et al. 1996) (Goutebroze, Dunant et al. 1997).  
MT itself is a major substrate for activated pp60c-src, which phosphorylates a number 
of tyrosines on MT. Three of the most well characterised phospho-tyrosine residues act as 
binding sites for adaptor protein Shc (Y250) (Campbell, Ogris et al. 1994, Dilworth, Brewster 
et al. 1994), the SH2 or Phospho Tyrosine Binding (PTB) domains of PI3K (Y315) 
(Whitman, Kaplan et al. 1985) and PLC-γ1 (Y322) (Su, Liu et al. 1995). 
 
1.10.3 PI3 Kinase 
The MT-associated PIK activity correlated well with transformation potential that was only 
observed in transformation-competent MT species (Whitman, Kaplan et al. 1985, Kaplan, 
Whitman et al. 1986). The PIK activity is associated with a prominent phosphorylated 
polypeptide of 85 kDa in size that immunoprecipitated with transformation-competent MT 
molecules. The polypeptide was later found to be the regulatory subunit of PI3K (Kaplan, 
Whitman et al. 1986, Courtneidge and Heber 1987). PI3K p85 was found phosphorylated 
upon PDGF stimulation, which provided the first link between MT transformation and RTK 
signalling. Therefore MT can be considered a permanently activated GFR (Dilworth 1995). 
PI3K p85 contains two SH2 domains, which bind to specific phospho-tyrosine on activated 
RTK (Escobedo, Kaplan et al. 1991, Hu, Margolis et al. 1992). Both SH2 domains can bind 
to phosphorylated Y315 on MT, which has a consensus sequence pYMPM (Kaplan, Whitman 
et al. 1986, Talmage, Freund et al. 1989). The N-terminal SH2 domain of p85 was used as a 
prototype for establishing specificity of the SH2 domain and have contributed to the 
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definition of Src-homology 2 domain (Birge, Fajardo et al. 1993, Dilworth 2002, Fluck and 
Schaffhausen 2009).  
PI3K is made up of an adaptor regulatory subunit p85 and a catalytic subunit p110 
(Carpenter, Auger et al. 1993). Binding of p85 to MT recruits p110 to the MT complex at the 
plasma membrane, which generates an increase in PIP3 level. Proteins with pleckstrin 
homology (PH) domain bind to PIP3 on the inner leaflet of the plasma membrane. Amongst 
these are phosphoinositide-dependent protein kinase 1 (PDPK1) and the Ser/Thr Kinase 
AKT. PDPK1 is a known activator of AKT by phosphorylating AKT on Thr308. Activated 
AKT in turn phosphorylates downstream targets regulating cell growth and DNA replication. 
One of these is the transcription factor E2F that promotes G1/S phase transition during cell 
cycle. Activated AKT can also block apoptosis by phosphorylating and inactivating the 
apoptosis regulator, BAD, hence promoting cell survival in cells expressing MT. Also 
activated is Rho GTPase Rac1, a PH domain-containing small GTP-binding protein involved 
in actin dynamics that promotes membrane ruffle formation upon GFR or H-Ras activation 
(Ridley and Hall 1992, Ridley, Paterson et al. 1992, Urich, Senften et al. 1997). Dominant 
negative mutants of Rac can block transformation by MT in fibroblasts and endothelial cells 
(Urich, Senften et al. 1997, Connolly, Soga et al. 2000). Rac activation is also required for 
MT to activate c-fos (Chen, Freund et al. 1999).  
It is not clear how PI3K is activated but there is evidence that the interaction between 
the p85 SH2 domains and phosphotyrosine can stimulate p110 PI3K activity (Carpenter, 
Auger et al. 1993). The PI3K regulatory subunit is encoded by two genes, resulting in two 
forms of p85, α and β. Both polypeptides can bind MT without any differences in MT 
function (Cohen, Liu et al. 1990, Cohen, Yoakim et al. 1990). PI3K catalytic subunit p110 
has three isoforms, α, β and δ. Only p110α is involved in MT transformation (Utermark, 
Schaffhausen et al. 2007). The PIK3CA gene encoding p110α is frequently mutated in many 
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types of cancer (Samuels and Velculescu 2004) whereas the PIK3CB gene, encoding p110β, 
is only amplified in some tumour type (Fluck and Schaffhausen 2009). PI3K p110α plays an 
important role in RTK signalling, while loss of p110β has little impact on RTK activation 
(Fritsch and Downward 2013). Instead p110β is essential for G protein coupled receptor 
(GPCR) signalling (Guillermet-Guibert, Bjorklof et al. 2008). Studies on transgenic mice 
with a tissue specific deletion of p110α gene found that the loss of p110α alone was enough 
to block tumour growth induced by MT, indicating that PI3K binding is essential for MT 
transformation (Utermark, Schaffhausen et al. 2007). MT as a strong and selective activator 
of p110α has attracted attention from the drug industry, in the light of developing specific 
inhibitors for this PI3K, which is heavily implicated in cancer formation (communication 
with Tom Roberts, DNA Tumour Virus Meeting 2013). 
 
1.10.4 Shc  
Phosphorylation of Y250 is important for MT transformation (Hunter, Hutchinson et al. 
1984). Mutation of Y250 and residues in the NPTY motif inhibited transformation without 
affecting binding to PP2A, Src and PI3K (Druker, Ling et al. 1990, Druker, Sibert et al. 
1992). Dilworth and others later demonstrated that Y250 is a binding site for adaptor protein 
Shc (Campbell, Ogris et al. 1994, Dilworth, Brewster et al. 1994), an SH-domain containing 
transforming protein coupled to activated GFR and become phosphorylated, which provides 
binding sites to recruit other adaptor proteins to activate mitogenic signalling (Pelicci, 
Lanfrancone et al. 1992, Yokote, Mori et al. 1994). Three shc genes have been identified. 
ShcA is ubiquitously expressed in mammalian cells, while ShcB and ShcC expression appear 
limited to neuronal cells (Ravichandran 2001). Shc family proteins have three isoforms, p46, 
p52 and p66 (Pelicci, Lanfrancone et al. 1992). MT binds to all three of them, with p52 as the 
most prominent MT binding partner (Campbell, Ogris et al. 1994, Dilworth, Brewster et al. 
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1994). Shc isoforms share common domain structure, an N-terminal PTB domain, a C-
terminal SH2 domain and a central collagen homology 1 (CH1) domain (Schlessinger and 
Lemmon 2003). Both PTB and SH2 domains can bind to phospho-tyrosine. Dilworth and co-
workers have demonstrated that both the p66 and p52 Shc associated with MT via SH2 
domain and become phosphorylated, probably by pp60c-src (Dilworth, Brewster et al. 1994). 
Shc can be phosphorylated on at least 3 tyrosine residues, Y317, Y239 and Y240, all of 
which are phosphorylated in complex with MT. These phospho-tyrosine residues are located 
at the central CH1 domain, which interact with the SH2 domain of adapter protein Grb2, 
which is recruited to the MT signalling complex (Nicholson, Empereur et al. 2001). 
Association with Grb2 is important for MT transformation as it provides the means by which 
MT stimulates the MAPK pathway (Rozakis-Adcock, McGlade et al. 1992, Dilworth 2002). 
Although replacement of sequence surrounding Y250 on MT with that of Shc Y317 or 
Y239/Y240 allows direct binding between MT and Grb2, it requires the presence of both Shc 
tyrosine motifs on the same polypeptide in order to fully reconstitute the transforming 
potential of MT (Nicholson, Empereur et al. 2001). Therefore, association with ShcA is 
indispensible for MT to propagate mitogenic signals. 
 Grb2 bound to MT is phosphorylated on multiple sites and allows more signalling 
proteins to bind. With its SH3 domains, Grb2 can associate with Sos1 guanine nucleotide 
exchange factor as well as the docking molecule Gab1 and 2. Sos1 mainly associates with the 
N-terminal SH3 while the C-terminal SH3 domain of Grb2 interacts with Gab1, an insulin-
receptor substrate-1 –like docking protein (Nicholson, Empereur et al. 2001).  
In MT transformed cells, Gab1 is constitutively tyrosine phosphorylated while it is 
barely detectable in normal non-stimulated cells (Ong, Dilworth et al. 2001). Gab1 associated 
with MT signalling complex is tyrosine phosphorylated, which provides binding sites for 
other SH2/PTB domain-containing proteins such as PI3K and SHP2, a protein tyrosine 
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phosphatase (Nicholson, Empereur et al. 2001, Ong, Dilworth et al. 2001). Loss of ShcA 
binding resulted in a marked decrease in MT-associated PI3K activity (Ong, Dilworth et al. 
2001). Therefore MT can recruit PI3K directly or indirectly through ShcA-Grb2-Gab1 
complex (Ong, Dilworth et al. 2001). A recent report has shown protein tyrosine phosphatase 
SHP2 can inhibit MT induced transformation by inhibiting Stat3 activity in endothelial cells 
(Yang, Jiang et al.). The presence of SHP2 in MT signalling complex also raises the question 
of whether this tyrosine phosphatase play a role in the removal of regulatory pY527 on C-
terminal tail of c-Src thus priming the tyrosine kinase for MT binding (Yang, Jiang et al.).  
 
1.10.5 PLC-γ1 
Phospholipase C-γ1 (PLC-γ1) binds to phosphorylated Y322 on MT via an SH2 domains, 
which recognises the motif YLDI at the third major phosphor-tyrosine site (Y322) (Su, Liu et 
al. 1995). MT transfected cells show elevated level of tyrosine phosphorylated PLC-γ1. 
Activated PLC-γ1 catalyses the conversion of PIP2 to DAG and IP3. IP3 stimulates an 
increase of Ca
2+
 level inside the cell and subsequent calcium dependent signalling pathways. 
DAG activates PKC family of protein kinase. The role of PLC-γ1 in MT signalling is not yet 
clear. Loss of Y322 in MT has limited effect on MT transformation of adherent cell. 
However, in immune cells, PLC-γ1 association and activation alone is sufficient for the 
activation of IL-2 promoter and NEAT transcription factor, which is normally stimulated by 
T-cell receptor activation (Kennedy, Sekulic et al. 1998). In MMTV-MT breast cancer model, 
dominant negative PLC-γ1 expression reduced lung metastasis in mice (Shepard, Kassis et al. 
2007). Therefore the contribution of PLC-γ1 activation to MT transformation is probably cell 
type dependent. 
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1.10.6 Regulatory Protein 14-3-3 
Serine 257 is another major phosphorylation site on wild type MT and is a binding site for 
cytoplasmic regulatory protein 14-3-3 (Pallas, Fu et al. 1994, Cullere, Rose et al. 1998). 
However it is not clear which kinase phosphorylates this residue. Lack of 14-3-3 binding had 
little effect on MT transformation of cells in culture and only had tissue-specific reduction in 
MT-induced tumour formation in vivo (Cullere, Rose et al. 1998). S257C MT is defective in 
inducing salivary gland tumours when inoculated into new-born mice (Cullere, Rose et al. 
1998). 14-3-3 family proteins are highly conserved ubiquitously expressed regulatory 
proteins that play a functional role in subcellular localisation of target proteins. They form 
homo- and hetero-dimeric cup-shape structures to bind to phospho-serine on target proteins, 
often transcription activators such as TAZ (transcriptional co-activation with PDZ-binding 
motif) and regulate their functions by sequestering in cytoplasm, often by masking the 
nuclear import/export sequence (Kanai, Marignani et al. 2000). Because each monomer in 
dimeric 14-3-3 can bind phospho-serine at the same time, it was thought to induce 
dimerisation of MT molecules. Using cell lines co-expressing mutant MT, Senften and co-
workers showed that MT capable of membrane association and 14-3-3 binding can be co-
immunoprecipitated. However, the ability to co-immunoprecipitated with one another is 
essential for MT transformation (Senften, Dilworth et al. 1997). MT mutant, dl8, lacking 14-
3-3 binding site transforms fibroblasts with efficacy even greater than wild type and are 
known for forming unusually large colonies in soft agar (communication with Dilworth and 
Schaffhausen).  
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1.11 Proline –rich Region 
Several reviews have noted a Proline-rich region from residue 332-347, C-terminal to PLC-
γ1 binding region and N-terminal the TMD. This region contains three consecutive Proline 
residues surrounded by very hydrophobic amino acids (Fluck and Schaffhausen 2009, 
Schaffhausen and Roberts 2009). A deletion mutant, dl1015, in this region (339-347) is 
defective in transforming cells in culture despite its association with normal tyrosine kinase 
activity and binds to all known MT-associating proteins (Magnusson and Berg 1979, 
Magnusson, Nilsson et al. 1981) (unpublished data). It was suggested that signalling 
downstream of PI3K may have been affected by mutation in the Proline-rich region (Fluck 
and Schaffhausen 2009).   
 
1.12 Additional Tyrosine Phosphorylation 
Additional phospho-tyrosine sites (Y258, Y288 and Y297) have been identified in MT. MT-
induced transcriptional activities were only completely lost when all six tyrosine sites were 
abolished. This suggests some unknown functions associating with these minor phospho-
tyrosines, which are likely to overlap with the pathways from the three major phospho-
tyrosine sites. All three relatively minor tyrosines are located between the Y250 Shc binding 
site and Y315 PI3K p85 binding site. It has been shown previously that this region on MT 
can be mutated without affecting transformation (Nicholson, Empereur et al. 2001, Ong, 
Dilworth et al. 2001). 
Despite such long history of research on MT, not all MT associated proteins and 
downstream effecter proteins have been found. Additional knowledge on how MT mediates 
oncogenic signalling will continue to benefit our understanding of normal and aberrant 
signalling events induced by growth factor activation. 
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1.13 Subcellular Localisation of MT 
Early sucrose gradient fractionation experiment showed that [S
35
] methionine-labelled MT 
and associated Src tyrosine kinase activity are mostly found in the plasma membrane. Some 
were observed in the ER fraction but little was associated with the mitochondrial or heavy 
membrane fractions or with the soluble proteins (Schaffhausen 1982). Using immuno-
electron microscopy method, it was shown that a fraction of the MT was found in the plasma 
membrane with majority of the protein found in ER membranes (Dilworth, Hansson et al. 
1986). These contradictory observations may be attributed to the use of virally infected cells 
in the later experiment, which is more representative of the location of newly synthesised 
MT. Therefore, the ER probably represents the location where MT was first synthesised. 
Migration of newly synthesised MT to the plasma membrane is a slow process. In virally 
infected fibroblasts, MT was observed in the ER as early 10 hrs post-infection. After 20 hrs, 
large amount of MT was found in the ER of most cells. Only after 30 – 40 hrs after infection, 
can the viral protein reach the plasma membrane in high amount (Dilworth, Hansson et al. 
1986). It is still not clear whether MT-induced transformation signals are generated from the 
plasma membrane, like the classical model of growth factor signalling (Hoeller, Volarevic et 
al. 2005), or intracellular membrane compartments, such as the strategy used by bovine 
papilloma virus (BPV) oncoprotein E5 (Sparkowski, Anders et al. 1995).  BPV E5 is another 
viral oncoprotein that binds to membrane and transforms human and rodent fibroblasts in 
culture (DiMaio and Mattoon 2001). It exists as a homodimer via a disulphide linkage 
between two Cysteine residues on the short C-terminal tail orientated towards the Golgi 
lumen and this dimer formation is important for transformation (Burkhardt, DiMaio et al. 
1987, Zhang, Lewis et al. 1987). BPV E5 is localised to the ER and Golgi membranes, where 
it binds mainly to the immature form of the PDGFRβ and promotes ligand-independent 
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activation of the receptor (Goldstein, et al., 1992a, Goldstein, Kulke et al. 1992, Sparkowski, 
Anders et al. 1995). Mutants of E5 that localise in the ER can interact with the immature 
PDGFRβ and induce autophosphorylation but this does not cause transformation. The 
transformation signals induced by BPV E5 therefore are generated in the Golgi apparatus 
(Sparkowski, Anders et al. 1995). 
In normal cells, the classical model of growth factor signalling involves the binding of 
ligand to growth factor receptor monomers, dimers or multimers on the surface of the plasma 
membrane, which induces a conformational change of the intracellular domain of the receptor 
that leads to tyrosine kinase activation either on the RTK or through the recruitment of 
protein tyrosine kinases. This in turn leads to the recruitment of effector proteins to the 
activated receptor complexes at the plasma membrane. This  assembly of multi-component 
active signalling complexes, termed ‘signalosomes,’ in the plasma membrane is thought to be 
where downstream signalling cascades are initiated (Hoeller, Volarevic et al. 2005). 
Activation of growth factor signalling is a tightly regulated and often transient. Growth factor 
receptors such as EGFR1 and PDGFRβ are rapidly internalised following their ligand-
stimulated activation. The internalised receptors and ligand may be degraded by trafficking to 
lysosomes or recycled back to the cell surface after dissociation and degradation of the 
ligands via a subset of intracellular vesicles. Receptors can be internalised through clathrin-
coated pits into EEA-1 positive endosomes, or caveolae, which are clathrin-independent 
membrane invaginations formed by caveolin-1 coated membrane domains. Receptors may 
continue to signal in endosomal compartments. Some activated EGFR are internalised into 
early endosomes carrying APPL-1, an effector of GTPase Rab5. The EGF stimulated APPL-1 
subsequently translocate to the nuclei where it regulates cell proliferation (Miaczynska, 
Christoforidis et al. 2004). Other cell surface receptors such as transferrin receptor do not 
enter APPL-positive endosomes (Miaczynska, Christoforidis et al. 2004). There is some 
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evidence to suggest that receptors such as EGFR and PDGFRβ located in the endosomes can 
activate MAPK and AKT signalling pathways albeit at much lower magnitude compared to 
those at the cell surface (Wang, Pennock et al. 2002, Wang, Pennock et al. 2004). MT is 
located in most intracellular membranes except the mitochondria. It is not clear whether MT 
molecules in the intracellular membrane compartments are actively generating mitogenic 
signals.  
 
1.14 Cytoskeletons and Focal Adhesion Complexes 
Cells expressing MT appear transformed, which may be a result of increased microtubule 
instability and diminished actin stress fibres (da Costa, Wang et al. 2000). Cytoskeleton re-
organisation is an important process for cell adhesion and migration. It is not clear whether 
MT directly or indirectly influences cytoskeletal structures. Some reports suggest that MT 
may associate with actin or actin binding proteins directly. Early antibodies raised against the 
MT sequence surrounding the PI3K p85binding site have been found to immune-label 
microfilaments in untransformed cells similar to those labelled with anti-actin antibodies 
(Sugawara, Fujinaga et al. 1983). In a later study, phosphorylated MT molecules were 
immunoprecipitated by anti-vinculin serum (Ballmer-Hofer, Ziegler et al. 1988). Vinculin is 
an actin-binding protein, which mostly localises to focal contacts. These are sites of focal 
adhesion which anchors the cell basal membrane to the extracellular matrix. Focal adhesion is 
mediated by integrin binding to fibronectin in the extracellular matrix (ECM) or other 
integrin molecules on the surface of adjacent cells, which then activates distinct integrin-
associated signalling molecules, such as integrin-linked kinase (ILK), focal adhesion kinase 
(FAK) and c-Src. Integrin also connects to the actin cytoskeleton via a wide range of actin-
binding proteins including vinculin and affects cell movement by re-modelling the actin 
cytoskeleton. It has been suggested that MT/pp60c-src complexes may be bound to vinculin 
48 
 
at focal contacts, as was found with v-Src, which may contribute to the disorganisation of 
actin filament network required for transformation morphology (Ballmer-Hofer, Ziegler et al. 
1988). Normal migration in polarised cells involves regulated actin cytoskeleton 
rearrangement with coordinated focal adhesion assembly and disassembly. Actin 
polymerisation into actin bundles or stress fibres forms protrusions at the leading edge of the 
cell. Focal adhesion complex assembly is important for the cell to lay down new processes in 
the direction of migration. Disassembly of focal adhesion complexes and actin stress fibres at 
the rear of the cell are required to release the bulk of the cell for it to move forward (reviewed 
by Wehrle-Haller 2012). 
 
1.14.1 Focal Adhesion Kinase 
In cancer cells, many of the components involved in cell migration and adhesion are 
deregulated, which may lead to enhanced migration potential and metastasis (Wehrle-Haller 
2012, Wehrle-Haller 2012). One of these components is FAK, a protein tyrosine kinase 
localised to focal adhesion sites. Upon integrin complexes engagement on the ECM, FAK is 
recruited to the integrin cluster and is phosphorylated. Its activation plays an important step 
in initiating cell migration. FAK is highly phosphorylated in v-src transformed chicken 
fibroblasts and rat fibroblast transformed by MT (Kanner, Reynolds et al. 1990, Guan and 
Shalloway 1992, Bachelot, Rameh et al. 1996). Similar to Src family tyrosine kinases, FAK 
activity is stimulated by the removal of an auto-regulatory domain from the central kinase 
region and the phosphorylation of a tyrosine residue on the activation loop. Unlike Src, FAK 
lacks SH2 and SH3 domains and does not possess a myristoylation site. The focal adhesion 
targeting (FAT) domain at the C-terminus is responsible for the localisation of FAK to focal 
adhesion plaques probably through interaction with actin-linker proteins such as talin and 
paxillin (reviewed by Zhao and Guan 2009). The N-terminal region of FAK contains a 
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FERM domain that binds to the cytoplasmic domain of integrin β or other activators. Upon 
engagement with integrin, FAK is phosphorylated on Y576 within the activation loop of its 
kinase domain. Once activated, FAK auto-phosphorylates on Y397, which serves as a 
binding site for the SH2 domain of activated pp60c-src and pp59c-fyn non-receptor tyrosine 
kinases (Cobb, Schaller et al. 1994, Schlaepfer and Hunter 1996), which can then 
phosphorylate FAK on multiple sites on the FAK C-terminus to create additional binding 
sites for signalling molecules such as Grb2 and the PI3K p85 subunit (Schlaepfer, Hanks et 
al. 1994, Bachelot, Rameh et al. 1996). Src is also activated by binding to FAK phospho-
Y397 as a result of displacing the auto-inhibitory Y527 of Src from its kinase domain. 
Therefore, FAK and Src tyrosine kinases can be mutually activated to propagate a wide range 
of signalling events. In addition to integrin, FAK has been found to interact with activated 
PDGF, EGF and HGF receptors via its N-terminal FERM domain. FAK association with 
these growth factor receptors is important for ligand stimulated cell migration (Sieg, Hauck et 
al. 2000). Therefore FAK mediates cross talk between integrin and growth factor receptor 
signalling.  
Given the similarity between MT mitogenic signalling and growth factor activation, 
there are likely to be many ways by which FAK can be recruited to the MT signalling 
complex. However, direct interaction between MT and FAK has not been reported. Also, the 
role of FAK in normal and oncogenic signalling is unclear. Over-expression, deletion or 
deregulation of FAK catalytic activity did not affect normal cell growth or morphology 
(Hildebrand, Schaller et al. 1993). However, deletion of FAK inhibits tumorigenesis in 
MMTV- MT, -Ras and Neu mouse model by induces apoptosis in tumour cells (Pylayeva, 
Gillen et al. 2009).  
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1.14.2 Vinculin 
Vinculin is a membrane associated cytoskeletal protein found in focal adhesion plaques, 
which are large focal adhesion complexes at the cell periphery. It plays an important role in 
linking integrin adhesion molecules to the actin cytoskeleton. The association of receptors 
with the actin cytoskeleton is often mediated by cytoskeletal proteins, such as talin, vinculin, 
paxillin and α-actinin. Using a GFP fusion with the PI3K subunit p85, Gullick and co-
workers showed that EGF-ligand stimulation redistributed PI3K to the peripheral cell 
membrane, where it colocalises with vinculin (Gillham, Golding et al. 1999). Vinculin plays 
an important role in regulating migration, transmitting mechanical signals and establishing 
cell polarity (Carisey, Tsang et al. 2013). Vinculin consists of head and tail domains 
separated by a flexible Proline-rich neck region. In the inactive form, the head and tail 
domain bind to each other by intramolecular interaction, forming a globular structure, which 
prevents vinculin from binding to the cytoskeleton and to receptors (Johnson and Craig 
1994). Stable integrin complex formation at the sites of focal adhesion is often accompanied 
by a high concentration of talin and vinculin at the plasma membrane (Burridge, Molony et 
al. 1987). Talin contains both a FERM domain for interaction with the integrin β cytoplasmic 
tail and a vinculin binding site.  Upon recruitment to the integrin-talin complex at focal 
adhesions, vinculin adopts an open, rod-like conformation that allows access to its binding 
partners. Other examples of vinculin binding proteins include α-actinin that binds to the head 
domain; Arp2/3, an actin nucleation factor, that binds to the neck region; filamentous or F-
actin, paxillin and PIP2 that bind to the tail domain (Humphries, Wang et al. 2007, Carisey, 
Tsang et al. 2013).  
 
51 
 
1.14.3 Integrin 
Adhesion molecules such as integrin have been heavily implicated in tumour initiation and 
metastasis. Integrins are integral transmembrane proteins complexes consisting of 
heterodimeric α and β subunits. The long extracellular domain of integrin binds to 
components of extracellular matrix (ECM). The short cytoplasmic tails of integrin serves as a 
platform for the recruitment of protein tyrosine kinases including FAK and Src, and actin 
binding proteins. In mammalian cells there are 8 isoforms of each subunit. Antibody –
induced integrin clustering and adhesion to fibronectin coincides with FAK activation and its 
recruitment to focal adhesion plaques (Kornberg, Earp et al. 1992). Integrin β1 - FAK 
signalling has been shown to activate cyclin-dependent kinases and is implicated in the 
proliferation of mammary epithelial cells (Li, Zhang et al. 2005). Integrin β1 has been shown 
to be required for mammary gland tumorigenesis in MMTV-MT mice but not the MMTV-
Neu strain, although β1 integrin is required for metastasis at a later stage of MMTV-Neu 
induced mammary gland carcinoma (White, Kurpios et al. 2004, Huck, Pontier et al. 2010). 
Ablation of β1 integrin limits the proliferative capacity of cells derived from established 
tumours driven by MT (White, Kurpios et al. 2004). 
 
1.15 Lipid Rafts 
Cellular membranes can be divided into regions or domains with distinctive features, 
according to their lipid composition or resident proteins, which differentiate them from the 
contiguous membrane (Anderson and Jacobson 2002). Membrane regions enriched with 
bulky lipids such as cholesterol, which increase the rigidity of phospholipid bilayer, serve to 
attract and accommodate integral membrane proteins and proteins with lipid modifications. 
Lipid rafts is a term that is generally used to describe these micro-domains that are rich in 
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glycosphingolipids, sphingomyelin, or glycoproteins. They are detergent insoluble and their 
functions are dependent on cholesterol (Carter and Hakomori 1981, Chang, Rothberg et al. 
1992).  
Some membrane proteins are targeted to cholesterol-rich lipid rafts. Several 
mechanisms have been proposed, namely lipid modification especially acylation, 
palmitoylation, and the interaction between TMD sequence and membrane lipids (Scheiffele, 
Roth et al. 1997, Melkonian, Ostermeyer et al. 1999); (Levental, Lingwood et al. 2010). 
Interestingly, a lipid modification sequence, CAAX box at the C-terminus of H-Ras can 
functionally replace the C-terminus of MT (Elliott, Jones et al. 1998), which seems to suggest 
a common specificity to MT and H-Ras membrane binding. Ras GTPases have been widely 
used as a model to study cluster formation on the inner leaflet of the plasma membrane. H-
Ras and K-Ras have been shown to form distinct separate nano-clusters, mediate by their C-
terminal lipid modifications. Wild type H-Ras normally resides in both lipid rafts and 
cholesterol-independent microdomains in an equilibrium (Prior, Muncke et al. 2003). But 
nano-clusters of activated H-Ras, when it is GTP-bound, are cholesterol-independent 
therefore it was thought that the activated H-Ras has lower affinity for lipid rafts (Yang, 
Nickerson et al. 2012). H-Ras is targeted to the membrane by the C-terminal CAAX box. The 
Cysteine in the CAAX box is farnesylated. Farnesylpyrophosphate is a lipid intermediate in 
the cholesterol biosynthesis pathway. The final three residues, –AAX, is removed by 
proteolytic cleavage and the C-terminal Cysteine can then be methylated (Hancock, Magee et 
al. 1989). There are two additional Cysteine residues immediately upstream of the CAAX 
box, which can be palmitoylated and this targets H-Ras to cholesterol –dependent lipid rafts 
(Hancock, Magee et al. 1989). K-Ras, which lacks palmitoylation sites, is localised at 
cholesterol-independent non-raft micro-domains. Palmitoylation can be reverted by 
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thioesterases, and the state of palmitoylation of H-Ras influences its location to cholesterol-
dependent or cholesterol-independent microdomains (Yang, Nickerson et al. 2012). 
Other examples of well defined raft-like domains in the plasma membrane include 
clathrin or caveolin-1 coated membrane micro-domains involved in endocytosis. Caveolae is 
a well-studied raft structure. These are flask-shaped membrane structures lined with caveolin-
1 on the inner leaflet of the plasma membrane. They sequester both small or macro-
complexes of cell surface receptors and internalise them upon ligand binding, a process that 
differs from clathrin-dependent endocytosis and is sometimes described as potocytosis 
(Mineo and Anderson 2001). It has been proposed that caveolae rafts measuring 50 to 200 nm 
in size can aggregate to form even larger lipid domains that function to segregate membrane 
proteins during cell signalling and endocytosis (Anderson and Jacobson 2002). 
The bulky hydrophobic residues of the TMD of membrane proteins that are located 
near the outer leaflet of the lipid bilayer could shape the TMD structure in a way to 
accommodate cholesterol in the microdomain (Scheiffele, Roth et al. 1997). The hydrophobic 
sequence near the C-terminus of MT is enriched with residues with bulky side chains 
(ICLMLFILI) but it is not known whether MT activated partition into cholesterol-rich 
microdomains (see Figure 1.3 below for TMD sequence and supplementary figure S2.1 for 
complete MT protein sequence). 
 
1.16 Membrane Localisation Region 
Membrane localisation of MT was first reported by Ito et al (Ito, Brocklehurst et al. 1977). 
Association with the cell membrane is absolutely required for MT to induce cellular 
transformation (Novak and Griffin 1981, Carmichael, Schaffhausen et al. 1982). MT with a 
truncated C-terminal region was unable to transform (Carmichael, Schaffhausen et al. 1982). 
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Membrane binding requires a 22 residue stretch of hydrophobic amino acids located near to 
the MT C-terminus (Soeda, Arrand et al. 1979) (see underlined sequence in Figure 1.3 or 
supplementary figure S2.1 for complete MT protein sequence ). The C-terminal membrane 
anchoring sequence is flanked on each side by positively charged amino acids, see Figure 1.3. 
The positively charged Arginine residues are important for MT transformation (Dahl, 
Thathamangalam et al. 1992). Glutamate substitution of the Arginine immediate N-terminal 
to the hydrophobic sequence abolished MT transformation potential (Dahl, Thathamangalam 
et al. 1992). However, it is not clear why the Arginine-rich sequence is important, although 
interaction with the cytoskeleton has been suggested. The basic residues C-terminal to the 
hydrophobic sequence can be deleted without affecting transformation  (Dahl, 
Thathamangalam et al. 1992). However, some past mutants generated in our lab with 
mutations made to the hexapeptide have suggested otherwise (unpublished observation). 
 
AHSM QRHLRRLGRTLLLVTFLAALLGICLMLFILIKRSRHF           C-terminus 
 
Despite a number of attempts, MT was undetectable on the outside of cells, so it was 
proposed that it is probably situated on the cytoplasmic face of the membrane since it was not 
degraded by trypsin in intact cells and was only phosphorylated when cells were made 
permeable before in vitro [γ-32P] ATP labelling (Schaffhausen, Dorai et al. 1982). It is not 
clear how the MT C-terminus is inserted into the membrane. Some proteins spontaneously 
insert into the membrane, for example, cytochrome b5. Using isolated microsomes, Kim et 
al., have demonstrated that MT TMD does not insert into the membrane spontaneously. 
Therefore, MT probably requires an active insertion mechanism. Those TMDs that passively/ 
Figure 1.3 Transmembrane domain sequence of MT 
Above sequence represents residue 381 to 421 on the C-terminus of MT. The hydrophobic sequence is 
underlined and is followed by a hexapeptide. Basic amino acids surrounding the hydrophobic sequence 
are in bold. 
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spontaneously insert into the membrane tend to form hair-pin structures in the membrane 
(Kim, Janiak-Spens et al. 1997). Therefore, the C-terminus of MT probably spans the lipid 
bilayer, however, this is not proven for MT. Efforts to generate monoclonal antibodies 
targeting the MT C-terminus have not succeeded so far (unpublished data). 
MT with a truncated C-terminus is found mostly in the soluble fraction (Carmichael, 
Schaffhausen et al. 1982). Although this mutant can still bind to PP2A core dimers, it fails to 
associate with any of the c-Src tyrosine kinases. However, it was later found that MT 
molecules that fail to associate with membranes were relocated to the nucleus, probably 
through interaction with PP2A, as a double mutant lacking both PP2A binding region and the 
C-terminus showed a cytoplasmic distribution (Glover, Brewster et al. 1999). Therefore, 
although MT does not seem to be targeted to a particular intracellular compartment, the 
ability to bind PP2A seems to influence MT localisation. Further work is needed to 
investigate the requirement for membrane targeting mechanism and the role of the MT 
hydrophobic region.  
 MT is located in most cell membranes (Dilworth, Hansson et al. 1986), so the 
hydrophobic region presumably does not seem to target one specific membrane compartment 
site. However, this region must do more than specify general membrane association, as 
hydrophobic domain mutants have been isolated that still bind to membranes but fail to 
transform (Markland, Oostra et al. 1986). Similarly, replacement with the transmembrane 
region from vesicular stomatitis virus glycoprotein G (Templeton, Voronova et al. 1984)or 
cytochrome b5 (Kim, Janiak-Spens et al. 1997), resulted in transformation defective mutants 
that still associate with the membrane. So far, only the lipid modified CAAX sequence at the 
C-terminus of H-Ras can functionally replace the C-terminus of MT (Elliott, Jones et al. 
1998). CAAX box is responsible for targeting H-Ras to cholesterol-dependent lipid rafts (see 
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1.14 above). Consequently, it is likely that the hydrophobic domain in MT does more than 
target generalised membrane location, but what this extra activity consists of is unknown. 
The similarity between MT and activated tyrosine-kinase-associated growth factor 
receptors are striking. Both are membrane bound. When phosphorylated on multiple tyrosine 
residues both GFR and MT act as docking sites for the recruitment and activation of cellular 
signalling proteins such as PI3K and PLC-γ1 as well as bringing adaptor protein SHC to the 
complex to form a scaffolding for signal propagation. However, many GFRs such as the 
EGFR family and PDGFR family growth factor receptors dimerise upon ligand binding to the 
extracellular domains. It is not yet established whether MT TMD sequence mediates 
dimerisation in the way of RTK activation and whether dimerisation is required for MT 
transformation. However, it has been shown that dimer formation between MT molecules 
requires association with 14-3-3, but mutants lacking 14-3-3 binding site transformed cell just 
as well if not better (Senften, Dilworth et al. 1997). Some RTKs such as the EGFR family 
receptor kinases are well known for their ability to homo- or hetero-dimerise, through the 
interaction of their transmembrane α-helices. It is not known whether MT TMD can interact 
with other transmembrane proteins, although it has been recently reported that MT 
immunoprecipitates with insulin receptor and IGF-I receptors in tumours derived from 
MMTV-MT mouse models and this association seems to be required for the formation of new 
tumours (Novosyadlyy, Vijayakumar et al. 2009). 
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1.17 Aims:  
The aim of this project is to study the role of the TMD sequence that is specific for MT 
function. In particular: 
i) to clarify the topology of MT C-terminus and how the MT hydrophobic sequence is 
inserted into the membrane; 
 ii) to investigate in which compartment of the cell that transformation signals are generated; 
iii) with the aid of site directed mutagenesis, to identify any additional property encoded by 
the TMD that is important for MT transformation; 
iv) to relate our results to growth factor receptor signalling. 
 
 
58 
 
CHAPTER 2 - MATERIAL AND METHODS 
 
2.1 Cell Culture 
Rat2 rat fibroblast cell line was maintained in Dulbecco’s Modified Eagles Medium 
(DMEM), high glucose (Invitrogen 41965, + D-glucose, + L-glutamine, - pyruvate) 
supplemented with 0.29 mg/ml L-glutamine, 100 units of penicillin, 100 µg streptomycin 
(from Gibco® 100x Penicillin-Streptomycin-Glutamine stock and 10% foetal bovine serum 
(FBS), and incubated at 37
o
C and 10% CO2.  
 To freeze cells for long term storage, trypsinised cells were collected to the bottom of 
15ml Falcon tube by centrifugation then re-suspended in DMEM with 20% FBS, + 10% 
dimethylsulfoxide (DMSO) (Sigma).  
 Inhibitors used in this project can be found in supplementary Table ST 2.4. 
 
2.2 Plasmids 
All mutations were made to the pUC MT plasmid, consisting of vector pUC19 containing the 
BamHI–EcoRI fragment of polyomavirus lacking the MT intron (Nicholson, Empereur et al. 
2001).  
 In vitro transcription requires T7 promoter. Wild type MT or MTKDEL cDNA were 
cloned into pcDNA3.1 from BlpI to EcoRI site after excision from pUC MT plasmids. 
 pYX containing mouse ASNA1 cDNA cloned into NotI to EcoRI restriction sites 
(pYX-Asc) was obtained through Open Biosystems (clone ID:5717763). Plasmid contains 
both T3 and T7 promoters. 
N-terminal 2XMYC-tagged human Ras family small GTP binding protein H-Ras 
G12V (constitutively active) cloned into pcDNA3.1+ at KpnI (5’) and XhoI (3’) was 
obtained from UMR cDNA Resource Centre, University of Missouri-Rolla. The 
constitutively activated mutant H-Ras (G12V) with Myc–tag is expressed under CMV 
promoter. 
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2.3 Mutant Generation 
To construct wild-type MT with a FLAG tag, A forward primer (HA for), which is an exact 
match to the MT cDNA sequence upstream of the hydrophobic domain-encoding region, was 
used together with a reverse primer that contained an EcoRI site and the sequence encoding 
the FLAG tag (DYKDDDDK), and a priming sequence that matches MT C-terminus coding 
sequence. PCR reaction was performed with 4ng pUC MT and 20ng appropriate forward and 
reverse oligos using Phusion polymerase (NEB) according to manufacturer’s conditions.  
PCR conditions: step 1: 94
o
C for 180 sec; step 2: 94
o
C for 45 sec; step 3: 57
o
C for 60 
sec; step 4: 72
o
C for 120 sec; step 5: 25 cycles from step 2. The reaction was finished off by 
incubation at 72
o
C for 600 sec.  
 The PCR productsand pUC19MT plasmids were digested with restriction enzymes 
BlpI and EcoRI (NEB) in Buffer 4. Digested fragments were purified by 1% Agarose gel 
electrophoresis followed by Qiagen Gel Extraction kit. The purified fragments of PCR 
products and large fragment of pUC19 MT double-digest products were combined and 
ligation was performed at room temperate (RT) with Quick Ligase (NEB). The resulting 
plasmids were transformed into 50 µl chemically competent DH5α E.coli in LB broth by 
incubation on ice for 40 min before heat-shock at 42
o
C for 60 sec, followed by 5 min 
incubation on ice. 250 µl LB media without ampicillin and incubated at 37
o
C with shaking 
for 2 hrs. 100 µl of the transformed bacteria were spread and grown over night on LB-agar 
containing ampicillin. Plasmid DNA was purified using QIAprep Spin Miniprep Kit for 
clonal selection and Qiagen HiSpeed Mini prep for subsequent large scale purification. ∆416-
421 MT and 416G6 MTHA+ were generated using a similar method (see supplementary table 
ST2.1 – 2.3 for primer sequences).  
All mutants were verified as correct by DNA sequencing before use. Sequencing data 
were obtained using Imperial College MRC CSC Genomics Core Laboratory service. DNA 
sequences were analysed by EditSeq DNASTAR software. The complete protein sequence of 
MT can be found in supplementary figure S2.1. 
 
2.4 Agarose Gel Electrophoresis 
50 ml of Agarose was prepared by dissolving 0.5 g agarose powder in 50 ml 1x Tris Borate 
EDTA (TBE). 5 µl of nucleic acid stain (SafeView) was added to the 0.9 % agarose solution 
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highlight the DNA. The agarose solution was poured into a gel tank with a gel comb and the 
gel was left to set. 1x TBE buffer was poured to cover the gel after setting.   0.5 - 2 µg of 
DNA sample was added to 6x DNA loading buffer (NEB, B7021S). The gel was run at 50V 
and 50mA for 30 min or until the bromophenol blue dye run to the middle of the gel. The gel 
was removed and place on top of a UV light box to visualise the DNA. The band containing 
PCR products was excised into a clean, pre-weighed 1.5 ml eppendorf tube using a clean 
scalpel. DNA was extracted by Qiagen Gel Extraction kit according to manufacturer’s 
protocol. .  
 
2.5 Ethanol Precipitation of DNA 
After confirming plasmid sequence for cloned MT sequence, scale-up productions of 
appropriate plasmids was carried out using HiSpeed Plasmid Midi kit (Qiagen). The purified 
plasmids were then concentrated to 1 µg/µl. Concentrations of plasmid was measured by 
NanoDrop ND-1000 Spectrophotometer, UV absorbance wavelength = 260 nm. 1 volume of 
purified plasmids were mixed with 1/10 volume of 3 M sodium acetate pH 6.5, followed by 2 
x volumes of 100% ethanol, then stored at – 20oC overnight. The precipitated DNA was 
centrifuged at 13,000x g for 10 min. Supernatant was discarded and 0.5 ml of 70% ethanol 
was added to remove residual salts. After 5 min incubation at RT, the mixture was 
centrifuged at 13,000x g for 5 min. Supernatant was removed and the pellet of DNA was 
allowed to air-dry at RT. The dried DNA was re-suspended in sterile 10 mM Tris-HCl pH7.4 
to a final concentration of 1 µg/µl. Concentrations of plasmids were re-assessed by 
NanoDrop. 
 
2.6 Foci Formation Assay and Stable Cell Line Isolation 
Sub-confluent Rat2 fibroblasts grown in 10 cm diameter (Φ) tissue culture dish were 
incubated in 5% FBS culture media for 6 hours prior to transfection. Cells were transfected 
with 10 µg plasmids containing MT or mutant DNA overnight using calcium-phosphate 
method. Plasmids were mixed in 125 mM CaCl2, 0.7 mM Na2HPO4, 0.7 mM NaH2PO4, 1x 
(w/v) Hepes buffer pH7.1, with aeration then incubated at RT for 15 min, which were then 
added to the cells. The following day, media was changed to 10% FBS tissue culture media. 
Cells were cultured in the same dish and fed every 3 - 4 days for 14 days. Foci were stained 
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by incubation with Leishmann’s staining solution (VWR-BDH Chemicals, Leichmann’s 
Eosin Methylene Blue Solution in methanol) for 5 minutes at RT, followed by extensive 
washing with distilled water.  
 To generate stable cell lines expression MT or its mutant, sub-confluent Rat2 
fibroblasts in 60 mm (Φ) dishes were transfected with 5µg plasmid DNA plus 0.5µg 
pSV2neo plasmid using above method.pSV2neo contains the neomycin resistance gene under 
the control of the SV40 early promoter. MTFLAG expression Rat-2 fibroblast cell line 2.11 
was transfected with MTHA expression plasmid plus puromycin-resistance plasmids. After 
transfection, cells were selected by addition of 750 µg/ml G418 (Calbiochem) for 14 days. 
Individual colonies were picked and subcloned. Clones were evaluated for MT or mutant 
content by WB and IF.  
 
2.7Attractene Transfection and Transient Expression 
In order to obtain higher copy number/ higher expression level, cells were transfected with 
Attractene Transfection Reagent (Qiagen). The day before transfection, cells were seeded on 
to 24-well plate to achieve 80% confluency on the day of transfection. 0.4 µg DNA was 
diluted with DMEM without serum, antibiotics or additional L-glutamate to a total volume of 
60 µl. 1.5 µl Attractene Transfection Reagent was added to the diluted DNA and incubated at 
RT for 15 min to allow complex formation. During DNA-lipid complex formation, cells were 
fluid changed to 500 µl fresh DMEM supplemented with 10% FCS, antibiotics and 
glutamate. The transfection complexes were added drop-wise onto the cells, followed by 
incubation at 37˚C and 10% CO2 for 6 – 8 hrs. Media containing transfection complexes were 
removed and cells were allowed to grow in normal 10% FCS-DMEM media. The day after 
transfection, or 24 hrs post-transfection, cells were trypsinised and seeded on to glass 
coverslips for IF staining on the next day, 48 hrs post-transfection. 
 
2.8 Cell Lysis, SDS-PAGE and Western Blotting 
Confluent cells grown in a 10 cm petri dish were washed twice with cold PBS the lysed in 1 
ml ice cold lysis buffer:100mM TrisCl, pH8.3, 100mM NaCl, 0.5% Nonidet P40 (Roche), 
containing complete EDTA-free protease inhibitor cocktail tablet (Roche). After incubation 
for 20 min on ice, the supernatant was removed and centrifuged at 15,000xg before the final 
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supernatant was taken and frozen at -80
o
C. To analyse for MT content, lysate was mixedat 
2:3 dilution with Laemmli SDS-sample buffer (Laemmli. Nature, 1970) then was heated to 
90
o
C for 5min. When analysising for GFR expression, cells were lysed in above lysis buffer 
containing 1% Triton-X100 and proteins samples were prepared without boiling. 
Polypeptides were separated by electrophoresis on a 10% polyacrylamide gel 
containing SDS, then transferred onto 0.2µm pore size nitrocellulose (GE Healthcare) by 
Western blotting. The membrane was blocked by addition of 5% powdered skimmed milk in 
PBS and incubation for 30 min at room temperature. Membranes were sometimes stained 
with Ponceau S to visualise protein bands (Sigma Adrich P3504, dissolve 0.2 g in 5% acetic 
acid) before blocking in milk. After washing with 1xTBS-T the membrane was incubated for 
60 minat room temperature with the appropriate dilution of primary antibody in 5% milk in 
TBS-T. After washing again for 30 minutes with frequent buffer changes, antibody binding 
was detected by incubation with a 1:5000 dilution of either anti-mouse, or anti-rabbit IgG 
coupled to HRP (DAKO) for 60 min at room temperature. After a further 30 minutes of 
washes, the proteins were revealed by incubation with Immobilon Western 
Chemiluminescent substrate (Millipore) and exposure to X-ray film.  
 When necessary, protein concentrations were analysed using Pierce BCA Protein 
Assay (Thermo Scientific #23227) according to manufacturer’s protocol. Serial dilutions of 
decreasing concentrations of BSA were made from 2 mg/ml stock solution provided with the 
kit. Protein samples were prepared in 96-well plate at 10 µl per well. Reagents added to each 
well containing protein samples or BSA standards changed colour after 30 min incubation at 
37˚C.  Absorbance at 562 nm (λ) was measured using OPTImax microplate reader. 
 
2.9 Co-immunoprecipitation (IP) and in vitro Kinase Assay 
Confluent plates of cells grown in 100-mm petri dishes were lysed in 1 ml per plate lysis 
buffer containing 0.5 % Nonidet P-40 as described above. 50 µl samples of lysates were 
analysed for MT content as described before while the rest of the lysates were kept at -80˚C. 
A volume of lysate corrected for equal amounts of MT was thawed and incubated with 3 µg 
PAb762 for 60 min on ice. 30µl of (50% w/w) Protein A-Sepharose CL-4B (GE Healthcare) 
in TBS-N buffer (150 mM NaCl, 50 mM Tris-Cl, pH 8.3, 0.05% Nonidet P-40) was added 
and incubated on ice for 30 min with constant mixing. The Sepharose beads were collected to 
the bottom of the 1.5 ml eppendorf by very brief centrifugation at 4,800 x g and then washed 
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4 times by re-suspension in TBS-N buffer. Following removal of the last wash supernatant, 
proteins were eluted from the Protein A-Sepharose by incubation with 30 µl of SDS sample 
buffer at RT for 10 min, and then centrifuged at 13,000 x g for 5 min. The protein samples 
were removed from the Sepharose and then analysed as described above. The same 
membrane was often used for the detection of multiple MT-binding proteins in the order of 
pp62c-yes, pp60c-src, ShcA, PI3K p85, PLC-γ1, PP2A A and C subunit. In between different 
antibody detection, the membrane was washed extensively for at least three times 0.5 hr in 
TBS-T.  
For In vitro protein kinase assays, MT was immunoprecipitated as described above 
until the last wash of the Protein A-Sepharose, which was collected to the bottom of the 
eppendorf tube. The Sepharose beads with immunoprecipitated MT and Src kinase protein 
complex were incubated with 50 µl of 25 mM Tris-Cl, pH 7.4, 5 mM manganese acetate, and 
2µ Ci of [γ-32P] ATP for 30 min at 30˚C. The Sepharose was then washed twice with TBS-N. 
Proteins were eluded and separated by SDS-FAGE as described. After separation, the gel was 
fixed with 40% methanol and 10% acetic acid for 60min, then dried and autoradiographed 
using X-ray film.  
 
2.10 Antibodies  
2.10.1 In-house Antibodies: 
PAb762, a mouse monoclonal directed against the N-terminus of MT; biotinylated anti-MT 
monoclonal PAb762 . F2.5G4, anti-PP2A PR35 (subunit C); G3 8F11, anti-PP2A PR65 
(subunit A); rabbit anti-ASNA1 antibody was a kind gift from Dr Matthias Seedorf from 
Heidelberg University. 
 
2.10.2 Commercial Antibodies: 
Rabbit monoclonal IgG anti-Src (32G6); (Cell Signaling Technology, #2123); rabbit 
polyclonal anti-Shc (BD Signal Transduction Lab, S14630); rabbit PI3K p85 (Upstate 
Biotechnology, 06-497); mouse monoclonal anti-PLC-γ1, clone 10 IgG1 (BD Biosciences, 
610027),;rabbit monoclonal anti-Yes1 [EPR3173] (Abcam, ab109265); ; rabbit anti-phospho-
FAK (Y397), clone D20B1 (Cell Signaling Technology #8556); mouse monoclonal [P1F6] 
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anti-integrin alpha V+beta 5 (Abcam, ab24694); rabbit anti-phosphorylated tyrosine residues 
(Y317 and Y239) of ShcA (Upstate Biotechnology #07-206 for pY317 and #07-209 for 
pY239);mouse monoclonal IgG1anti-HA epitope HA.11 (clone 16B12) (Covance  MMS-
101P);rabbit anti-FLAG polyclonal antibody(Cell Signaling Technology #2368).  
 
2.11 In Vitro Translation  
Vector pcDNA3.1 containing wild type or mutant MT cDNA were used for in vitro 
translation (with or without pYX-Asc plasmid) using TNT® T7 Quick Coupled 
Transcription/Translation System (Promega, #L1170). 2 µl plasmid DNA were added to 40 
µl TNT T7 Quick Master Mix (formulated rabbit reticulocyte lysate), together with 1 µl of 1 
mM methionine, and 7 µl of nuclease-free water to give a final volume of 50 µl. For MT and 
ASNA1 co-translation, 2µl of each plasmid were used with adjusted water volume. The 
mixture was then incubated at 30˚C for 90 min. 1 µl of the newly translated MT was added to 
SDS sample buffer for Western Blot analysis of MT content. PAb762 was added to the rest of 
the reticulocyte lysate immunoprecipitate MT as described in before. The immunoprecipitates 
were analysed for ASNA1 by Western Blotting.  
 
2.12 Detergent Resistance Membrane Fractionation 
Confluent cells on 10 cm tissue culture dishes were trypsinise and centrifuged at 3000 g for 
5min at RT. The pellet of cells was then washed in cold PBS (4
o
C) and centrifuged again at 
4
o
C. Cells were then re-suspended in 500 µl of 20 mM Tris-HCl pH7.0 with protease 
inhibitors (Roche). The suspension of cells was then passed through a 23G needle for at least 
10 times on ice to break open the cells. A sample of 50 µl was taken as whole cell lysate 
(WCL). The broken cells were centrifuged at 45000 g at 4
oC for 1 hr with Beckman’s ultra-
centrifuge. The supernatant was kept as a sample for non-membrane fraction (NMF). The 
pellet was the re-suspended in 500 µl cold PBS with above protease inhibitors to wash the 
membranes. An aliquot of 50 µl re-suspended membrane was kept as membrane fraction 
sample (MF). The remaining membranes were centrifuge again at 45000 g at 4
o
C for 0.5 hr. 
Supernatant was discarded. The pellet was re-suspended in 200 µl cold PBS, 1% Triton X-
100 with above inhibitors and incubated on ice for 0.5 hr to solubilised cell membranes. The 
suspension was then centrifuge at 45000 g at 4
o
C for 1 hr. Supernatant was stored as 
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detergent soluble fraction (DSF). The remaining pellet was solubilised in 100 µl 1% SDS in 
PBS plus inhibitors. To fully solubilise the detergent insoluble fraction (DIF), the pellet was 
passed through a 21G needle for at least 15 time then a 27G needle for at least 20 times.  
 For immunoprecipitation, the detergent insoluble pellet was re-suspended in 200 µl 
cold PBS with protease inhibitors. 30 µl Protein-A Sepharose (50% w/w) was added to DSF 
and DIF and incubated on ice for 20 min with agitation every 2 – 5 min. Sepharose beads 
were collected to the bottom of the eppendorf tubes by centrifugation at  4800 g for 20 sec. 
The pre-cleared supernatant was transferred to a new eppendorf tube. 100 µl of DSF or DIF 
was incubated with PAb762 anti-MT monoclonal mouse IgG on ice for 1 hr and 
immunoprecipitated as described before.  
 
2.13 Immunofluorescent (IF) Staining 
2.13.1 Total MT 
Cells were grown on 13mm glass coverslips in a 24 well plate for 24 hr. For staining of total 
MT in fixed-cells, the cells were washed twice with complete Dulbecco’s phosphate-buffered 
saline (PBS supplemented with CaCl2 and MgCl2 or DPBS) at 37
o
C, and then fixed by 
incubation with 0.5 ml 4% formaldehyde solution (stock: 16 % formaldehyde solution w/w, 
Methanol-free, Thermo Scientific, # 28908) in DPBS for 10 min at RT. After washing with 
DPBS three times, the cells were permeabilised by incubation with 1% NP-40 (Roche, 
Nonidet P40 aqueous solution, 10 % w/v) diluted in DPBS, for 5 minutes at RT. Cells were 
washed three times 5 min in DPBS, and then treated with 30 µl per coverslips Image-iT FX 
Signal Enhancer solution (Invitrogen, # I36933) for 30 min at RT. After further three washes, 
the cells were incubated with a 1:200 dilution of primary purified monoclonal antibody 
against MT N-terminus (PAb762) for 60 min at RT. After the cells washing three times 5 min 
with DPBS, the antibody was detected by incubation with a 1:1000 dilution of Cy3- or Alexa 
Fluor 488-conjugated anti-mouse antibody (Jackson Immunoresearch or Invitrogen). The 
cells were washed a further three times 5 min in PBS, and then two times 5 min in purified 
water to reduce non-specific signals coming from salt precipitates in PBS before the 
coverslips weremounted in ProLong Gold anti-fade mounting reagent with DAPI nucleic acid 
stain (Invitrogen, P36935).  
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 Immunofluorescent labelled cells were viewed on a Nikon inverted fluorescent light 
microscope and captured using a Princeton Instruments MicroMax Charge-Coupled Device 
(CCD) camera using Metamorph software. 
 For high resolution analysis, and multi-colour immunofluorescent labelling, images 
were viewed and captured with Leica Microsystems TCS SP5 laser scanning confocal 
microscope and Leica LAS AF software system. Images were taken at 20% overall laser 
power, with HCX PL APO lambda blue 63.0x1.40 oil UV lens. Area of 41 µm x 41 µm was 
selected for multi-channel laser scanning (zoom factor = 6). Only cells with intact nuclei 
were selected for imaging.  
 
2.13.2 Surface MT 
For labelling surface HA- or FLAG-tagged MT, cells on coverslips were fluid changed to 1 
% FBS DMEM 15 min prior to immune-labelling in order to reduce non-specific binding to 
coverslips and cell debris. In the meantime, antibody solution was prepared in 1 % FBS, 
DEME, with anti-HA antibody used at 1:200 dilution and anti-FLAG antibody used at 1:100 
dilution. 250 µl solution per well was required to cover the cells completely. Antibody 
solutions were centrifuged at 13,000 x g for 5 min before use. Surface tags were labelled by 
incubating the living cells on coverslips with the antibody solutions at 37
o
C for 20min. Cells 
were then washed twice in DPBS at 37
o
C then fixed by incubation with 4% formaldehyde 
solution in warm DPBS for 10 min at RT and carried forward with above protocol but 
without permeabilisation of the cell membranes.  
For co-staining surface MTHA with phosphorylated ShcA on internal membranes, 
cell membranes were permeabilised after surface HA labelling and formaldehyde fixation as 
described above then incubated with rabbit anti-activated ShcA (pY317 and pY239), 
followed by Alexa Fluor 488-conjugated anti-mouse or Alexa Fluor 555-conjugated anti-
rabbit secondary antibodies. For cold staining, cells were incubated in DMEM with 5% FBS, 
20 mM Hepes buffer at RT for 15 min, before anti-epitope tag antibodies were added and 
incubated at 4
o
C for 30 min.  
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2.13.3 IF Labelling of Actin 
LifeAct-MARS plasmids were kind gifts from Dr Nicola Brownlow at London Research 
Institute. The plasmid contains sequence that encodes a 17-amino-acid peptide, with F-actin 
binding property, fused to red fluorescent protein (Riedl, Crevenna et al. 2008). Plasmids 
were transfected into Rat-2 fibroblast cell lines expressing wild type epitope-tagged MT 
using Attractene Transfection Reagent. Green-fluorescent labelling for surface tags of MT 
was performed on transfected cells 48 hrs post-transfection as described before. 
 
2.13.4 Vybrant® Lipid Raft Labelling  
Cholesterol-rich lipid rafts on living cells were labelled with Vybrant® Alexa Fluor 555 
Lipid Raft Labelling Kit (Invitrogen, V-34404). The Alexa Fluor-conjugated cholera toxin 
subunit B (CT-B) binds to the polysaccharide chain of monosialotetrahexosyl ganglioside 
(GM1), which is a membrane lipid that selectively partitions into lipid rafts. 
 Living cells were incubated in anti-HA or anti-FLAG antibodyin the presence of 
Alexa Fluor 555-conjugated CT-B in 1% FCS tissue culture media for 20 min at 37˚C. Lipid 
rafts labelling at 4˚C were performed in some experiments.  
 
2.13.5 Plasma Membrane Labelling 
Plasma membranes on live cells were labelled with Image-iT
TM
 LIVE Plasma Membrane 
Labelling Kit (Invitrogen, I34406) according to manufacturer’s recommendation.  
 
2.14 Image Analysis with FIJI ImageJ Software 
Image in channel 1 (red, total phospho-ShcA) or channel 2 (green, surface HA) was 
processed using macro 1. The resulting images from the two channels were then merged to 
give rise to a combined image. Scale bar = 2 µm. 
 An area of 20.5 µm x 20.5 µm from the combined image was selected for 
colocalisation analysis using JACoP. M1 is the fraction of red pixels colocalising with green 
pixels while M2 is the green pixels colocalising with red pixels. Since green pixels were 
generated from labelling HA-tags on cell surface, the value of M2 represents the fraction of 
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surface MT colocalising with activated ShcA. Pearson’s coefficient is measured using 
Costes’ randomisation based colocalisation analysis with automatic threshold as part of 
JACoP(Bolte and Cordelieres 2006). 
When measuring complex size, images of surface HA or FLAG tagged MT were 
processed with Macro 1. An area of 20.5 µm x 20.5 µm was selected. A mask was made from 
the selected area to exclude background signals by setting threshold to 15. Using the mask, 
go to ‘Analyse: set measurement’ and redirect analysis to the actual fluorescent image, 
measuring ‘Area’ on the parameter list. Then using the ‘Analyse particles’ function and 
setting ‘Area covered (µm2): 0-infinity’, the size of individual complex were measured. 
 
Macro 1: 
run("8-bit"); 
run("Median...", "radius=1"); 
run("Subtract Background...", "rolling=50"); 
run("Multiply...", "value=2"); 
 
JACoP setting: 
Measure M1 & M2, using threshold 60 for channel 1, 30 for channel 2 
Costes’ randomisation based colocalisation analysis with automatic threshold 
Number of randomisation rounds: 200 
Bin width: 0.001 
 
2.15 Receptor Expression Level Analysis 
2.15.1 RNA Extraction and Conversion into cDNA 
Confluent cells grown in 6-well plates were lysed in 1 ml Trizol at RT. After vigorous 
scrapping, lysates were transferred to a 1.5 ml eppendorf tube. 200 µl chloroform were added 
to each 1 ml trizol sample and mixed well. Cellular RNAs were separated by centrifugation at 
5,000 x g at 4˚C for 15 min. The top aqueous phase containing RNA was removed carefully, 
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avoiding white precipitates of genomic DNA in the middle, and transferred into a sterile 1.5 
ml eppendorf. Each sample of extracted RNA were mixed with 0.5 ml isopropanol and 
incubated at RT for 10 min. The precipitated RNA was centrifuged at 11,000 x g for 10 min 
at 4˚C. The isopropanol supernatant was discarded and the pellet was washed with 1 ml 75% 
ethanol. After centrifugation at 7,500 x g for 5 min at 4˚C, the ethanol was carefully removed 
without disturbing the pellet containing extracted RNA and the pellet was allowed to air-dry. 
The dried pellet of RNA was re-dissolved in 30 µl TE buffer (10 mM Tris-HCl, pH 7.4) and 
the concentration analysed by NanoDrop. 300 ng of RNA extract were used for generating 
cDNA using RNA Superscript (invetrogen) according to Table T2.1. Contents were mixed 
gentle and spun down to the bottom of the eppendorf, and then incubated at 42
o
C for 30 min, 
then 50
o
C for 30 min to increase specificity. 
 
Table T2.1 Reagents used for making cDNA from extracted RNA  
Reagent Volume (µl) 
Sample of RNA extract 300 ng (~ 0.2µl) 
Random primers 0.5µl 
Water 27.3 µl 
dNTP  1 µl 
5x buffer 8µl 
0.1M DTT 1 µl 
Superscript III 1 µl 
RNase OUT 1 µl 
Total volume 40 µl 
 
 
2.15.2 Primer Design and Expression Assay for Growth Factor Receptors 
Genomic DNA sequences of rat EGFR1, PDGFRβ, ErbB2, ErbB3 and ErbB4 were obtained 
through UCSC genome browser(Kent, Sugnet et al. 2002). Forward and reverse primer-pairs 
were designed by inputting two exon regions of a receptor into Primer3 programme 
(Koressaar and Remm 2007, Untergasser, Cutcutache et al. 2012). Primer sequence were 
checked by UCSC BLAT of rat genome to make sure each primer only produce one 
complementary hit in the rat genome (Kent, Sugnet et al. 2002).   
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o
C for 5min to 
initiate RNA 
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PCR reactions were performed with each cDNA sample generated and a pair of 
forward and reverse primer designed specifically for the receptor of interest according to 
Table T2.2. 20 µl PCR products were separated on a 5% 19:1 Bis-Acrylamide gel in 0.5% 
TBE buffer. After electrophesis, gels were incubated in 150 ml 0.5% TBS buffer with 1 µl 
ethidium bromide for 15 min at RT. DNA bands were visualised under UV. 
 
Table T2.2 PCR mix preparation for receptor expression analysis 
Reagents Volume 
Forward +Reverse mixed 
primers at 1:5 dilution 
2 µl 
cDNA sample 1 µl 
PCR master mix 12.5µl 
Nuclease-free water 9.5 µl 
Total volume 25 µl 
 
Websites used for primer design: 
http://primer3.ut.ee/ 
http://genome.ucsc.edu/  
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CHAPTER 3 – MPyV MT BINDS SIGNALLING PROTEINS AT DISCRETE 
SUBCELLULAR MEMBRANE SITES 
 
3.1 INTRODUCTION:  
MT association with the cell membrane association requires a 22-residue stretch of 
hydrophobic amino acids located near to the MT C-terminus (Soeda, Arrand et al. 1979). 
Deletion of this region abolishes transforming activity and prevents binding to all signalling 
molecules except PP2A (Novak and Griffin 1981, Carmichael, Schaffhausen et al. 1982). 
However, the role of the C-terminus in MT-induced transformation is not well studied. The 
protein cannot be labelled with protein-modifying reagents from the extracellular side of the 
plasma membrane (Schaffhausen, Dorai et al. 1982). However, the very hexapeptide 
following the hydrophobic regions might be too short for an interaction with modifying 
reagents (Hofer, Wehrle et al. 1995). The position of the MT hydrophobic sequence is very 
close to the C-terminus, which suggests MT may be a tail anchored (TA) protein (Borgese, 
Brambillasca et al. 2007). TA proteins are typically characterised by the location of 
hydrophobic sequence near the C-terminus. This is followed by a short translocated polar 
region orientated towards the extracellular surface of the cell, which is made up of no more 
than 30 amino acid residues. The N-terminal functional domain faces the cytosol (Borgese, 
Brambillasca et al. 2007).  
To examine how MT is inserted into membranes we have isolated and studied a series 
of mutations of the C-terminal region. We report here that an epitope tag added to the C-
terminus of MT can be detected on the surface of transformed cells, demonstrating that MT is 
a tail anchored (TA), integral membrane protein. Inserting the ER retention sequence KDEL 
at the C-terminal end of MT located it to the ER and cis-Golgi only, showing that MT is first 
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inserted into membranes at the ER. This ER localised MT species was able to bind to PP2A 
and Src but failed to bind ShcA, PI3K and PLC-γ1, and did not transform, indicating that MT 
has to migrate out of the ER to associate with further signalling proteins in order to generate a 
mitogenic signal. Replacing the MT TMD with one from an ER-resident membrane protein 
(Sec61β) did not entirely trap the MT in the ER, suggesting that other properties of MT in 
addition to the TMD allow MT to exit the ER.  Mutations in the N-terminus of MT suggest 
this property is the binding of PP2A.  
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3.2 RESULTS:  
3.2.1 MT is a tail-anchored transmembrane protein  
The MT hydrophobic domain is positioned only six amino acids from the C-terminus. The 
location of the hydrophobic domain so close to the C-terminus suggests strongly that MT 
belongs to a class of tail-anchored (TA) transmembrane proteins (Borgese, Brambillasca et al. 
2007). However, one important requirement for TA protein is that the hydrophobic sequence 
must span the lipid bilayer and this has not been proven for MT. In order to study MT C-
terminus topology, a slightly extend hemagglutinin epitope (HA) tag, AYPYDVPDYASL, 
was added to the C-terminal end of MT sequence to see whether this epitope tag can be 
detected on the cell surface. The resulting protein (wtMTHA+) was transformational 
competent as shown by similar levels of foci formed by the transfection of wild-type or 
tagged MT cDNAs (Figure 3.1 B). The focus formation assay is routinely used to assess the 
ability of various oncogenes to induce cellular transformation (Morgan, Kaplan et al. 1988, 
Sparkowski, Anders et al. 1995). Cells transformed by oncogenes such as MT, lose contact 
inhibition and exhibit anchorage independent growth. A raised lesion or focus is formed by 
the piling-up of cells, which can be visualised by Leishmann’s Stain labelling cytoplasmic 
structure (stained by eosin) and the nuclei (stained by methylene blue). The HA tag was 
detected on the surface of the cells stably expressing wtMTHA+ using antibody specific for 
HA added to living cells prior to formaldehyde fixation (Figure 3.1 C (ii)). An in-house 
mouse monoclonal antibody directed against the N-terminal sequence of MT (PAb762 anti-
MT) did not react with wild type or HA-tagged MT when added to living cells. This antibody 
reacted strongly to wild type MT and MTHA+ only after the cells were fixed and 
permeabilised (Figure 3.1 C (a)).  Results shown in Figure 3.1 C suggested that at least a 
detectable amount of MT C-termini were translocated to the extracellular surface of plasma 
membrane while the bulk of the MT N-termini were facing the cell interior.  
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Figure 3.1 MT C-terminus is translocated across to the cell surface 
A. Amino acid sequences of the MT C-terminus and the epitope tags added. Wild type MT 
sequence is shown at the top. Positions in the complete protein sequence are indicated with 
numbers at 10-residue interval above the corresponding amino acids. Designation of each MT 
species is listed on the left. Single-spacing separates the hydrophobic sequence from sequences 
on either side. MTHA+ plasmid was generated by Dr N. Ichaso. 
B. Epitope tag did not affect transformation. Rat2 fibroblasts on 10 cm tissue culture dishes were 
transfected with 10 µg plasmids carrying wild-type MT (a) or tagged MT sequence (c). Mock 
transfection was performed without any plasmid (b). Cells were cultured for 14 days before 
staining in Leishmann’s solution.  
C and D. Epitope tags can be detected on cell surface. Cell lines stably expressing wtMT (i) or 
epitope tagged MT (ii) were established and immunofluorescence (IF) staining was performed 
with primary antibody against MT N-terminus (anti-MT) or epitope tag, anti-HA (C), anti-FLAG 
(D) added before (Live) or after (Fixed) cell fixation. Cells were imaged at low magnification on 
Nikon inverted epifluorescence microscope. Experiment in C was performed by Professor 
Stephen Dilworth. 
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 In order to verify our findings with MTHA+, a different epitope, FLAG tag 
(DYKDDDDK), was added to the C-terminus of MT. The resulting wtMTFLAG transformed 
Rat-2 fibroblasts to the same level as wild-type MT (Figure 3.1 B lower panels). The FLAG 
tag can be detected by incubating MTFLAG expressing cells live, in a primary antibody 
specific for the tag before fixation (Figure 3.1 D), hence further confirmed that MT C-
terminus was translocated across to the cell exterior with the hydrophobic sequence spanning 
the lipid bilayer in a single-pass topology.  
 
3.2.2 MT localised in the Endoplasmic Reticulum failed to transform 
We demonstrated that a short amino acid sequence can be added to the MT C-terminus 
without affecting its ability to transform Rat-2 fibroblasts. A similar approach was used to 
examine the role of subcellular localisation in MT function. MT is found in most internal cell 
membranes but little is known about where the oncoprotein is first inserted into a membrane 
and where the transforming signal is generated (Dilworth, Hansson et al. 1986).  To 
determine whether MT located solely in the endoplasmic reticulum (ER) can produce a 
transforming signal, a specific ER- retention sequence, KDEL, was added to MT C-terminus 
(MTKDEL). Proteins bearing the KDEL sequence in the ER lumen are recognised and bound 
by KDEL receptors in the cis Golgi membranes and are subsequently returned to the ER 
through retrograde transport (Lewis and Pelham 1992).  The amino acid sequence, GGDV, 
was used to make a control (MTGGDV), which lacks the four critical amino acids recognised 
by the KDEL receptor thus should not be retained in the ER lumen. These are the same 
sequence additions that demonstrated that bovine papillomavirus E5 must locate to the distal 
Golgi compartments to transform fibroblasts (Sparkowski, Anders et al. 1995). 
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Figure 3.2 ER-retention sequence abolishes MT transformation of fibroblast monolayer  
A. ER retention sequence KDEL or a non-functional control mutation GGDV was added to MT 
C-terminus. In addition, the MT hydrophobic sequence was replaced with that of an ER-
resident TA protein, Sec61β. Designation of each MT species is listed on the left. Single-
spacing separates the hydrophobic sequence from sequences on either side.  
B. Foci formation assay for transformation ability. Sub-confluent Rat2 fibroblasts on 10 cm 
tissue culture dishes were transfected as described previously. The MT cDNA that were used 
are indicated above or below each panel.  
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 The resulting MTKDEL failed to transform Rat-2 fibroblasts while MTGGDV 
transformed Rat2 fibroblasts at the same level as wild type (Figure 3.2 B). IF labelling of MT 
in cells expressing MTKDEL showed a distinctive distribution of the protein. While the wild-
type MT can be found throughout the cell including the peripheral plasma membrane, the 
mutant located solely in reticular structures in the cytoplasm which resembled the ER (Figure 
3.3 A).  The distribution of MTGGDV was the same as wild-type MT (Figure 3.5 A). Co-
staining MT with a known ER marker – calreticulin, confirmed that MTKDEL resided in the 
ER compartment (Figure 3.3 B). Wild-type MT was targeted to membrane sites beyond the 
ER, such as the Golgi and the plasma membrane, so did not colocalise strongly with this ER 
marker. MTKDEL was unable to reach the Golgi apparatus as the protein failed to colocalise 
with the Golgi marker giantin (Figure 3.4). Retention of MT in the ER by the KDEL 
sequence suggests strongly that the protein is initially inserted into membranes at the ER as 
integration at any other membrane organelle would bypass the KDEL receptor and generate a 
different distribution. ER-retention of MTKDEL also provided further evidence that the C-
terminus of MT must have translocated across the lipid bilayer exposing the KDEL sequence 
to the ER/ cis Golgi lumen.   
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Figure 3.3 MTKDEL is localised to the ER membrane  
A. MT distribution in cells stably expressing wtMT or MTKDEL. Cells were fixed and 
permeabilised before incubation with PAb762 anti-MT mouse monoclonal antibody alone.  
B. Dual-fluorescent labelling of MT and an ER-marker calreticulin. Mouse anti-MT primary 
antibody PAb762 was added in conjunction with rabbit anti-calreticulin monoclonal 
antibody. Alexa Fluor 488-conjugated anti-mouse and Alexa Fluor 633-conjugated anti-rabbit 
secondary antibodies were added in order to label total MT in green or calreticulin in red 
respectively. Cells were imaged on Leica SP5 confocal microscope using 63.0x1.40 oil UV lens. 
Co-localisation between MT and calreticulin is seen as yellow in the combined channel.  
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We then investigated whether MTKDEL localised to the ER associated with known 
MT-binding proteins. All protein binding sites were unchanged in the MTKDEL polypeptide. 
To determine whether these sites were occupied, immunoprecipitation of MT was performed 
using PAb762 anti-MT antibody on cell lines stably expressing each mutant and then 
analysed by SDS-PAGE and Western blotting for known MT associating proteins required 
for oncogenic signalling. Figure 3.5 B shows that MTKDEL failed to bind ShcA, PI3K and 
PLC-γ1 even though it was able to bind to PP2A core dimer and pp60c-src at levels 
comparable to those of the wild type MT. The pp60c-src bound by MTKDEL was fully 
Figure 3.4 MTKDEL is absent from the Golgi apparatus  
Rat-2 fibroblasts stably expressing MTKDEL (i) or wtMT (ii) were fixed and permeabilised before 
incubation with PAb762 anti-MT mouse monoclonal antibody (a) and with Alexa Fluor 488-
conjugated rabbit anti-giantin monoclonal antibody (b).  Alexa Fluor 555 anti-mouse secondary 
antibody was subsequently added to fluorescently label MT. Total MT staining is shown in red. 
Giantin in Golgi is shown in green. DAPI nuclear staining is shown in blue in the combined channel 
(c). Cells were imaged on Leica SP5 confocal microscope using 63.0x1.40 oil UV lens with zoom 
factor 4.5.  An area of 30 µm x 30 µm was selected for analysis. Scale bar = 5 µm.  
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active as this mutant in the MT immunoprecipitates was found to be phosphorylated by in 
vitro kinase assay (performed by Prof. Dilworth, Figure 3.6). Low level of PI3K activity was 
detected MTKDEL by in vitro kinase assay, probably due to high sensitivity of the assay 
(Figure 3.6). Two very weak bands that correlate to PI3K p85 and PLC-γ1 can sometimes be 
detected in MTKDEL immunoprecipitates, which is probably due to the leakage of a small 
amount of MTKDEL from the ER compartment. Alternatively, some protein binding might 
have occurred in the after cell lysis. Therefore the absence of ShcA, PI3K and PLC-γ1 in the 
MTKDEL precipitate was not due to the lack of phosphorylated binding sites on this mutant 
but was likely a consequence of these signalling molecules not having access to MT localised 
in the ER. 
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Figure 3.5 Analysis of MTKDEL location and association with known MT-binding proteins 
A. Rat-2 fibroblasts were transfected with expression plasmids carrying MT mutants 
described in Figure 3.2 A, using Attractene transfection kit, see Material & Methods. IF 
staining for total MT was performed at 48 hr post transfection, using PAb762 antibody. 
Plasmids transfected are indicated above or below each panel. Cells were photographed 
using a Nikon inverted epifluorescence microscope at 100x magnification. 
B. Protein binding properties of each of the mutants described in figure 3.2 A.  MT was 
immunoprecipitated (IP) by PAb762 from equal volumes of lyates collected from stable cell 
lines, as indicated above each lane. The immunoprecipitates were separated by SDS-PAGE 
and transferred on to nitrocellulose membrane for Western blotting. Antibodies used to 
immune-bind (IB) known MT-associating proteins are shown above each panel. The 
migratory position of each detected polypeptide species is indicated by an open arrow to the 
right. Experiments were performed by Prof. S. Dilworth. 
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Since MT retained in the ER cannot transform, there must be signals on MT that 
target itself to additional membrane locations once inserted into the ER membrane. In other 
TA proteins, the TMD sequence alone is thought to determine where the polypeptide is 
finally located (Borgese, Brambillasca et al. 2007). To investigate whether MT hydrophobic 
sequence alone directs MT out of the ER to additional membrane sites, we replaced the 
sequence with that from an ER-resident TA protein, Sec61β. It is part of the ER co-
translational membrane insertion complex and resides mainly on ER membranes (Hartmann, 
Sommer et al. 1994). Although Sec61β does not have retrieval peptide sequences like KDEL, 
this TA is found exclusively in the ER-Golgi intermediate compartment (ERGIC) but not the 
trans Golgi network, a property thought to be mediated by its TMD sequence only 
Figure 3.6 Kinase activity associated with 
MTKDEL  
MT from stable expression cell lines was 
immunoprecipitated then incubated with [γ-
32P] ATP. The radio-labelled 
immunoprecipitates were separated by SDS-
PAGE and autoradiographed. The MT species is 
indicated above each lane and the migration 
positions of MT and its associated proteins are 
indicated with closed arrows on the right. 
Experiment was performed by Prof. S. 
Dilworth. 
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(Greenfield and High 1999, Butler, Lee et al. 2007, Butler, Watson et al. 2011). This new 
hydrophobic region should target the new mutant MTSec61β to the ER membrane only. Foci 
formation induced by MT was reduced but not abolished by the substitution of Sec61β 
hydrophobic sequence (Figure 3.5 B). Unlike MTKDEL, MTSec61β was not trapped in the 
ER (Figure 3.5 A). It was found not only in the ER but also in peripheral plasma membranes 
(Figure 3.5 A). Apart from the ability to bind PP2A core dimers and pp60c-src, MTSec61β 
was able to bind ShcA, PI3K and PLC-γ1 (Figure 3.5 B, in vitro kinase assay can be found in 
Figure 3.6). The lower level of ShcA and PLCγ1 may reflect a lower level of the mutant 
present in cell lysate. An HA tag added to the C-terminus of MTSec61β showed the tag was 
detect on cell surface although at reduced levels (data not shown). Therefore MTSec61β was 
targeted to membranes other than the ER. Together, these results suggest the TMD of MT 
plays a role in targeting the polypeptide to the plasma membranes otherwise MT 
transformation would have been unaffected by the substitution of the ER-targeting TMD 
sequence from Sec61β. However, component(s) outside the hydrophobic sequence may also 
contribute to membrane targeting as the MTSec61β inhibition of ER exit was incomplete.  
 
3.2.3 Association with PP2A is required for MT to migrate out of the ER 
The observation that the TMD may not be sufficient to specify MT migration out of the ER 
prompted us to examine whether another property of MT plays a role in the relocation of MT 
in the ER to additional membrane sites. Our lab had previously reported that a MT mutant 
lacking the ability to bind PP2A was retained in cytoplasmic membranes, probably the ER 
(Brewster, Glover et al. 1997). In a series of deletion mutants generated in the study, amino 
acid sequence 185 – 210 on MT was identified as the region required for pp60c-src binding. 
Mutant 200∆10 is defective in pp60c-src binding while 180∆10 has a shortened PP2A-
binding region and therefore lacks both PP2A and Src binding (Brewster, Glover et al. 1997) 
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(see List of Mutants). Using PAb762 IF labelling of MT (Figure 3.7 A) showed that mutant 
180∆10 accumulated in the perinuclear region and was completely absent from the plasma 
membrane. This mutant had a distribution pattern most similar to MTKDEL while mutant 
200∆10 was distributed to the peripheral plasma membrane just like wild type MT. Treatment 
with okadaic acid (OA), an inhibitor of PP2A, resulted in accumulation of MT in cytoplasmic 
membranes after 48 hrs. However, the level of MT in the plasma membrane was not affected 
by the level of OA tested. Similar observations were made when the treatment period was 
shortened to 24 hrs. The experiment was repeated at 5 nM OA but required a treatment period 
of 48 hrs to achieve a similar level of MT staining at the ER. Treatment with dasatinib, a dual 
Bcr-Abl and Src tyrosine kinase inhibitor, did not change MT distribution in the cells (Figure 
3.7).  
 
  
85 
 
 
 
 
  
  
Figure 3.7 MT mutant 180∆10 lacking PP2A binding is localised to ER region 
A. MT distribution in mutants defective in PP2A or pp60c-src binding. MT was labelled by 
PAb762, which targets the MT N-terminus, after cell fixation and permeabilisation. MT 
species in stably cell lines are described in the top panel. The ability of each MT mutant to 
bind PP2A and pp60c-src is indicated below each image.  
B. Cells stably expressing wtMT were treated with 10 nM okadaic acid (OA) for 48 hrs before 
IF labelling of total MT using PAb762 anti-MT.  
C. In a separate experiment, wtMT cells were treated with 50 nM dasatinib for 48 hrs before 
IF labelling MT as above.  
Cells were imaged on a Leica SP5 confocal laser scanning microscope using 63.0x1.40 oil UV 
lens. Scale bar, 10 µm. Images are representative of at least 8 independent frames. 
Experiments with inhibitor treatment have been repeated for at least two times. 
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In order to determine whether other mutants defective in PP2A binding also fail to 
reach the plasma membranes, the location of the MT polypeptide in cell lines expressing 
mutants NS2, DC1, and DC2 (Dilworth, Brewster et al. 1994) were examined by IF using a 
number of anti-MT monoclonal antibodies (see Figure 3.8 for each mutant lesion position and 
the antibody recognition region). In all cases, MT mutants that are defective for PP2A 
binding were observed to be present only on cytoplasmic membranes and not the plasma 
membrane, irrespective of  the antibodies that were used to detect MT (Figure 3.9, see Table 
T3.1 for a summary of IF results). With antibodies PAb762, PAb754 and PAb750, significant 
amounts of wild type MT was detected at the plasma membrane (Figure 3.9, panels a, b and 
c). It has been suggested that the binding of Hsc70 to the J domain in PP2A binding defective 
mutants of MT might account for their cytoplasmic retention (Whalen, de Jesus et al. 2005). 
To determine whether this was case, a mutant that contained both the deletion of the Hsc70 
and PP2A binding sequence was generated by Professor S. Dilworth (mutant ∆J-DC1) 
(Markland and Smith 1987; Whalen, de Jesus et al. 2005, Zhou, Ichaso et al. 2011). 
HPDKGG sequence at position 42-47 in MT J domain is required for interaction with Hsc70 
(Whalen, de Jesus et al. 2005) and the DC1 deletion disrupts PP2A binding (Markland and 
Smith 1987). In mutant ∆J-DC1 both sites and the sequence in between were deleted, see 
Figure 3.6. This mutant was then transfected into Rat2 cells and the MT was detected by 
immunofluorescence with antibody PAb762 after 48 hours post-transfection. It was found 
that ΔJ-DC1 MT does not locate to the plasma membrane, and the location resembles that of 
DC1 (Figure 3.9, panel g). It seems likely, therefore, that Hsc70 binding is not responsible for 
maintaining PP2A binding defective MT mutants within cytoplasmic membranes (Zhou, 
Ichaso et al. 2011). Finally, to examine the role of PP2A binding in MT subcellular 
distribution in the absence of a mutation, we performed immunofluorescence analysis on 
cells that expressed wild type MT using monoclonal antibody PAb701. This antibody reacts 
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with the N-terminal region of MT required for PP2A binding and fails to bind to the MT-
PP2A complex (Dilworth and Horner 1993). The MT detected by PAb701 therefore is not 
associated with PP2A and showed very little plasma membrane staining (Figure 3.9, panel h). 
Table T3.1 summarises the immunofluorescence labelling of MT in mutants examines in 
section 3.2.3. It represents clearly the correlation between the lack of PP2A association and 
MT localisation in cytoplasmic membranes. Taken together, our data suggests strongly that 
association with PP2A is required for MT to relocate from the ER to the plasma membrane. 
 
 
 
 
 
 
Figure 3.8 Schematic representations of the MT mutations and antibodies used in Chapter 
3.2.3 studies  
Lesions deleted are indicated with black bars on the MT sequence.  DC1, DC2, NS2 and 180∆10 
carry deletion lesions in the PP2A binding region. ∆J-DC1 is truncated from dnaJ-domain to 
DC1 region. 200∆10 carries a deletion in the Src-binding region. The approximate binding 
regions for PAb762, PAb701, PAb754 and PAb750 are indicated by black lines. The gray bar 
represents the TMD. PP2A and pp60c-src binding regions are indicated by brackets below the 
MT sequence.  Also see List of Mutants for description. Monoclonal antibodies and mutants 
were generated by Professor S. Dilworth and others. 
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Figure 3.9 Mutants lacking PP2A binding failed to reach the plasma membrane  
Mutants DC1, DC2 and NS2 are defective in PP2A binding. ∆J-DC1 fails to bind Hsc70 and PP2A. 
Cells expressing each mutant were fixed and permeabilised before incubation with individual 
monoclonal antibody to detect MT. MT species and the antibody used are indicated above each 
image. Antibody PAb762 reacts with MT N-terminus, PAb701 reacts with region required for 
PP2A-binding. PAb754 and 750 reacts with regions near the C-terminus. See figure 3.6 for 
detailed lesion positions on MT sequence and the region targeted by each antibody.  Cells were 
photographed using Nikon inverted epifluorescence microscope at 100x magnification. 
Immunofluorescence analysis was performed on cells expressing various MT mutants by Prof. 
S. Dilworth. 
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Table T3.1 
MT Species / Antibody PP2A Cytoplasmic  Plasma Membrane 
Wild Type / PAb762  +  +++  ++ 
Wild Type / PAb754  +  +++  ++++  
Wild Type / PAb750  +  +++  ++++ 
Wild Type / PAb701  -  +++  + 
DC1 / PAb762  -  ++++  - 
DC2 / PAb750  -  ++++  - 
NS2 / PAb754  -  ++  - 
∆J-DC1 / PAb762  -  ++++  - 
180∆10 / PAb762  -  ++   -  
200∆10 / PAb762  +   ++  +++ 
 
  
 
Table T3.1 Summary of MT distribution in chapter 3.2.3 immunofluorescence staining analysis  
The MT polypeptides expressed and the antibodies used are listed on the left. The ability of the 
MT and antibody combination to IP with PP2A is indicated in the second column. Strength of 
immunofluorescence signals in cytoplasmic or plasma membranes are presented by ‘+’ in the 
last two columns. IF staining of MT in above mutants was performed by Prof. S. Dilworth.  
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3.2.4 MTKDEL and Src Tyrosine Kinase Association 
3.2.4.1 MTKDEL fails to bind pp62c-yes 
Tyrosine kinase activity associated with MT is attributed to the Src-family tyrosine kinases 
bound to MT. This association with Src-family tyrosine kinases is essential for polyomavirus-
induced cellular transformation and the ability to induce tumour formation in animals 
(Dunant, Senften et al. 1996). MPyV MT has been shown to preferentially associate with 
pp60c-src (Courtneidge and Smith 1983), pp62c-yes at lower affinity (Kornbluth, Sudol et al. 
1987), and, to a lesser extent, pp59c-fyn (Cheng, Harvey et al. 1988, Kypta, Hemming et al. 
1988). MT association with pp62c-yes had not been investigated previously in this lab due to 
the lack of a good antibody against this non-receptor tyrosine kinase. A number of 
commercially available antibodies targeting pp62c-yes were purchased and screened by MSc 
student Ewelina Pino Lopez for their recognition of pp62c-yes in Rat-2 fibroblasts lysates. It 
was found that only the rabbit anti-Yes1 monoclonal antibody (EPR3173) effectively labelled 
pp62c-yes by Western-Blotting and by indirect immunofluorescence (IF) labelling in 
permeabilised Rat-2 fibroblasts (Figure 3.10 A and data not shown).  
 Curiously, it was found that MTKDEL failed to bind pp62c-yes despite its ability to 
bind pp60c-src (Figure 3.10 A). This differential tyrosine kinase binding in MTKDEL was 
verified by immunofluorescence labelling of MT with each of the two Src-family tyrosine 
kinase members. Immunofluorescence staining of the pp62c-yes showed granular distribution 
throughout the cytoplasm to the plasma membrane, Figure 3.10 B. Unlike wild-type MT that 
shared similar subcellular distribution with pp62c-yes, ER-localised MTKDEL was devoid of 
pp62c-yes labelling (Figure 3.10 B). Co-immunofluorescence labelling of pp60c-src and MT 
produced colocalisation in both wild-type and MTKDEL expressing cells (Figure 3.10 C). 
Therefore the lack of MTKDEL and pp62c-yes association is probably due to the mutant not 
having access to this tyrosine kinase while pp60c-src remains accessible to MTKDEL. 
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Figure 3.10 MTKDEL failed to 
associate with pp62c-yes 
A. MTKDEL failed to bind pp62c-
yes. MT polypeptides were 
immunoprecipitated as 
described in figure 3.4. The 
presence of Src-family tyrosine 
kinases were detected with 
antibody specific to pp60c-src 
(Cell Signaling Technology) or 
pp62c-yes (Abcam), as indicated 
above each lane. Non-
transfected Rat-2 fibroblast 
lysate was used as a negative 
control. Experiment was 
performed by student Ewelina 
Pino Lopez. 
B. MT trapped in the ER does not 
have access to pp62c-yes. Cell 
lines stably expressing wt (i) or 
KDEL MT (ii, iii) were fixed and 
permeabilised then incubated 
with both mouse PAb762 and 
rabbit monoclonal antibody 
against pp62c-yes. Alexa Fluor 
488 or 555-conjugated 
secondary anti-mouse or rabbit 
IgGs were added to label MT 
(green) or pp62c-yes (red) 
respectively.  
High resolution images of dual MT - pp62c-yes 
staining were taken by Leica TCS SP5 confocal 
microscope using 63.0x1.40 oil UV lens with zoom 
factor 4.5. MT species expressed are indicated on the 
right. Two independent frames of MTKDEL are 
shown. One is focused in the middle cross-section (ii). 
The other is focused on the bottom of a different cell 
(iii).  
C. MTKDEL colocalises with pp60c-src in the ER. Dual 
labelling MT and pp60c-src was performed on cells 
expressing wtMT or MTKDEL as described in B. 
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3.2.4.2 MTKDEL redistributes pp60c-src but not pp62c-yes 
We noticed that pp60c-src distribution was changed in cells expressing MTKDEL. Figure 
3.11 and 3.12 represent the results of colocalisation studies between MT and pp60c-src in 
Rat-2 fibroblasts with wild type or ER-localised MTKDEL in low and high magnifications 
respectively. In normal non-transfected Rat-2 fibroblasts, this tyrosine kinase was 
asymmetrically distributed in the perinuclear region as well as the plasma membrane. 
Staining of pp60c-src was observed at the edge of cells as well as area of cell-cell contact 
(white arrows in Figure 3.11 panel i). In cells expressing wild-type MT, pp60c-src can be 
found in membrane ruffles and area where strong MT fluorescence signal was observed 
(Figure 3.12 panel ii). However, in cell expressing MTKDEL, pp60c-src distribution was 
limited to cytoplasmic area around the nuclei and was almost symmetrical located with very 
little fluorescence signal detected at the cell periphery (Figure 3.11 and Figure 3.12). The 
distribution of pp60c-src colocalised perfectly with MTKDEL in cells (Figure 3.10 – 12). 
Unlike pp60c-src, pp62c-yes subcellular distribution was not affected by this MT mutant 
(Figure 3.13). Therefore it is likely that the formation of MTKDEL-pp60c-src complexes 
redistributed this tyrosine kinase in cells.   
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Figure 3.11 MTKDEL redistributes pp60c-src 
Cells were fixed and permeabilised before staining for total MT (ii, green) and pp60c-src (i, red) 
as described before. Open arrows indicates pp60c-src at the cell periphery. Cell type was 
indicated above each column of images. Non-transfected Rat-2 fibroblasts were used as control. 
Images were taken on TCS SP5 confocal microscope using 63.0x1.40 oil UV lens with zoom 
factor 1.  
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Figure 3.12 Single-cell images showing pp60c-src and MT distribution in cell lines 
Single-cells from images shown in Figure 3.11 were selected for high resolution imaging. 
Antibodies used are indicated above the top panel. Cell types are indicated on the right. Images 
were taken on a TCS SP5 confocal microscope using 63.0x1.40 oil UV lens.  Scale bar, 5 µm. 
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3.2.5 MT Membrane Insertion Mechanism 
Several lines of evidence suggest MT is inserted by the newly discovered GET/TRC 40 
system. The hydrophobic TMD is so close to the C-terminus that it must be released from the 
ribosome before it can interact with the membrane machinery for insertion (Borgese, 
Brambillasca et al. 2007). Membrane insertion of MT C-terminus does not happen 
spontaneously but is likely to require post-translational targeting machinery (Kim, Janiak-
Spens et al. 1997). The TMD of MT has an estimated hydrophobicity value of 63.7, 
calculated as described by Kyte and Doolittle (Kyte and Doolittle 1982) as the sum of 
hydrophobicity values for the amino acids in MT hydrophobic sequence (see Table T3.2).  
  
Figure 3.13 pp62c-yes distribution is not affected by the MT expressed in cells 
Dual MT - pp62c-yes staining was performed as described in Figure 3.11. Cell type is 
indicated above each column of images. Non-transfected Rat-2 fibroblasts were used as 
control. Images were taken on TCS SP5 confocal microscope using 63.0x1.40 oil UV lens with 
zoom factor 4.5.  
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Table T3.2 
Side-chain 
Single letter  
amino acid code 
Hydrophobicity 
index 
Isoleucine I 4.5 
Valine V 4.2 
Leucine L 3.8 
Phenylalanine F 2.8 
Cysteine/cystine C 2.5 
Methionine M 1.9 
Alanine A 1.8 
Glycine G -0.4 
Threonine T -0.7 
Tryptophan W -0.9 
Serine S -0.8 
Tyrosine Y -1.3 
Proline P -1.6 
Histidine H -3.2 
Glutamic acid E -3.5 
Glutamine Q -3.5 
Aspartic acid D -3.5 
Asparagine N -3.5 
Lysine K -3.9 
Arginine R -4.5 
 
The same hydrophobicity scale was used by Rabu et al, as well as Kalbfleisch et al in 
a bioinformatics study to identify TA proteins in the human genome (Kalbfleisch, Cambon et 
al. 2007, Rabu, Wipf et al. 2008).  Integration of TA proteins with such a high 
hydrophobicity is not obligatory clients for the Hsp40/Hsc70 chaperone (Rabu, Wipf et al. 
2008), but more likely to utilise the high ATP-input route mediated by the recently 
discovered cytosolic TMD-recognition complex (TRC) (Stefanovic and Hegde 2007) or a 
combination of the two pathway. The 40 kDa subunit of TRC is an ATPase, identified as 
Table T3.2 Kyte and Doolittle’s hydrophobicity scale  
Amino acids with increasingly hydrophobic side chains are assigned with more positive 
values while hydrophilic side chains are assigned with more negative values.  
Adapted from Kyte and Doolittle, 1982. 
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TRC40/ASNA1. Here we investigate whether MT can physically associate with the TRC 
core ATPase, ASNA1 (a mammalian homologue to arsenite-stimulated ATPase in bacteria). 
Commercially available antibody raised against ASNA1 (Abcam, ab81979) did not 
bind strongly to ASNA but cross-reacted with a high molecular weight polypeptide in rabbit 
reticulocytes lysate (results not shown). A rabbit anti-ASNA1 serum was kindly donated to us 
by Dr Matthias Seedorf from Heidelberg University. After careful optimisation of this 
antibody, immunoprecipitation of MT in cells expressing wild type or MTKDEL was 
analysed for ASNA1 association but did not yield any detectible band in the region of 40 
kDa, Figure 3.14.  
 
 
 
Figure 3.14 Analysis of MT and ASNA1 association by immunoprecipitation 
Equal volumes of lysates from wtMT or MTKDEL stable cell lines were immunoprecipitated with 
PAb762. Non-transfected Rat-2 lysates was used as a control. The volume of lysates used was 5 
times more than the volume used for MT-binding signalling molecule analysis. Wash buffer with 
0.005% NP40 was used instead of the normal 0.05% NP40. 5 µl lysate samples were analysed 
for total ASNA1 content using a rabbit antibody against ASNA1 from Dr Matthias Seedorf (i). 
Immunoprecipitated samples were analysed for ASNA1 (ii) and MT (iii) using biotinylated 
mouse monoclonal PAb762. Migration positions of target molecules are indicated with open 
arrows on the right. 
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Using a TNT reticulocyte lysate in vitro translation system, we attempted to assess 
whether newly synthesised MT polypeptide can associate with ASNA1. In this system, RNA 
is synthesised in vitro from T7 RNA polymerase promoters in cell-free rabbit reticulocyte 
lysate. These mRNAs are subsequently translated into polypeptides, which are capable of 
binding to cellular proteins already present in the reticulocyte lysate as well as co-translated 
proteins. pcDNA3.1 plasmids carrying MT cDNA under the T7 promoter were previously 
constructed by Prof. Dilworth. Initial immunoprecipitates of the in vitro translated MT failed 
to show the presence of ASNA1 (results not shown). This may be due to the low level of 
native ASNA1 in the reticulocytes lysate. An expression plasmid of mouse ASNA1 with a T7 
promoter (pYX-ASNA1) was subsequently obtained from Open Biosystems. Co-translating 
equal amounts of wild-type MT and ASNA1expression plasmids in vitro, the newly 
synthesised MT molecules were immunoprecipitated with PAb762 and separated by SDS-
PAGE. Rabbit polyclonal antibody against ASNA1 was used to detect the presence of the 
ATPase. Analysis of post-reaction samples showed there is a small increase of ASNA1 when 
pYX-ASNA1 plasmid was added (Figure 3.15 A (ii)).  There is a very weak signal in MT 
immunoprecipitates that co-migrates with the band detected in the positive control when both 
plasmids were added (Figure 3.15 A (i)).  When MT and ASNA1 were co-translated, there 
was also a strong lower molecular weight protein (~ 30 kDa) that was reactive to anti-
ASNA1 antibody. However, this molecule was not seen again in subsequent in vitro co-
translation experiments (Figure 3.15 B (i) and results not shown). Immunoblotting for PP2A 
subunit A on the same nitrocellulose membrane showed the MT binding partner was co-
immunoprecipitated with the newly synthesised MT by PAb762, thus indicating that in vitro 
translated MT was capable of associating with signalling molecules proteins present in 
reticulocyte lysates.  
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 MTKDEL which localises to the ER should in theory be more accessible to the 
membrane insertion machinery that includes TRC40/ASNA1 and therefore a larger 
population of MTKDEL may associate with the ATPase. In an attempt to trouble shoot the 
MT – ASNA1 binding assay, pcDNA3.1 plasmid carrying MTKDEL cDNA was constructed 
by substituting the pcDNA3.1 wtMT C-terminus sequence with that of pUC19 MTKDEL. 
However, pcDNA3.1MTKDEL plasmid did not translate well in vitro despite DNA 
sequencing data confirming the presence of the MTKDEL sequence (data not shown).  
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Figure 3.15 In vitro co-translated MT and ASNA1 failed to associate 
A. Analysis of MT immunoprecipitates after in vitro translation. 1µg of pcDNA3.1-MT plasmid 
was added with or without 1µg pYX-ASNA1 to a TNT reticulocyte lysate in vitro translation 
system according to the manufacturer’s recommendation. PAb762 was added to reaction 
mixtures after in vitro translation to immunoprecipitate MT and subsequently analyse for 
ASNA1 association (i). 1 µl of reticulocyte lysate without DNA was loaded in lane d as a positive 
control. Mouse IgG band at 55 kDa was cut away to reduce non-specific signals. 1 µl post-
translation lysate from each reaction mixtures was analysed for ASNA1 content (ii). cDNA added 
is indicated above each lane. Migration positions of target molecules are indicated with open 
arrows on the right. 
B. Independent repeat of experiment described in A. Antibodies used are indicated above each 
blot. Rat monoclonal antibody against PP2A subunit A (6G3) (Santa Cruz) or rabbit antibody 
against ASNA1 were used to detect their presence in the MT immunoprecipitates (i). 1 µl post-
translation lysate from each reaction mixtures was analysed for ASNA1 or MT content (ii). 
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3.2.6 The C-terminal hexapeptide has a functional role  
The MT hydrophobic sequence is followed by a hexapeptide, KRSRHF, rich in positively 
charged amino acids and is exposed on the extracellular surface of the cell. Although Dahl 
and co-workers concluded that the hexapeptide C-terminal to the MT hydrophobic sequence 
is dispensable for transformation, some mutants generated in this lab suggest that positively 
charged amino acids on both sides of the hydrophobic sequence are equally important for 
transformation (data not shown). We next looked at the effect on MT transformation when 
the hexapeptide is partially or completely deleted. Deletion mutants of the C-terminus were 
generated from MTHA+ plasmid by Dr N. Ichaso. ∆419-421MTHA+ is missing the latter 
half of the hexapeptide (RHF) while ∆416-421MTHA+ has the whole hexapeptide 
(KRSRHF) sequence removed (see Figure 3.16 A for sequence comparison). Transformation 
abilities of the two mutants were assayed by foci formation in Rat-2 fibroblast monolayer. 
Removal of the final three amino acids from the MT C-terminus had no effect on 
transformation ability while deletion of the whole hexapeptide completely abolished foci 
formation (Figure 3.16 B). In stable cell lines, the amount of ∆416-421MTHA+ was similar 
to wtMTHA+ (Figure 3.16 C). In fact, the transforming mutant ∆419-421MTHA+ was 
expressed less well. Therefore the lack of foci formation was not due to difference in 
expression level. ∆416-421MTHA+ was able to associate with PP2A core dimer and pp60c-
src, but associated weakly with ShcA and PI3K p85 subunit. The amount of pp62c-yes in 
416-421MTHA+ was very low (Figure 3.17 A). The weak detection of signalling molecules 
bound to ∆419-421MTHA+, a transformation-competent mutant was probably due to a lower 
level of MT immunoprecipitated from cell lysate. Immunoprecipitation analysis had been 
repeated and the findings were consistent (data not shown). HA tags can be detected on the 
cell surface of ∆419-421MTHA+ but not ∆416-421MTHA+ (Figure 3.17 B upper panels). 
Analysis of MT distribution revealed that ∆416-421MTHA+ appeared to be trapped in 
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intracellular membranes (Figure 3.17 B lower panels). However, Western-blotting analysis of 
∆416-421MTHA+ showed that the HA tag had been cleaved in this mutant, Figure 3.17 C. 
 
 
 
Figure 3.16 Loss of hexapeptide is inhibitory in HA-tagged MT 
A. Amino acid sequences of MTHA+ C-terminus with the deletion of three or six final residues. 
Designation of each MT species is listed on the left. MT mutant plasmids were generated by Dr 
N. Ichaso.  
B. Transformation potential is assayed by foci formation. Sub-confluent Rat2 fibroblasts on 10 
cm tissue culture dishes were transfected with 10 µg of plasmids carrying the above sequences.  
Images are of two independent foci assays.  
C. Expression of MT in mutants shown in part A. Cell lines expressing each of the mutant MTs 
shown in panel A were isolated. Lysates were collected from confluent plates of cells. An equal 
volume of cell lysate from each line was separated by SDS-PAGE, Western-blotted, and then 
probed with anti-MT monoclonal antibody PAb762. 
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Figure 3.17 Immunofluorescence and immunoprecipitation analysis of ∆416-421MTHA+ 
A. Analysis of ability to bind signalling molecules in mutants shown in Figure 3.12. MT-
immunoprecipitates were obtained as described before. Antibodies used to immune-bind (IB) 
known MT-associating proteins are shown above each panel. The migratory position of each 
detected polypeptide species is indicated by an open arrow to the right. 
B. Hexapeptide mutant distribution was assessed by IF. Antibody against HA (HA11) or MT 
(PAb762) was added before or after fixation to label surface or total population of MT 
molecules, respectively, in cell lines indicated above the top panels. Cells were photographed 
using a Nikon inverted epifluorescence microscope at low magnification. Images of MT mutants 
are representative of an average of 11 independent frames. 
C. Cleavage of HA tag in mutant ∆416-421MTHA+. Lyastes from stable expression cell lines were 
separated by SDS-PAGE, Western-blotted, and then probed for HA. Membrane was then stripped 
of HA antibody before re-probing for MT using PAb762. Volume of mutant lysates were 
normalised against MT level in wtMTHA+. Two clones of ∆416-421MTHA+ were tested as 
indicated above the top panel.   
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In order to further investigate the sequence specificity of the C-terminus hexapeptide, 
a deletion mutant was made without the HA tag (∆416-421MT) (Figure 3.18 A), based on the 
one designed by Dahl et al. (Dahl, Thathamangalam et al. 1992), along with a six-Glycine 
substitution of the region in HA-tagged MT (416G6MTHA+) (Figure 3.19 A). The number of 
foci formed by ∆416-421 MT was clearly lower than the wild-type MT-transfected cell 
monolayer (Figure 3.18 B). Uneven drying of the plates resulted in large circles of darker 
colours in the background. Similar to ∆416-421MT, 416G6MTHA+ show low frequency of 
foci formation when transfected into Rat-2 fibroblasts (Figure 3.19 B). Expression levels of 
both ∆416-421MT and 416G6MTHA+ were comparable to wild type (Figure 3.20). This 
suggests the sequence of the hexapeptide has a functional purpose for MT transformation of 
fibroblasts. 
 Cell lines expressing ∆416-421MT showed normal MT distribution, in perinuclear 
and peripheral membrane (Figure 3.18 C). The mutant 416G6MTHA+ can be detected at 
perinuclear region as well as peripheral membrane, much like wtMTHA+. However the HA 
tag was not detected on the cell surface of 416G6MTHA+ (Figure 3.19 C). Western blotting 
for total MT in both ∆416-421MT and 416G6MTHA+ revealed lower molecular weight 
fragments reactive to anti-MT antibody, and only the upper band of 416G6MTHA+ was 
reactive to the HA antibody (Figure 3.20). ∆416-421MT and 416G6MTHA+ were able to 
associate with all signalling molecules, including pp62c-yes, to the same level as 
corresponding wild type. Immunoprecipitation experiments had been repeated with additional 
clones for each mutant (data not shown). 
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Figure 3.18 Loss of C-terminal hexapeptide reduced the ability of MT to transform fibroblasts  
A. ∆416-421 MT sequence compared to wild type. Designation of each MT species is listed on 
the left.  
B. Transformation potential was assayed by foci formation. Sub-confluent Rat2 fibroblasts on 
10 cm tissue culture dishes were transfected with 10 µg of plasmids carrying the above 
sequences.  Images are representative of two independent foci assays.  
C. ∆416-421 MT distribution at the plasma membrane. PAb762 was used to label MT in cells 
after fixation and permeabilisation. Cells were photographed using Nikon inverted 
epifluorescence microscope at low magnification. Images of ∆416-421 MT are representative 
of at least 11 independent frames from two independent experiments. Open arrows indicate 
the presence of MT at peripheral plasma membranes.  
D. Analysis of the ability of ∆416-421 MT to bind signalling molecules. Lysates from Rat-2 
fibroblasts stably expressing each mutant, as indicated above each lane, were analysed for MT 
content then normalised volumes of lysates were used for IP with PAb762. The 
immunoprecipitates were separated by SDS-PAGE for Western blotting. Cell line used for IP is 
indicated above each lane. Two different clones of ∆416-421 mutants were analysed (see 
numbers in brackets). Antibodies used to immunobind (IB) known MT-associating proteins are 
shown above each panel. The migratory position of each detected polypeptide species is 
indicated by an open arrow to the right. 
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Figure 3.19 Six-Glycine substitution of the C-terminal hexapeptide inhibited transformation 
A. 416G6 MTHA+ sequence compared to wild type. 
B. Transformation potential was assessed by foci formation, as described in Figure 3.18. 
C. 416G6 MTHA+ distribution at the plasma membrane. Antibody against HA (HA11) or MT 
(PAb762) was added before or after fixation to label surface or total population of MT 
molecules, respectively, in cell lines indicated above the top panels. Open arrows indicate the 
presence of MT at peripheral plasma membranes. Images of cells were obtained with Leica 
TCS SP5 confocal microscope using 63.0x1.40 lens. 
D. Analysis of 416G6 MTHA+ ability to bind signalling molecules. MT molecules were 
immunoprecipitated from lysates after normalising against of MT expression level as 
described in Figure 3.18.  
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Figure 3.20 Expression levels of hexapeptide region mutants  
A. ∆416-421 mutant expression levels are comparable to wild type. MT cDNAs carrying 
deletion or glycine substitution of sequence ∆416-421 were expressed in Rat-2 fibroblasts. 
Lysates were collected from confluent stably clones grown on 10 cm tissue culture dishes. 
Varying volume of each lysate were analysed for MT contents compared to wild type by 
Western blotting using PAb762 anti-MT antibody. MT species expressed are indicated above 
the panels. Volumes (µl) of lysate loaded are indicated below each lane.  
B. HA-tag analysis in 416G6 MTHA+. Equal volumes of lysates from cell expressing MT species 
indicated above each lane were separated by SDS-PAGE and transferred on to membrane by 
Western blotting. Membrane was first probed for HA tag then thoroughly washed in 1x TBS-T 
before MT detection. The upper half of the membrane was separated and probed for Hsp90 as 
a loading control. MT species expressed is indicated above each lane Antibodies used for 
immune-binding are indicated above each panel. Migratory positions of target molecules are 
indicated by open arrows. 
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3.3 DISCUSSION: 
3.3.1 Summary 
Murine PyV MT is a transmembrane protein that binds signalling molecules in discrete 
subcellular membrane sites (Figure 3.21). In this study, we have demonstrated that MT is a 
true tail-anchored integral transmembrane protein with a C-terminus translocated to the 
surface of the cell and a cytosolic N-terminal domain that binds signalling molecules. Newly 
translated MT can probably bind PP2A subunit A and C core dimer in the cytosol as MT 
lacking TMD has been shown to co-immunoprecipitate with PP2A (Messerschmitt, Disela et 
al. 1996). MT is first inserted in to ER membrane where it can bind pp60c-src but must 
migrate out of the ER in order to associate with additional signalling molecules such as 
pp62c-yes, ShcA, PI3K p85 and PLC-γ1 en route to the plasma membrane to fully transform 
fibroblasts (Figure 3.21). The ability of MTKDEL to selectively sequester pp60c-src in the 
ER provides the possibility of differentiating signal pathways controlled by pp60c-src and 
pp62c-yes. The TMD sequence plays a role in targeting MT to the membrane insertion 
machinery, which is mostly likely to involve the recently discovered TRC40/ASNA1 post-
translational membrane insertion complex. In addition, association and probably the 
activation of PP2A are required for MT migration out of the ER to higher membrane sites.   
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Figure 3.21 A schematic representation of the sequence of events during the maturation of a 
transforming MT complex  
Starting in the bottom right hand corner, where MT is synthesised in the cytoplasm on free 
polysomes, the stages in MT maturation through the ER, exocytic membranes to eventually 
reach the plasma membrane are shown. At each stage, the cellular proteins added to the MT 
complex are illustrated. A representative mutant that blocks each individual step is also 
indicated. Published on Zhou, et al. J Virol, 2011. 
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3.3.2 MT is an integral transmembrane protein that is first inserted in the ER 
By the addition of two independent epitope tags, HA and FLAG, to the MT C-terminus, we 
can now confirm that MT is a transmembrane tail-anchored protein with a cytoplasmic N-
terminus, a hydrophobic sequence spanning the lipid bilayer and that the C-terminus is 
translocated to the outer surface of cells. HA- and FLAG-tagged MT can be detected on the 
surface of transfected cells when primary antibodies specific for each tag sequence are added 
to living cells before fixation and without the need for permeabilisation of cell membranes 
(Figure 3.1). Both tags are widely used for studying the function and distribution of a wide 
range of proteins as well as purification and identification of the fusion proteins. Due to their 
small sizes, these epitope tags can be added to the C-terminus of MT without affecting its 
ability to transform cells, unlike a GFP insertion into MT sequence, which disrupted MT 
function (unpublished data).  
In order to assess whether MT located in the endoplasmic reticulum (ER) can 
generate transforming signals, a specific ER- retention sequence, KDEL, was added to MT C-
terminus. The complete localisation of MTKDEL in the ER suggests MT must be first 
inserted into membrane at the ER as insertion in any other localisation would bypass the 
KDEL receptor. Our results agree with previous observation that newly synthesised MT first 
accumulated in the perinuclear membranes soon after MPyV infection (Dilworth, Hansson et 
al. 1986). 
 We found that MT localised to the ER by KDEL cannot transform fibroblasts and that 
MTKDEL fails to associate with ShcA, p85 subunit of PI3K and PLC-γ1 despite binding and 
activating pp60c-src (Figure 3.2 - 3.5). Therefore the inability of MTKDEL to transform 
fibroblasts is probably due to the lack of access to ShcA, PI3K and PLC-γ1 rather than the 
lack of phospho-tyrosine sites on MT as MTKDEL was phosphorylated by the activated 
pp60c-src bound to this mutant (see Figure 3.6 for kinase assay results).  
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Our results correlate well with reports that BPV E5 localised in the ER inhibited 
transformation despite the mutant’s ability to induce PDGFRβ activation and auto-
phosphorylation (Sparkowski, Anders et al. 1995) (see section 1.12 for introduction). Bovine 
papilloma virus (BPV) E5 is thought to activate the PDGFRβ in the Golgi by stabilising the 
active conformation of the receptor that is normally induced by the binding of ligands to the 
extracellular domains at the cell surface (Sparkowski, Anders et al. 1995, Lai, Henningson et 
al. 1998). We observed that mutant ∆402-406 is retained in the Golgi but can associate with 
all know signalling molecules of MT, indicating that they are all accessible to MT at this 
location in the cell (see Figure 4.14 in Chapter 4 or List of Mutants). However, in addition to 
the association with mitogenic signalling molecules, additional properties are required for 
MT to transform cells as mutant ∆402-406 failed to transform fibroblasts. 
 
3.3.3 MTKDEL redistributes pp60c-src but not pp62c-yes 
MTKDEL binds and redistributes pp60c-src but not pp62c-yes to the ER (Figure 3.10 - 3.12). 
This is most probably because MT has a higher affinity for pp60c-src over pp62c-yes 
(Kornbluth, Sudol et al. 1987). It is also possible that the known differences in trafficking 
between pp60c-src and pp62c-yes might be of relevance. Newly synthesised pp62c-yes 
initially accumulates in the Golgi region and is then trafficked to the plasma membrane 
through the exocytic pathway, a process mediated by the palmitoylation sites in the N-
terminus (Sato, Obata et al. 2009). Unlike pp62c-yes, pp60c-src is not palmitoylated and does 
not traffic through the Golgi (McCabe and Berthiaume 1999, Resh 1999, Sato, Obata et al. 
2009). pp62c-yes is of known importance to MT transformation because in mouse models of 
hemangioma (benign tumours of the blood vessels). pp62c-yes knock-out mice respond much 
more weakly to MT, forming fewer tumours and with longer latency that do pp60c-src or 
pp59c-fyn knock-outs (Thomas, Aguzzi et al. 1993, Kiefer, Anhauser et al. 1994). In 
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contrary, pp60c-src is more important for mammary tumour formation in the MMTV-MT 
mouse model (Guy, Muthuswamy et al. 1994). Consequently it would be of interest to study 
the general role of pp62c-yes in signalling in isolation from the much better studied pp60c-
src. MTKDEL may be a useful tool for this purpose.  
 
3.3.4 PP2A plays a role in MT migration to higher membrane sites 
Since ER-localised MT cannot transform fibroblasts, there must be some kind of signal on 
the MT sequence that targets the tumour antigen to the plasma membrane where it can 
associate with additional signalling molecules such as ShcA adaptor proteins, p85 subunit of 
PI3K and PLC-γ1. The generally accepted view is that the plasma membrane targeting signal 
is contained within and round the TMD of the TA protein (Borgese, Brambillasca et al. 
2007). We investigated whether the hydrophobic sequence alone can dictate where in the cell 
MT is eventually located and we found two lines of evidence that the hydrophobic sequence 
in itself is not sufficient for targeting MT to the plasma membrane, association with the PP2A 
core dimer is also important. We first substituted the MT hydrophobic sequence with a 
transmembrane sequence from another TA transmembrane protein Sec61β, which resides 
mainly in the ER and its localisation is thought be mediated through its TMD sequence 
(Butler, Watson et al. 2011). Transformation efficiency assayed by foci formation was 
reduced in MT Sec61β but not inhibited (Figure 3.2). More of MTSec61β was located in the 
ER compared to normal MT but a substantial amount still reached the plasma membrane 
(Figure 3.5). This indicates that there is a dominant MT property outside of the 
transmembrane region which contributes to directing MT to the plasma membrane. 
 Our lab and others have previously reported that MT mutants lacking the ability to 
bind PP2A are retained in cytoplasmic membranes, probably the ER (Brewster, Glover et al. 
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1997). Re-examining the subcellular distribution of these mutants confirmed the correlation 
between the lack of PP2A association and localisation of these mutants in cytoplasmic 
membranes resembling the ER (Figure 3.5 – 3.9 and Table T3.1). Using antibody PAb701 
which specifically binds to the MT N-terminal region required for PP2A association (Figure 
3.8), we visualised the sub-population of MT, which has not yet associated with PP2A or has 
lost this association in the cell, and found that this subpopulation of MT is localised to mostly 
cytoplasmic or perinuclear regions (Figure 3.9 and Table T3.1). Taken together, our data 
suggests strongly that association with PP2A is required for MT to relocate from the ER to 
the plasma membrane (Zhou, Ichaso et al. 2011). 
Interestingly, treatment with OA, an inhibitor of PP2A Ser/Thr phosphatase activity, 
also resulted in accumulation of MT in the cytoplasmic membrane, while inhibition of Src 
kinase activity with dasatinib did not affect MT distribution (Figure 3.7). This observation 
could be due to OA inhibition of PP2A or to general disruption of protein export through the 
Golgi which has also been reported (Dinter and Berger 1998, Pryde, Farmaki et al. 1998). 
The nano molar concentrations of OA used in our study are likely to inhibit PP2A with high 
specificity. In fact, PP2A in complex with MT becomes extra sensitive to OA inhibition, 
probably due to changes in PP2A substrate specificity upon binding to MT (Cayla, Ballmer-
Hofer et al. 1993, Favre, Turowski et al. 1997). 
There is increasing evidence to support a role for PP2A in regulating exocytosis. 
PP2A has been shown to regulate cell surface expression of the T cell receptor (Lauritsen, 
Menne et al. 2001), mast cell degranulation (Sim, Ludowyke et al. 2006) and insulin 
secretion in rat pancreatic cell line INS-1 cells (Kowluru, Seavey et al. 1996). It has been 
suggested that phosphatases such as PP2A bound to multi-unit complexes such as the MT 
signalosome, which contains kinases, may act as a constitutive regulatory complex for rapid 
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response to positive or negative stimuli (Mandavia and Sowers 2012). Overall, we have 
found strong evidence that PP2A plays a regulatory role in trafficking.  
 
3.3.5 Membrane Targeting and Insertion Mechanism for Tail-Anchored Proteins  
While the C-terminal hydrophobic sequence of MT is responsible for association with 
cellular or artificial membranes, in vitro microsome association assays demonstrate that the 
wild-type protein does not spontaneously insert into membranes (Hofer, Wehrle et al. 1995, 
Kim, Janiak-Spens et al. 1997). Unlike many cell surface GFRs which are inserted by a co-
translation insertion mechanism, MT lacks the ‘signal peptide’ N-terminal to the hydrophobic 
sequence (Templeton, Voronova et al. 1984). Because of the close proximity of the 
transmembrane hydrophobic region to the C-terminus of TA proteins, the translated peptide 
needs to be released from the ribosome first before membrane integration. There are two 
distinct pathways for assisted insertion of TA proteins, the Hsp40/Hsc70-mediated pathway 
and the newly discovered TRC40/ASNA1 mediated pathway, which is homologous to the 
post-translational Guided Entry of Tail-anchored (GET) protein pathway found in yeast 
(Stefanovic and Hegde 2007, Favaloro, Spasic et al. 2008). Several lines of evidence suggest 
MT is inserted by the Transmembrane Domain Recognition (TRC) pathway. The 
hydrophobicity of the TA region dictates whether a precursor is delivered to the ER via the 
molecular chaperones Hsp40/Hsc70 or the TRC40/ASNA1-dependent route (Stefanovic and 
Hegde 2007, Favaloro, Spasic et al. 2008, Rabu, Wipf et al. 2008). The hydrophobicity value 
of MT TMD is similar to those found in the hydrophobic region of many SNARE proteins 
which regulate the transport of vesicles inside the cell. It was found that SNARE proteins 
preferentially utilise the TRC40/ASNA1 pathway for their insertion into the ER membrane 
(Borgese, Brambillasca et al. 2007, Rabu, Wipf et al. 2008). However, many obstacles 
prevented the elucidation of possible MT and ASNA1 association. Among all the known 
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GET pathway components in yeast (Get1/Get2/Get3/Get4/Get5/Sgt2), only Get3 ATPase 
homology, TRC40/ASNA1 has been identified in the mammalian system so far (Jonikas, 
Collins et al. 2009, Stefer, Reitz et al. 2011, Kubota, Yamagata et al. 2012). Therefore, it is 
possible that MT does not have to directly bind to TRC40/ASNA1. In order to study MT 
membrane insertion mechanism, expression of MT mutants in the yeast system is probably 
required.  
There are over 300 Tail-anchored (TA) proteins found in mammalian cells, examples 
include many SNARE proteins, subunits of the cytochrome complex (cytochrome b5) found 
on the outer membrane of mitochondria and Bcl-2 family proteins that regulate apoptosis 
(Borgese, Colombo et al. 2003, Rabu, Schmid et al, 2009). MT and its C-terminal mutants 
may be additional tools for the study of the process of TA transmembrane protein biogenesis 
in mammalian cells. 
 
3.3.6 Residues KRS adjacent to the hydrophobic sequence are important for MT 
function 
We have also found that deletion or mutation of the three residues immediately C-terminal to 
the hydrophobic sequence can also affect transformation (mutant ∆416-421 and 416G6 MT).  
It has been suggested amino acids immediately surrounding the hydrophobic regions are 
important for the function of MT in transformation and may act as anchors at the membrane 
borders (Templeton, Voronova et al. 1984). Focus assay results in Figure 3.18 and 3.19 
suggest sequence KRS (416-418), has a role in MT function. Removal or Glycine substitution 
of this sequence resulted in proteolytic cleavage from the C-terminal end as the lower 
fragment of 416G6MTHA+ was only reactive to anti-MT but not anti-HA antibody. It seems 
that the C-terminus hexapeptide enriched with positively charged amino acids may serve to 
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protect the MT C-terminus from degradation. Both mutant ∆419-421MT and 416G6MTHA+  
bind to all tested MT-associating signalling molecules, including pp62c-yes, at levels 
comparable to wild type MT (Figure 3.18 and 3.19). Therefore, additional properties other 
than binding to Src and signalling molecules are important for MT transformation. The HA-
tag added to 416G6 was not detected on the cell surface (Figure 3.19).  The lack of HA-
tagged MT on cell surface suggests that the C-terminus of mutant 416G6MTHA+ fails to 
translocate across the lipid bilayer, such that both the N- and C-termini are orientated towards 
the inside of the cell. Positively charged residues, often located near the boundaries of 
transmembrane segments, appear to be involved in specifying the topology of membrane 
proteins (Dalbey 1990) (Dahl, Thathamangalam et al. 1992). The juxtamembrane region near 
the cytosol-membrane or extracellular-membrane interface of a GFR often modulates TMD 
dimerisation, oligomerisation and kinase domain activation (Irusta and DiMaio 1998, 
Arkhipov, Shan et al. 2013). The role of MT TMD topology is explored in the next chapter. 
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CHAPTER 4 – ONCOGENIC SIGNALLING BY MPyV MT OCCURS IN 
DISCRETE MEMBRANE COMPLEXES 
 
4.1 INTRODUCTION: 
We have demonstrated in the previous chapter that once inserted into the ER, the MT binds to 
pp60c-src, and then a combination of the TMD sequence and the PP2A binding site is 
responsible for MT migrating into the membrane compartment beyond, where it interacts 
with PI3K, ShcA and PLC-γ1 (Figure 3.21).  However, there must be an additional function 
for the TMD as hydrophobic domain mutants have been isolated that still bind to membranes 
but fail to transform (Markland, Cheng et al. 1986). In the previous chapter, we also 
demonstrated that deletion of the three amino acids immediately C-terminal to the 
hydrophobic sequence, KRS, also reduced foci formation, but still associated with 
membranes and all known MT-binding proteins (Figure 3.18 and 3.19). Hydrophobic 
sequence of VSV G protein and cytochrome b5 failed to functionally replace MT TMD 
sequence. Both hybrid MT species associated with membranes but failed to transform 
(Templeton, Voronova et al. 1984, Kim, Janiak-Spens et al. 1997). All of this evidence points 
to additional properties encoded in the MT TMD sequence, which is probably required for 
transformation. 
 To examine the membrane binding and location requirements for MT to transform, a 
series of mutants in the C-terminal region were generated and studied in detail by 
immunofluorescence (IF) and immuno-electron microscopy (IEM). We report here that MT 
can be detected in discrete signalling clusters in the outer cell membrane. New non-
transforming mutants defective in their ability to form clusters, despite their association with 
all known signalling partners, have been isolated from this study, therefore suggesting that 
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assembly of a macromolecular complex is an essential requirement for MT oncogenic 
signalling. Activated growth factor receptors are also found in similar clusters suggesting 
complexes are also required for their activity. In addition, we show that the length and 
sequence of the TMD are important for targeting MT from the Golgi apparatus to the plasma 
membrane. 
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4.2 RESULTS: 
4.2.1 MT forms large complexes on cell surface 
Previously, we have shown that a short epitope tag, such as an extended version of the HA 
tag or  the FLAG tag can be added to the C-terminus of MT without affecting its 
transforming potential Both epitope tags can be detected on the surface of cells expressing 
these tagged MT species. Therefore at least a detectable population of MT is located on the 
cell surface. Close examination of surface MT with either an anti-HA or anti-FLAG antibody 
at high magnification revealed that surface MT molecules are not uniformly distributed but 
are present in discrete patches (Figure 4.1 A). When a single cell was imaged from top to 
bottom at high magnification, the punctate spots were observed throughout the whole 
external membrane, from the top of the nucleus (where the spots are observed in a single 
small area) to the bottom under the bottom surface of the cell (Figure 4.1 B). Some of these 
patches are over one micron across (Figure 4.2), which is too big to contain only one MT 
molecule.  
These complexes are not likely to be caused by endocytosis induced by antibody cross 
linking because permeabilisation of the plasma membranes after live incubation with anti-HA 
antibodies did not increase the level of epitope tag staining (Figure 4.3) and surface MT 
clusters did not colocalise with markers for endocytosis. APPL-1 is a marker for peripheral 
recycling vesicles and EEA-1 and Rab-5 are early endosome markers (Figure 4.4). Upon 
binding to primary antibody, MT does not readily enter into the cells, unlike transferrin 
receptors. The process of endocytosis can be tracked by incubating cells expressing MT-
FLAG in media containing Alexa Fluor 488-conjugated human transferrin and rabbit anti-
FLAG antibodies for 30 min at 37ºC and very little FLAG antibody was found inside the 
cells (results not shown).  
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Figure 4.1 Surface MT is found in discrete focal patches over the whole surface of the cell 
A. IF analysis of surface labelled MT viewed under x 100 high magnification. Cells expressing 
epitope-tagged MT, as indicated below the panel, were incubated with anti-HA or anti-FLAG 
primary antibody at 37oC before fixing. Images were acquired using Nikon inverted 
epifluorescence microscope with 100x magnification lens. Surface labelled of HA was 
performed by S. Dilworth. Surface FLAG labelling was performed on a separate occasion. 
B. Surface MT clusters were distributed on the whole of cell surface. IF labelling surface MT 
was performed, as described above. Z-stack images were taken at 0.13 µm intervals on Leica 
SP5 confocal microscope at high magnification. Cell types are indicated on the left. Antibodies 
added are indicated on the right. Images are shown from the bottom (a), middle (b) and top 
(c) of the stack. Scale bar, 5 µm. Images in A and B are representative of at least 4 cells for 
each mutants from at least 4 repeated experiments. 
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Figure 4.2 Large complexes of MT on the cell surface membrane 
Cells expressing epitope-tagged MT, as indicated on the left were incubated with anti-HA (a, 
c) or anti-FLAG (b, d) primary antibody before fixing. Non-transfected Rat-2 fibroblasts 
were used as a control (c, d). High magnification images of cell under surface are acquired 
using confocal microscope. Antibody used is indicated above and below the panels. 
Examples of MT surface clusters with an equivalent diameter of 1 µm are circled. Scale bar, 
2 µm. 
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Figure 4.4 Surface MT does not colocalise with endosome markers 
MT on cell surface was labelled by incubating live cells in media containing anti-HA or anti-
FLAG antibodies (green) for 30 min before fixing. Cells were subsequently permeabilised 
and antibodies targeting individual endosome markers were added, as indicated in red. 
Nuclei were stained by DAPI (blue). Scale bar = 5 µm. 
 
Figure 4.3 Permeabilisation of plasma membrane does not enhance the fluorescence signals 
of externally labelled HA-tags 
Cells expressing HA-tagged MT were incubated with anti-HA primary antibody before fixing 
with (b) or without (a) membrane permeabilisation step. Fluorescent-conjugated secondary 
antibody was added to label HA. Non-transfected Rat-2 fibroblasts were used as control (ii). 
X20 magnification images of cells were acquired using Nikon fluorescent light microscope. 
Cell types are indicated on the left.  
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Surface MT analysis was performed by adding antibody for 20 – 30 minutes to living 
cells as we found it impossible to exclude a small amount of antibody penetration into cells 
after fixation. However, even though the time was short, it is still feasible that the patches 
observed were a consequence of cross-linking the MT through the use of divalent antibodies. 
To exclude this possibility, we first varied the time of addition of the anti-HA primary 
antibody between 1 minute and 6 hours, and in various buffers. In Dulbecco’s PBS (DPBS), 
the number of complexes and their size did not vary with time, only the intensity of staining 
altered (data not shown). However, in DMEM the number and size of complexes remained 
similar up to 4 hours, but then smaller quantities of larger complexes were observed. It seems 
likely, therefore, that incubations of 30 minutes or less are unlikely to cross link the MT. To 
Figure 4.5 MTFLAG clusters on the cell surface can be labelled at 4˚C  
Surface labelling of FLAG tag at 4˚C and 37˚C was performed with the same antibody dilution as 
described in material and methods. After fixing, fluorescent-conjugated secondary antibody was 
subsequently added at RT to label the FLAG tag. The fluorescent signals on the basement 
membrane of a cell were captured using Leica SP5 confocal microscope with 63.0x1.40 oil lens, 
zoom factor 6. Each image represent an area of 20.5 x 20.5 µm. Scale bar = 2 µm. 3 independent 
frames are shown for IF labelling FLAG at 4˚C (top panels) and 37˚C (bottom panels), 
respectively. 
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provide confirmation of this, we next performed live cell labelling at 4
o
C when the surface 
proteins are unlikely to move within the 30 minute time scale of the experiment. Previous 
experiments performed by Stainman et al had established that the process of endocytosis 
slows down at lower temperatures and become negligible below 10
o
C (Steinman, Silver et al. 
1974, Silverstein, Steinman et al. 1977). The number and size of MT containing clusters 
labelled with anti-FLAG antibodies on the surface of cells expressing wild type MTFLAG 
did not change between incubation at 4
o
C or 37
o
C (Figure 4.5), only the intensity varied. 
Therefore it seems likely that these clusters are not caused by the addition of the antibody to 
living cells, but already exist on the cell surface. These patches are much too large (generally 
larger than 0.1 µm
2
, an area equivalent to a circular complex with a diameter of 400 nm) to 
represent a single MT molecule, so it seems likely that MT is present in discrete complexes 
on the surface of cells. This is verified by a high degree of colocalisation between the FLAG-
tags labelled from the cell surface and MT labelled internally (Figure 4.6). Therefore the MT 
complexes detected by IF are a genuine representation of MT distribution on the cell surface. 
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In order to quantify the level of colocalisation between surface MT complexes and 
MT on the cytoplasmic leaflet of the plasma membrane, pixels from the two different 
fluorescent channels were analysed by using  the JACoP plug-in for Image J developed by 
Bolte and Cordelieres (Bolte and Cordelieres 2006). The degree of colocalisation between the 
red (MT N-terminus labelled with PAb762) and green (surface labelled MT) channel is 
measured by Mander’s overlap coefficient, M1 and M2, respectively. M1 represents the 
fraction of red pixels co-localising with the pixels in the green channel and M2 represents the 
fraction of green pixels co-localising with the red pixels at the same position. Since M2 is 
generated from the surface MT signals, it can be interpreted as the surface MT complexes co-
localising with internally labelled molecules. Pearson’s co-efficient (Pr) is a measurement of 
the quality of colocalisation that is how much each pixel is deviating from the central axis of 
colocalisation between the two channels. A Pr value of + 1 indicates perfect colocalisation; 0, 
reflects an independent relationship between the two channels; -1, represents mutually 
Figure 4.6 MT clusters labelled from the cell exterior correlate with MT molecules labelled from 
the inside of cells 
A. Dual IF labelling of surface FLAG and total MT. Rabbit anti-FLAG antibodies were added to 
living cell. After fixation and permeabilisation, cells were incubated in PAb762 mouse anti-MT 
N-terminus to label total MT from the inside. Species-specific Alexa Fluor 488- and 555-
conjugated secondary antibodies were added to label FLAG (green) and MT (red) respectively. 
Non-transfected cells were labelled in the same conditions. An area of 20.5 µm x 20.5 µm on cell 
basement membrane was shown. M1 and M2 values for each image are indicated below the 
panel. 
B. Surface FLAG tag colocalising with MT labelled from the inside of a cell. Zoom-in images from 
above highlighted area are shown (10.25 µm x 10.25 µm). The population of MT labelled in 
each channel is indicated above the panel, with surface labelled FLAG in green and total MT in 
red. Scale bar, 2 µm. 
C. Quantitative co-localisation analysis for surface MTFLAG complexes and MT at the plasma 
membrane compared to control cells.  Zoom-in images of 20.5 x 20.5µm were used for 
colocalisation analysis with ImageJ Plug-in (JACoP). 6 independent frames of MTFLAG and 4 of 
control were used for analysis. Results shown are representative from at least 3 independent 
experiments. 
See image on previous page. 
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exclusive relationship (www.svi.nl/ColocalizationCoefficients). As Figure 4.6 C shows, 
colocalisation between surface MT complexes and MT on the inside of the cell occurs at 
about 80%. Although Pr and M2 values are low, these may be distorted by the much more 
numerous and intense pixels from the red channel.  
 
4.2.2 Surface MT complexes contain signalling molecules 
Incubation of living cells expressing epitope-tagged MT with tag-specific antibodies allows 
the detection of the MT located on the extracellular surface of the plasma membrane, 
therefore separating the population of MT on the cell surface from those located on the 
cytoplasmic leaflet of the plasma membranes. Figure 4.6 shows this is a valid method for 
analysing surface MT colocalisation with molecules located on the inner membrane leaflet. 
Next, we investigated whether these large surface complexes of MT contain active signalling 
molecules. Most of the MT present in cells is associated with PP2A, but less than 20% binds 
to a Src family tyrosine ((Bolen, DeSeau et al. 1987) and unpublished data). Association 
between MT and pp60c-src causes a rapid phosphorylation of ShcA on tyrosine 239, 240 and 
317 (Nicholson, Empereur et al. 2001).  
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Figure 4.7 Colocalisation level between activated ShcA and surface MT complexes in cells 
expressing wild type or the non-transforming mutant 200∆10 MTHA+  
A. Dual IF labelling of surface HA complexes with activated ShcA. Surface MT was labelled 
with a mouse anti-HA antibody added to living cells before fixation. Total internal 
phosphorylated ShcA was labelled with rabbit antibody specific to phosphorylated Y317 and 
Y239 after membrane permeabilisation. Secondary anti-mouse IgG coupled to AlexaFluor488 
and anti-rabbit IgG antibody coupled to AlexaFluor555 was added to label MT (green) and 
phospho-ShcA (red). Images were taken on Leica SP5 confocal microscope. An area of 20.5 x 
20.5 µm was shown for each channel. Scale bar, 2 µm. The MT species expressed are 
indicated to the left of the panel, and the primary antibody used above each image. 
B. Colocalisation analysis for surface MT and phospho-ShcA Pixels in an area of 20.5 x 20.5 
µm were analysed using the ImageJ Plug-in (JACoP) using Costes’ randomisation method. At 
least 12 independent frames from each cell type were used for analysis. 
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In order to determine whether the clusters of HA-tagged MT on the cell surface 
membrane represent active signalling complexes or ‘uncomplexed’ inactive MT, we 
performed dual immunofluorescence labelling to detect the location of surface wtMTHA+ 
and phosphorylated ShcA (Y239/Y240/Y317) in the same cells. Figure 4.7 A shows there is a 
high degree of co-localising between surface MT complexes and phosphorylated ShcA in 
confocal micrographs with wild type MT expressing cells, but very little overlap in cells 
expressing a mutant 200Δ10 MTHHA+, which fails to bind c-SRC and subsequent signalling 
molecules including ShcA (Brewster, Glover et al. 1997). This mutant does not possess Src 
tyrosine kinase binding region near the N-terminal region while its PP2A binding sequence is 
preserved (Brewster, Glover et al. 1997). Despite not associating with SRC tyrosine kinase 
and other signalling molecules, 200Δ10 MTHA+ does still form surface clusters (Figure 4.7 
A). To confirm this qualitative observation of co-localisation, a series of these images were 
analysed by the ImageJ JACoP plug-in (Bolte and Cordelieres 2006). Figure 4.7 B shows the 
results of this analysis and demonstrates a significant co-localisation between surface MT and 
phospho-ShcA in wild type MT expressing cells, but little with the non-ShcA binding mutant 
200Δ10. Therefore, these surface MT clusters contain active ShcA molecules, so are likely to 
represent active signalling complexes, but probably do not require the binding of Src tyrosine 
kinase to form. 
To investigate whether the activity of Src tyrosine kinase is required for MT cluster 
formation, we next treated cells that express wild type MTHA+ with dasatinib, a tyrosine 
kinase inhibitor with dual specificity for Src and Bcr-Abl, for 48 hrs before labelling surface 
HA and activated ShcA. Figure 4.8 A shows the signal of phospho-ShcA was reduced 
dramatically by dasatinib treatment without affecting the formation of MT complexes on cell 
surface. Colocalisation analysis showed that the amount of surface MT complexes containing 
activated ShcA dropped to the basal level observed in mutant 200Δ10. A similar graph was 
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produced when Pearson’s coefficient was analysed (data not shown). Therefore the 
colocalisation between surface MT complexes with activated ShcA is specific to MT 
transformation activity. The formation of large MT complexes on the cell surface membrane 
does not appear to require Src tyrosine kinase activity. 
Figure 4.9 demonstrates the effectiveness of dasatinib concentration used in above 
assays. Tissue culture media containing 10 or 100 nM dasatinib inhibited foci formation 
normally induced by MT transfection when the inhibitor was added one day after the 
transfection with fresh drug added every 3 or 4 days. Transformed cells preferentially utilise 
the glycolytic pathway to generate energy to meet their high metabolic demands. The lactic 
acid produced as a by-product of glycolysis reduces the pH in the culture media and causes a 
colour change in the media from pink to yellow. Even at 1 nM, dasatinib slowed down the 
proliferation of cells expressing MT and prevented this colour change during the 48hr 
incubation period. 
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Figure 4.8 Dasatinib reduces colocalisation level between activated Shc and surface MT 
complexes  
A. Surface MTHA+ complexes and total internal phospho-Shc A were labelled as described in 
Figure 4.5A. An area of 20.5 x 20.5 µm is shown. Scale bar, 2 µm. Treatment is indicated to the 
right of the panel, and the primary antibody used above each image. Wild type MTHA+ cells 
were treated with either 50 nM dasatinib or vehicle (DMSO) in 10% serum tissue culture media 
for 48hr before IF staining. 
B. Fraction of surface MT complexes colocalising with phospho-Shc A. Analysis was performed 
as described in 4.5B. At least 12 independent frames from each cell type were used for analysis. 
M2 values, representing the fraction of surface HA colocalising with internal phospho-Shc A, 
were obtained from 5 frames of DMSO-treated MTHA+ cells, 9 frames of dasatinib-treated cells 
and 7 frames of 200∆10HA+ cells.  
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Figure 4.9 Growth inhibition of MT-expressing cells by dasatinib 
A. Colorimetric determination of effective dasatinib concentration. SubconfluentRat-2 
fibroblasts expressing wtMT or non-transfected cells were seeded on to 24-well plate. Next 
day, increasing concentrations of dasatinib were added to cells in 10% FCS tissue culture 
media. Equal volume of solvent, DMSO, was added to the well above or below the well with 
dasatinib. Cells were grown for 48hr before scanning. Effectiveness of dasatinib at various 
concentrations was inversely correlated to the colour change of the media.  
B. Dasatinib inhibits MT-induced foci formation. Subconfluent Rat-2 fibroblasts grown on 10 
cm tissue culture dishes were transfected with 10 µg wtMT plasmids overnight (b – e). Cells 
were grown for two weeks in tissue culture media with dasatinib at 10 nM (d), 100 nM (e) 
concentration, or, vehicle (DMSO) equivalent to 100 nM dasatinib (d). Tissue culture fluids 
were changed every 3 to 4 days with fresh inhibitor/ DMSO added. Mock transfection 
without DNA or drug treatment was used as a control. 
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4.2.3 New non-transforming mutants of MT TMD isolated 
The transmembrane region of MT must have properties important for transformation, in 
addition to its role in localising MT to the membrane since not all transmembrane domains 
can replace the MT hydrophobic sequence (Templeton, Voronova et al. 1984, Markland, 
Cheng et al. 1986) (Kim et al., 1997), suggesting that another property in addition to 
membrane binding is also required..  
 Upon ligand binding, many receptor tyrosine kinases dimerise via a central segment 
in the TMD (Sternberg and Gullick 1989). Introduction of a charged residue in the central 
region of the hydrophobic membrane spanning sequence of some receptors results in close 
packing of neighbouring α-helices by generating additional hydrogen bond links, hence 
constitutive dimer formation and receptor activation, which contributes to naturally occurring 
diseases (Sternberg and Gullick 1989, Gullick, Bottomley et al. 1992). Examples of 
constitutively activating mutant growth factor receptors include the oncogenic Neu/ErbB2 
mutation V664E (Hynes and Stern 1994) and FGFR3 mutation G380R implicated in 
achondroplasia, a form of dwarfism (Shiang, Wasmuth, et al. Cell, 1994). There is some 
similarity between a five-amino-acid stretch of the TMD of MT and Neu (Figure 4.10), 
although it should be noted that the two membranes have opposite topology.  Nevertheless, 
we were interested in testing the effect of equivalent neu mutation upon MT function. 
Consequently, the membrane spanning sequence on MT was replaced by those from wild 
type neu receptor and constitutively activated neu-mutant (V664E) by Dr N. Ichaso and Prof. 
S. Dilworth. In addition, MT L405E, which simulates the activating neu V664E, and MT 
G406L, which is equivalent to an inhibitory Neu mutation, were also generated (Gullick, 
Bottomley et al. 1992). Interestingly, the results were exactly the opposite of those expected 
from their effects on receptor kinase activation. The wild type neu hydrophobic sequence was 
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able to replace the MT TMD and induced foci formation, but the neu mutant sequence with a 
V664E mutation could not. G406L transformed almost as well as wild type MT, whereas 
mutant L405E completely inhibited foci formation (Figure 4.10). Deletion of the central five 
amino acids (Δ402-406, Figure 4.10) also abolished transformation but this may reflect the 
shortening of the hydrophobic sequence rather than any specific effect (see 4.2.5 below). 
Substituting short stretches of MT hydrophobic sequence with Alanine did not affect the 
transformation potential of MT (394A4 to 412A4, Figure 4.10) so there seems to be little 
sequence specificity in the hydrophobic region of MT. However, during this study, new 
mutants had been isolated which completely abolished foci formation and some of these were 
characterised here. 
 Cell lines stably expressing various MT mutants shown in Figure 4.10 were isolated. 
Analysis of immunoprecipitated L405E and the neu-mutant showed that the two non-
transforming mutants are capable of binding to all of the signalling molecules that bind 
directly to the transformation competent MT (Figure 4.11 A). Although there seems to be less 
ShcA in the L405E immunoprecipitates, this is likely due to a variation in the amount of 
mutant MT pulled down from that particular experiment. Repeated immunoprecipitation 
experiments found comparable level of ShcA and PI3K in complex with L405E as with wild 
type (see Figure 4.16). A kinase assay, performed by Prof. S. Dilworth, on the 
immunoprecipitated MT mutant, showed L405E and the signalling molecules bound to it 
were phosphorylated, including Grb2 (data not shown). Therefore, the lack of transforming 
activity in mutant L405E and neu-mutant was not due to a deficiency in association, and 
subsequent activation, with known MT-interacting signalling proteins. These results also 
imply  that the mutant MT species must have inserted into cellular membranes as expected, as 
mutants that fail to interact with membranes do not bind to pp60c-src and other signalling 
polypeptides (Carmichael, Schaffhausen et al. 1982, Markland, Cheng et al. 1986). 
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Figure 4.10 Mutagenesis of MT hydrophobic sequence and their effects on MT transformation 
Residues or sequence mutated are highlighted in gray. Bold letter indicates residues mutated 
in constitutive activation mutants of neu(neu-mutant) or FGFR3 receptor (FGFR3-
mutant).Transformation efficiency was assayed by the ability to induce foci formation when 
transfected into Rat-2 fibroblast cell monolayer and results are summarised on the right with 
‘-’ being non-transforming and, ‘++++’ being equivalent to wild type levels of transformation. 
Mutants were constructed by Dr Ichaso and Prof. Dilworth. Foci assays were performed by 
Kunal Shah and others.  
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Figure 4.11 Characterisation of non-transforming TMD mutants L405E and neu-mutant 
A. New hydrophobic domain mutants bind to signalling molecules. Cell lines expressing each 
MT species were generated and lysates were collected. Each MT expressed was 
immunoprecipitated from a volume of lysates normalised against MT level. WB analysis was 
performed to identify each MT-associated polypeptide, as indicated above each panel. Open 
arrows to the right indicate the migratory position of the target polypeptide labelled above 
each panel. IP and WB were performed by Prof. S. Dilworth. 
B. Lack of surface staining in non-transforming neu-mutant. IF staining for surface tag was 
performed using an anti-HA antibody added to living cells followed by fixation and then 
fluorescent-conjugated secondary added. Total MT was labelled by PAb762 after fixation. Cells 
were imaged at low magnification using a Nikon inverted epifluorescence microscope. IF was 
performed by Prof. S. Dilworth. 
C. HA tags on hydrophobic domain mutants remain intact. After normalising MT level, lysates 
from various hydrophobic domain mutants with added HA+ were analysed by Western-blotting 
for HA (i). The membrane was stripped and re-probed for total MT (ii). Lane f and g are from 
two clones of ∆416-421MTHA+ (b1 & d3), which were found to have lost their HA-tags. 
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4.2.4 Subcellular location and distribution of MT hydrophobic domain mutants 
The lack of transformation by MT mutants L405E and neu-mutant, despite their interaction 
with all the known MT associated proteins, suggested yet again that an unidentified property 
of MT related to membrane binding is also required for its transforming ability. To determine 
whether precise location could be this additional activity, the subcellular distribution of these 
mutants in stable cell lines were examined by immunofluorescence (IF) with the mouse 
monoclonal PAb762 reactive to MT N-terminal sequence (Figure 4.12 B (i)). The results for 
mutants G406L and L405E are compared to wtMT. Very little difference between all three 
cell lines could be observed. Like wild-type MT, the non-transforming mutant L405E is 
localised to both intracellular membranous compartment as well as the plasma membrane. 
We had previously observed the formation large complexes of wild type MT on the outer cell 
membrane (Figure 4.1 and 4.2). To examine whether these complexes are present on the 
surface of cells expressing these novel TMD mutants, an HA+ tag sequence was added to the 
C-terminal tails of these MT mutants and cell lines expressing each species were established. 
Properties of these epitope-tagged mutants, including transformation, protein binding and 
total MT immunofluorescence patterns, were similar to those of the untagged mutant (data 
not shown). The amount of HA+ tag exposed on the cell surface of these lines was then 
detected with an anti-HA antibody added to living cells before fixing. As Figure 4.12 B (ii) 
shows, there is very little HA+ exposed on the surface of L405E MTHA+ expressing cells 
compared to the wild type and transforming mutant G406L. Again, the results were verified 
by adding an HA+ tag to the MT neu-wt and MT neu-mutant constructs and examining 
surface HA-tags (Figure 4.11 B). Western blot analysis showed that the HA-tag was not 
cleaved from the C-terminus of L405E (Figure 4.12 C) and that the amount of HA tag present 
in the lysates of L405E and G406L were comparable after normalising MT content. 
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Therefore, it is likely that the C-terminus of the hydrophobic domain mutant, L405E, failed to 
translocate across to the cell surface membrane. Similar findings were observed with neu-
mutant MTHA+ (Figure 4.11 B & C), so we concentrated on the MT L405E and MT G406L 
mutations. 
 
 
 
  
Figure 4.12 L405E C-terminus failed to translocate to the outer cell surface 
A. Hydrophobic sequence of TMD mutants with HA+ tag. Cell lines stably expressing these 
mutants were generated by N. Ichaso and S. Dilworth.  
B. Lack of surface HA staining in non-transforming L405E HA+. Total MT in cell lines 
expressing untagged MT mutants (a - c) was labelled by PAb762 after fixation (i). Surface MT 
in cell lines expressing MT with HA+ tag (d – f) was labelled by anti-HA antibody added to 
living cells prior to fixation (ii). Cells were photographed using a Nikon inverted 
epifluorescence microscope. Magnifications are indicated on the right; antibodies used are 
labelled on the left; cell lines are indicated above or below the panel. 
C. HA tag is not cleaved in L405EHA+. After normalising MT level, lysates from hydrophobic 
domain mutants with HA+ tag were analysed by Western-blotting for HA (i). The membrane 
was stripped and re-probed for total MT (ii). Non-transfected Rat-2 lysate was used as control. 
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In order to verify our results with L405E HA+, FLAG-tagged versions of mutants 
L405E and G406L were constructed. The transformation potentials of the two mutants were 
assayed by their ability to induce foci formation when transfected into fibroblast cell 
monolayer (Figure 4.13 B). The mutant L405E MTFLAG was completely defective for its 
ability to transform, whereas G406L MTFLAG induced a moderate number of foci formation 
in Rat-2 fibroblasts (note that G406L also had a lower transformation potential compared to 
wild type, Figure 4.10). Stable cell lines were generated and L405E MTFLAG localisation to 
the plasma membrane was confirmed by labelling MT with PAb762 and the plasma 
membrane with Alexa Fluor 594-conjugated wheat germ agglutinin (WGA) (Figure 4.14 C). 
WGA binds to sialic acid residues, commonly found on glycosylated proteins and lipids on 
the cell surface membrane. The fluorescent conjugated WGA does not penetrate the cell 
membrane and therefore only labels the plasma membrane of cells. In stable cell lines, very 
little of the epitope tag was detected on the surface of stable cell lines expressing mutant 
L405E FLAG, while the transforming counterpart G406L FLAG showed translocation of the 
C-terminal tag to the  cell exterior (Figure 4.13 D). The FLAG tag remains intact on the 
L405E C-terminus (Figure 4.13 E).  
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Figure 4.13 Hydrophobic domain mutants with FLAG-tag  
A. Hydrophobic sequence of TMD mutants with FLAG tag. Mutations are indicated in bold with 
underline.  
B. L405E mutation abolishes transformation. Foci formation assays were performed with 10 µg 
plasmids carrying wild-type or TMD mutants as described before. Mock transfection without 
plasmid was used as control.  
C. L405E FLAG is present at the plasma membrane. Cell lines stably expressing mutants shown in 
A were generated. Plasma membranes in cells stably expressing wild-type or mutant MTFLAG 
were labelled with AlexaFluor594 WGA. After fixing and permeabilisation of membranes, total 
MT in cells was labelled with PAb762 anti-MT. Z-stack image of a single cell was obtained using a 
Leica SP5 confocal microscope 63.0x1.40 oil lens, step size = 0.13 µm. Only the cross-section near 
the bottom of the cell is shown. Open arrows indication colocalisation between MT (green) and 
WGA (red). Scale bar = 20 µm. 
D. IF analysis of FLAG-tag on cell surface. IF labelling for the surface tag was performed using an 
anti-FLAG antibody added to living cells stabling expressing the mutants (indicated above the 
panel), prior to fixing. Cells were imaged using Leica SP5 confocal microscope at low 
magnification Scale bar = 50 µm. 
E. FLAG tag is not cleaved in L405EFLAG mutant MT. After normalising MT level, lysates from 
wild-type and mutant MTFLAG were analysed for FLAG-tag (i) by Western-blotting. The 
membrane was then stripped and re-probed for MT using PAb762 (ii). Non-transfected Rat-2 
lysates was used as a control. 
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The lack of surface fluorescence signal for the epitope tag in L405E mutant was not 
due to its lower expression level in stable cell lines. Cells transfected with plasmids carrying 
FLAG- or HA-tagged L405E using Attractene transfection reagent, which allows transient 
but higher expression level of plasmids, also did not show surface HA or FLAG tag 
fluorescent signal (results not shown). Mutant L405E is stably expressed. A commonly used 
protein synthesis inhibitor, cycloheximide (CHX), at concentrations known to impact on the 
stability of cellular proteins (Schneider-Poetsch, Ju et al. 2010), did not affect L405E protein 
level over a 48-hr period (Figure 4.14). Therefore the lack of L405E C-terminus presentation 
on the cell surface is a genuine feature of this mutant that correlates with its inability to 
transform fibroblasts. Interestingly, AKT but not MAPK activation is highly compromised in 
cells expressing L405E (Figure 4.15). 
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Figure 4.15 Analysis of downstream signalling effectors in cells expressing mutant L405E  
Lysates collected from cells expressing wild type or mutant L405E MT were normalised against 
protein concentration before loading on to a 10% bis-acrylamide gel. After SDS-PAGE protein 
separation and WB, the nitrocellulose membrane was probed for phosphorylated AKT, phospho-
MAPK/ ERK. Non-stimulated parental Rat-2 cells were used as a control for the activated signalling 
molecules. Amount of α-tubulin was analysed as a loading control.  
Figure 4.14 Mutant L405E MT is stable 
A. Cycloheximide does not affect MT protein levels in the wild type MT and the L405E 
mutant. Cells stably expressing wtMT or L405E mutant were treated with 100 ng/ml 
cycloheximide (CHX) or the same amount of vehicle (ethanol). Lysates were collected at the 
indicated time points (hrs). Protein concentration for each sample was determined by BCA. 
After normalising lysate concentrations for each cell line, lysates were separated by SDS-
PAGE and WB for MT using PAb762 (i) and α-tubulin (ii).  
B. Ponceau S protein staining for the membrane shown in A. After polypeptides were 
transferred on to nitrocellulose membrane by WB, the membrane was incubated in Ponceau 
S protein stain for 15min to evaluate protein levels prior to blocking in 5% milk.  
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Our results suggest that the defect of L405E may be the change of its C-terminus 
topology. In order to verify the topology of L405E hydrophobic domain, the KDEL sequence 
was added to L405E C-terminus (Figure 4.16 A). Since the KDEL receptor is in the lumen of 
the ER and cis- Golgi, the ER localisation sequence should have no effect on the distribution 
of L405E, in contrast to MTKDEL (Chapter 3, Figure 3.3). Cell lines expressing L405E 
KDEL was generated and the distribution of this mutant was assessed by immunofluorescent 
labelling. Instead of forming a distinctive tubular network pattern in the cytoplasm like 
MTKDEL, L405E KDEL was seen as much diffused granular staining throughout the 
cytoplasm that reaches the cell periphery (Figure 4.16 C). MTKDEL can bind to PP2A and 
pp60c-src but because it is trapped in the ER it cannot bind to pp62c-yes, ShcA, PLC-γ1 and 
PI3K p85. Analysis of immunoprecipitated L405E KDEL showed that the mutant binds to 
normal level of PP2A and pp60c-src but the level of associated pp62c-yes, ShcA and PI3K 
p85 was much reduced compared to wild type MT and L405E; he mutant, however, does 
bind to PLC-γ1 (Figure 4.16 D). The expression levels of L405E KDEL in all of the clonal 
lines generated were very low (data not shown). The double mutant L405E KDEL is 
therefore probably unstable, which may affect its association with some of the signalling 
molecules tested. Overall, L405E KDEL does not seem to be trapped in the ER compartment 
by the added ER-retention sequence. Therefore, the C-terminus of L405E is likely to 
orientate towards the inside of the cell, probably in a hair-pin conformation.  
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Figure 4.16 Characterisation of L405E KDEL 
A. TMD sequence of L405E with KDEL added to the C-terminus. Positions in the complete 
sequence are indicated with numbers above corresponding amino acids at 10-residue intervals.  
B. Foci assay for L405EKDEL. Cells were transfected with wild-type or L405EKDEL plasmid 
using method descried previously. Plasmids used are indicated above the panel. 
C. L405EKDEL can be found at the peripheral cell membrane. Total MT were labelled with 
PAb762 after cells were fixed and permeabilised. Cell lines used are indicated below the panel. 
Open arrow indicated MT localisation at the peripheral plasma membrane. Scale bar = 10 µm.  
D. Protein binding property of L405EKDEL was analysed. PAb762 was used to IP MT from 
volumes of lysates normalised against MT level. Immunoprecipitates were separated and 
immunoblotted for known MT-binding partners. Mutants are indicated above each lane. 
Migration positions of polypeptides tested are indicated with arrows to the right.  
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Although the non-transforming mutants insert into the ER, and exit to other 
membrane compartments, they may still have a reduced level of surface expression that is 
difficult to observe (Figure 4.12 B). To investigate this further, immunofluorescent signals of 
the C-terminal HA-tag on cell surface were examined under high magnification using 
confocal scanning microscope, which is more sensitive than fluorescent light microscope and 
allows resolution of fluorescent beads of 170 nm apart (Bolte and Cordelieres 2006). The 
fluorescent signals generated from surface HA-tags were compared between wild type 
MTHA+, L405E HA+, dl1015 HA+ and non-transfected parental Rat-2 fibroblasts. Dl1015 
HA+ is a non-transforming mutant with a deletion of the Proline-rich region of MT and is 
known to associate with all immediate MT-binding proteins but cannot transform 
(Magnusson and Berg 1979, Magnusson, Nilsson et al. 1981) (unpublished data). Expression 
of this non-transforming mutant is relatively low (data not shown).  
 
 
Figure 4.17 Measuring surface HA fluorescence signals 
A. Examples of high magnification images of surface labelled HA used for analysis. Cells 
expressing wtMTHA+ (a), L405EHA+ (b) or dl1015HA+ (d) were incubated with anti-HA 
antibody before fixation. The fluorescent signals on the cell basement membrane were captured 
using Leica SP5 confocal microscope with 63.0x1.40 oil lens, zoom factor 6. An area of 20.5 µm x 
20.5 µm was selected for analysis. Scale bar = 2 µm. 
B. Average number of complexes counted per frame in cell lines shown in A. Macro 1 was 
applied to each image. A binary mask of each image was made with threshold =15. Using 
‘analyse particle’ the number of complexes were counted. 8 independent frames of each cell line 
were used for analysis. 
C. Distribution of MTHA clusters across a range of cluster size. Using ‘analyse particle’ function 
in ImageJ, the area covered (µm2) by each complex was measured and converted to diameter 
(nm). MT species expressed by the cells are indicated above each graph.  
D. Numbers of complexes larger than 300 nm across are compared between wild type and 
mutant MT. The total number of complexes with area greater than 0.071 µm2 or a diameter of 
300 nm was counted for each image. 
See image on next page. 
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The C-terminal HA-tag can be detected on the basement membrane surface of cells 
expressing dl1015 HA+ despite at much lower intensity (Figure 4.17 A). The surface 
fluorescent signals detected on cells expressing L405E HA+ were similar to background 
level. The number of fluorescent signals on the cell basement membrane can be counted 
using ImageJ software (see Material & Method). The area covered by individual cluster of 
fluorescent signals was measured (µm
2
), which was then converted to equivalent size in 
diameter (nm) (see Figure 4.18 for examples). Although some HA complexes were detected 
on the surface of L405E mutant, the majority of these complexes are 300 nm or less in 
diameter, which can also be detected in the control (Figure 4.17 A & B). The number of these 
background clusters in L405E HA was higher than the control but extremely low compared to 
wild type and dl1015 MTHA (Figure 4.17 B). In cells expressing wild type and dl1015 
MTHA, there are a lot of complexes with sizes larger than 300 nm in diameter, some of 
which are larger than 500 nm in diameter (Figure 4.17 C & D). The distribution of the 
L405EHA+ fluorescent signals counted follows the same pattern observed in control cells 
(Figure 4.17 C) with few complexes larger than 300 nm counted. These measurements seem 
to suggest that formation of large MT complexes on the outer cell surface may be required for 
transformation. However, confirmation would require a more sensitive method of 
microscopy. 
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Figure 4.18 Measuring surface fluorescent complexes 
A. Steps of measuring surface complexes of varying sizes. (a) Confocal image of HA tags on 
the cell surface in an area of 20.5 µm x 20.5 µm. Surface HA-tag of wild type MTHA+ was 
labelled as described previously. Scale bar (black line) = 2 µm. (b) Using ImageJ, a mask is 
generated (threshold =40). (c) Complexes with an area smaller than 0.05 µm2 are excluded.  
B. Defining complexes of increasing sizes or area covered by pixels. Left column: images of 
complexes matching the size limited are generated from (c). Middle column: limit on area 
covered by the pixels in each complex. Right column: equivalent numbers of complexes 
covered by the area defined on the left. 
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In order to resolve MT molecules with higher resolution, the location of MT in wild 
type MTHA+ and L405E MTHA+ was examined by immuno-electron microscopy with the 
help of our collaborators, Dr Forstova and Dr Zila. Here, PAb762 was used to label the total 
MT inside the cells and detected by binding with 10 nm gold particles (GPs) coated with anti-
mouse IgG. Electron micrographs show that wtMTHA+ is present at the plasma membrane. 
The wild type MTHA+ labelled with gold particles were usually found in clusters of 4 or 
more gold particles, therefore confirming that MT exists in large multimeric complexes at the 
plasma membrane (Figure 4.19 A (a, c)). In cells expressing L405E MTHA+, gold particles 
were also observed at the plasma membrane (Figure 4.12 A (b, d)), but very few were found 
in clusters. To quantify this, a large number of electron micrograph fields were analysed and 
clusters were evaluated by counting the gold particles at the plasma membrane. A cluster was 
defined as four or more gold particles continuously occupying the same discrete area at the 
plasma membrane. Three or less gold particles in close proximity were counted as ‘non-
clusters’. Figure 4.19 B (a) shows that over 20% of the gold particles labelled in cells 
expressing wild type MT are found in clusters of 4 or more particles, whereas less than 2% of 
the L405E MT was labelled in similar clusters. Counting clusters made of more than 4 GPs 
revealed a marked difference between WT MT and mutant L405E (Figure 4.19 B (b)). 
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Figure 4.19 IEM analysis of wild type and L405E MT at the plasma membrane  
A. IEM images of MT at the plasma membrane. Cells expressing wild type (a, c) or L405E (b, 
d) were immune-labelled with a mouse anti-MT monoclonal primary antibody, PAb762, and 
then a goat anti-mouse secondary antibody conjugated to 10 nm gold particles. Scale bar, 50 
nm. Experiments performed by Dr J. Forstova and Dr V. Zila. 
B. Cluster analysis of gold particles at the plasma membrane. Many sections of each cell line 
were used for evaluation. A total number of 1165 gold particles (GP) were counted in wtMT, 
261 gold particles were found in 54 clusters. For L405E cells, a total number of 1145 gold 
particles were counted and 24 of them were found in 6 clusters. Figures provided by Dr V. 
Zila. 
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Therefore, it seems likely that the defect in L405E MT is not its ability to bind to 
cellular membranes and to signalling proteins, but its incapacity to assemble efficiently into a 
multi-subunit complex once at the membrane, and this lack of complex formation may 
account for its inability to transform. Indeed, the ability to activate the downstream signalling 
effecter AKT was highly compromised in mutant L405E when compared to cells transformed 
by wild type MT (Figure 4.15).  
Together, these data indicate that L405E MTHA+ is inserted into the membrane but 
fail to translocate the C-terminus to the outer cell surface. As a consequence, L405E MTHA+ 
does not appear to form large multimeric complex, and does not transform. The ability to 
form large, active clusters in the plasma membrane is likely to be required for transformation 
of fibroblasts and is a new property discovered in the MT transmembrane domain.  
 
4.2.5 Characterisation of Other Hydrophobic Domain Mutants  
Although Alanine substitution in the hydrophobic domain did not affect MT-induced 
transformation, some different mutations in this region completely abolished foci formation. 
As it was demonstrated for neu-wt and neu-mutant MT, G406L and L405E MT, it is 
important to characterise the non-transforming mutants in order to deduce properties required 
for cellular transformation. Amongst the hydrophobic sequences of receptor tyrosine kinases 
tested, only those from wild type neu receptor and PDGFRβ can replace MT hydrophobic 
sequence without inhibiting transformation (Figure 4.10). Substitution of MT hydrophobic 
sequence with that of wild type FGFR3 (FGFR3-wt) or the activating mutation G380R 
(FGFR3-mutant), both failed to induce foci formation (Figure 4.10). Very little of the mutant 
FGFR3-wt or FGFR3-mutant MT was detected at the cell periphery (Figure 4.20). 
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Immunofluorescent labelling of the two MT mutants showed strong signals in the perinuclear 
region which colocalise with Golgi marker, giantin (results not shown). 
 
 
 
 
 Another non-transforming TMD mutant described earlier in Figure 4.10 is ∆402-
406MT, which lacks the five amino acid sequence, AALLG, central to the hydrophobic 
sequence. An HA+ tag added to the C-terminus of this mutant was not detected on the surface 
membrane in cells transiently expressing this mutant (data not shown), therefore the lack of 
transformation was initially attributed to a change in TMD conformation. Here, a cell line 
expressing ∆402-406 MTHA+ was generated and immunofluorescence analysis of MT 
distribution revealed an unusual localisation of this mutant. Figure ∆402-406MTHA+ was 
exclusively found in large distinctive patches next to the nucleus and colocalised perfectly 
with the Golgi marker, giantin (Figure 4.21 B). Cells expressing this mutant did not grow 
very well hence the low number of cells present in the image (Figure 4.21 A). Western blot 
analysis shows that some ∆402-406MTHA+ was degraded from the C-terminal end (Figure 
4.21 D). Despite this, ∆402-406MTHA+ associated with all known MT-binding molecules at 
Figure 4.20 Hydrophobic sequences from FGFR3 receptors localise MT to intracellular 
membranes 
Plasmids carrying wtFGFR3 MT or –mutant FGFR3 MT were transfected into Rat-2 cells using 
Attractene transfection kit. Location of the mutants were analysed after 48 hrs using PAb762 
monoclonal that binds to MT N-terminus. Cells were photographed at x100 magnification. 
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levels comparable to wild type MT (Figure 4.21 C), including pp62c-yes, which was not 
observed in MTKDEL (Chapter 3, Figure 3.10). However, the phosphorylation states of the 
associated signalling molecules were not evaluated. Although it is possible that mutant ∆402-
406 was relocated from the plasma membrane to the Golgi apparatus, fluorescence signal was 
not detected in endosome- or microsome-like structure near the cell periphery. It is more 
likely that the shortening of the hydrophobic sequence probably caused the retention of ∆402-
406 MT in the Golgi membrane. The length of the MT hydrophobic sequence is, therefore, 
important for targeting MT to the plasma membrane.  
Results with above transformation-defective mutants suggest that, once transported to 
the Golgi apparatus, MT probably will have access to all of its direct binding proteins such as 
pp62c-yes, ShcA, PI3K subunit p85 and PLC-γ1 in addition to the PP2A core dimer and 
pp60c-src bound in the cytoplasm and the ER, respectively.  
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Figure 4.21 MT localised to the Golgi apparatus associates with all signalling molecules 
A. ∆402-406MT is localised in Golgi apparatus. Total MT were labelled with PAb762 after cells 
were fixed and permeabilised. Cell lines used are indicated above the panel. Scale bar = 50 µm. 
B. Colocalisation between ∆402-406MT and Golgi marker. MT (red) was labelled as described 
above. Alexafluor-555-conjucated anti-mouse IgG was then added to cover-glass in 
conjunctionwithAlexafluor-488-conjucated rabbit anti-giantin antibody (green). Nuclei were 
labelled with DAPI (blue) imaged on Leica SP5 confocal microscope using 63.0x1.40 oil UV lens 
using zoom factor 4.5. Scale bar = 5 µm. Images are representative of at least 12 independent 
frames. 
C. Protein binding properties of ∆402-406MT were analysed. PAb762 was used to IP MT. 
Immunoprecipitates were separated and immunoblotted for known MT-binding partners. 
Mutants are indicated above each lane. Migration positions of polypeptides tested are indicated 
with arrows to the right.  
D. Analysis of MT expression level in ∆402-406MT mutant. Lysates proportional to the volume 
used for IP were analysed for C-terminal HA tag with HA11 (top) and then re-blotted for total 
MT with PAb762 (bottom). 
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4.2.6 Evaluating the amount of actively signalling MT 
In previous sections, we have demonstrated that in order to transform fibroblasts, MT must 
migrate to the peripheral plasma membrane. In addition, MT molecules must assemble into 
large multimeric clusters in order to generate transforming signals and this requires the 
translocation of the C-terminus to the outer cell surface. Therefore MT detected at the cell 
exterior represents the most active signalosomes. We next tried to address a long standing 
question of how much of the MT polypeptides are actively signalling. Since we have 
demonstrated that surface MT can be immune-labelled by adding an antibody specific to the 
C-terminal epitope tag, we then applied the same technique to immunoprecipitate MT with a 
mouse monoclonal HA11 added to living cells before cell lysis. The remaining MT in 
cytoplasmic membranes were immunoprecipitated with a different mouse monoclonal 
PAb762 recognising the N-terminal region of MT. Figure 4.22 shows, only a small 
proportion of MT (approximately 1%) can be immunoprecipitated from the cell surface, 
which should represent the proportion of MT that is actively signalling. This is verified by the 
very small amount of PP2A catalytic subunit C in complex with surface MT. It has been 
previously established that MT associates with PP2A subunit A and C at a ratio of 1:1:1 
(Glover, Brewster et al. 1999). However, while the bulk of the MT may be located on 
intracellular membranes, the levels of some of the MT-binding proteins immunoprecipitated 
from the cell surface are disproportionally high. An estimated 10% of the pp60c-src, 25% of 
PI3K p85 and 33% of PLC-γ1 was co-immunoprecipitated with MT from the cell surface. 
Inside the cells, MTKDEL is also immunoprecipitated with some PI3K p85, which probably 
indicates a small population of MTKDEL escaping into the Golgi. 
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4.2.7 Measuring the sizes of MT complexes on the cell surface  
Since we have established that the formation of large complexes on the cell surface 
membrane is probably important for MT transformation, we then re-examined and compared 
the distribution and the size of these complexes on the surface of cells expressing wild type or 
the non-transforming mutant 200∆10 MT in greater detail. Ligand stimulation seems to 
increase the number of larger EGFR clusters (Sako, Minoghchi et al. 2000). Therefore we 
wanted to investigate whether subtle changes in cluster size occur between active MT (wild 
type) and inactive MT 200∆10, which lacks Src binding. First, we defined the minimum cut-
Figure 4.22 Immunoprecipitation of MT from the cell surface 
Monoclonal anti-HA was added to living cells to bind MTHA+ at the cell surface before lysis. 
After washing in PBS, protein A-sepharose matrix was added to immunoprecipitate MTHA+. 
Mouse monoclonal anti-MT PAb762 was subsequently added to immunoprecipitate the 
remaining MT. The immunoprecipitates were analysed for their MT content and associated 
signalling molecules. Non-transfected Rat-2 cells were used as a control for the MT pull-down. 
Cells expressing MTKDEL were used as a negative control for the HA pull-down. The 
immunoprecipitated MT was detected by using biotinylated PAb762, followed by 
streptavidine-conjugated horse-radish peroxidise. 
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off size of a cluster. Images for cluster analysis were taken with a Leica SP5 confocal 
microscope with 63.0x1.40 NA (numerical aperture) UV oil immersion objective with a 
zoom factor of 6. Although a zoom factor of 8 or 12 had been used in some experiments and 
yielded images of slightly better resolution, they also caused rapid photo-bleaching of 
samples since laser power was focused in such a small area (data not shown). Since the 
smallest resolvable distance with this objective lens is 170 nm (Bolte and Cordelieres 2006), 
fluorescent signals covering an area smaller than 0.05 µm
2
 were discarded. An area of 20.5 
µm x 20.5 µm was selected for analysing particles to avoid counting out-of-focus complexes. 
The same threshold was used for analysing images taken from the same experiment, which is 
usually in the range of 30 - 40 %. Background level of fluorescence signals with a diameter 
(Φ) of 300 nm (area = 0.071 µm2) is relatively low (Figure 4.17). Therefore, fluorescent 
signal covering an area of 0.05-0.071 µm
2
 was counted as one MT cluster on cell surface. 
Fluorescent signals covering any greater area were counted as complexes with more than one 
cluster of MT. Increments of 0.071 µm
2
 (Φ 300 nm) was used to measure the number of 
equivalent clustered MT particles in a complex by using the ‘analyse particles’ function in 
FIJI ImageJ (Figure 4.18 for demonstration). For example, a fluorescence signal covering an 
area of 0.28 µm
2
 would be assigned a value of 4 (see Figure 4.18). 
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Figure 4.23 Analysis of MT complexes on the cell surface 
A. Surface MTHA complexes separated according to size. Surface HA labelling was performed 
on cells expressing wtMTHA+ (black) or 200∆10HA+ (grey) as described before. The 
fluorescent signals on the basement membrane of a cell were captured using Leica SP5 
confocal microscope with 63.0x1.40 oil lens, zoom factor 6. An area of 20.5 x 20.5 µm was 
selected for analysis. Macro 1 was applied to each image. A binary mask of each image was 
made with threshold =30. Using ‘analyse particle’ function in ImageJ, the size (in µm2) of each 
complex was measured. No complex was found in Rat-2 control with such setting. Numbers of 
complexes smaller or equal to 300 nm in diameter (area = 0.071 µm2) were counted and 
fractions of clustered MT complexes (> 300 nm) were presented.  
B. Distribution of clusters across a range of complex size. Using complex size of 0.071 µm2 as 
minimum, frequency of clusters within the defined size range was generated and presented as 
fractions to total complexes counted for each species of MT. 1145 wild-type MTHA complexes 
were counted from 7 independent frames. 714 complexes of 200∆10HA were counted from 8 
independent frames.  
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Out of the 1145 complexes counted for wtMTHA+, 65% of those in cells expressing 
wild-type MTHA+ were found to be bigger than 300 nm across and were considered to be 
clusters of MT molecules on cell surface (Figure 4.23 A). Similar figures were obtained with 
cells expressing 200∆10HA+ in the same experiment. The pattern of distribution between 
wild-type and 200∆10HA+ on the cell surface are very similar (Figure 4.23 B). 70% of these 
complexes are made up of two of those 300 nm clusters, therefore, are probably just over half 
a micron across in length. The remaining 30% of the clusters are one micron or bigger 
(Figure 4.23). Clearly 200∆10 does form clusters but is unable to transform because it lacks 
the Src binding site. Therefore the size of surface MT complexes is not dependent upon 
active Src and does not necessarily reflect the transformation potential of the species 
expressed.  
Similar complex measurements were made to cells treated with the Src kinase 
inhibitor, dasatinib (dasat.), or the PP2A phosphatase inhibitor, okadaic acid (OA). Figure 
4.24 shows that 48 hrs treatment with 100 nM dasatinib causes dissociation of ShcA and 
PI3K from MT without affecting the formation of MT/PP2A/Src complex. A similar effect 
was observed using 50 nM dasatinib (data not shown). Dasatinib reverses the transformed 
morphology of cells expressing wild type MT without affecting the subcellular distribution of 
MT (wtMTHA+ in Figure 4.25 A). When surface MT complexes were measured using the 
methods described previously, there is no obvious difference between the size of complexes 
on the surface of cells treated with dasatinib or vehicle. Acute treatment with higher 
concentration of the inhibitor also did not affect surface MT complex size (data not shown).  
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Figure 4.24 Dasatinib inhibits MT association with signalling molecules 
A. Effect of 48hr-treatment with dasatinib or okadaic acid on MT association with signalling 
molecules. Cells expressing MTHA+ were treated with 100 nM dasatinib (dasat.) or 20nM okadaic 
acid (OA) for 48hrs before lysis. MT after normalising MT content in each lysate, MT was 
immunoprecipitated using mouse monoclonal PAb762. The polypeptides were separated by SDS-
PAGE and immunoblotted for known MT-binding partners as indicated above each panel. Non-
transfected Rat-2 lysate was used as control. MTKDEL was used as a negative control for some 
signalling proteins.  Migration positions of polypeptides tested are indicated with arrows to the 
right.  
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Figure 4.25 Analysis of MT distribution after dasatinib treatment 
A. Dasatinib inhibits transformation but does not affect MT distribution. Cells expressing 
wtMTHA+ were cultured in media containing 100nM dasatinib or vehicle (DMSO) for 24 hrs 
before IF staining for surface HA (i) or total MT (ii). Scale bar = 50 µm. 
B. Dasatinib does not affect the distribution pattern of surface MT clusters. Images generated 
from the above experiment were used for complex analysis. Fluorescence signals in the centre of 
the basement membrane after labelling surface HA were captured using Leica SP5 confocal 
microscope with 63.0x1.40 oil lens, zoom factor 12. Macro 1 was applied to each image. The area 
covered by individual surface complex was measured as described in Figure 4.16. Binary mask 
was made with threshold set at 30. Distribution of complex counts were generated for cells 
treated with dasatinib (grey) or DMSO (black). 
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We then investigate whether PP2A binding is required for MT macro-complex 
formation on the cell surface. However, mutants lacking PP2A binding, such as 180Δ10 and 
NS2, are trapped in the ER and do not get to the cell surface, therefore cannot be used (Zhou, 
Ichaso et al. 2011). It has been reported that 5 - 10 nM okadaic acid reduced the level of 
PP2A and Src tyrosine kinase binding to MT (Glover, Brewster et al. 1999). Here, we 
showed that treatment with the phosphatase inhibitor only slightly reduced the amount of 
PP2A subunit A and pp62c-yes bound to MT. However, association with ShcA and PI3K was 
not affected (Figure 4.24). Here OA was added to cells expression MT for 48 hrs before IF 
staining for surface MT. Figure 4.26 shows that similar surface MT complexes were observed 
in cells with and without treatment. Experiments were repeated with higher concentration of 
OA and again no difference was found between in the size of surface MT complexes 
compared to control. Altogether, results suggest the size of MT macro-complexes on the cell 
surface is not influenced by the binding of signalling molecules on the cytoplasmic bulk of 
the MT molecule.  
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Figure 4.26 Distribution of MT after treatment with okadaic acid 
A. Dual IF labelling of surface FLAG and total MT with and without okadaic acid (OA). Cells 
were treated with 10 nM OA for 48 hrs before IF staining (ii). Rabbit anti-FLAG antibodies 
were added to living cell. After fixation and permeabilisation, cells were incubated in PAb762 
mouse anti-MT N-terminus to label total MT from the inside. Species-specific AlexaFluor-488 
and -555-conjugated secondary antibodies were added to label FLAG (green) and MT (red) 
respectively. Scale bar = 50 µm. 
B. Images of a single cell from A. Scale bar = 10 µm. 
164 
 
4.3 DISCUSSION: 
4.3.1 Summary 
Here, we have observed large complexes of MT on the cell surface, some of which measure 
over one micron in diameter. These macro-complexes contain phosphorylated ShcA (Figure 
4.7 and 4.8), so represent active signalling complexes. New mutations in the hydrophobic 
region (L405E and neu-mutant MT) prevented MT clustering, and also inhibited cell 
transformation without altering the association of MT with its known binding proteins, 
therefore suggesting that formation of a large macromolecular complex in the plasma 
membrane is required for MT signalling (see Figure 4.27) (see Mutant List for detailed 
mutation and phenotype). We have identified a mutant that is trapped in the Golgi (Δ402-406 
MT). Despite the association with above signalling molecules, it cannot transform Rat-2 
fibroblasts. Both the length and sequence of the TMD is important for targeting MT from the 
Golgi to the plasma membrane, where transformation signals are generated. A summary of 
the subcellular localisation of various MT mutants used in our study are represented in Table 
T4.1 together with their ability to associate with known MT-binding signalling proteins (see 
Mutant List). 
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4.3.2 MT transformation signal is generated at the plasma membrane  
Our results add support to the evidence that MT and certain oncogenic GFR must be correctly 
trafficked to the plasma membrane in order to transform fibroblasts (Nichols, Manger et al. 
1985, Beerli, Wels et al. 1994, Morley, Uden et al. 1999).  However, the requirement for the 
transformation of hematopoietic cells may be less stringent. This is particularly the case with 
a mutant form of receptor for human macrophage-colony stimulating factor (M-CSF or CSF-
1), c-FMS, a member of the PDGFR family (Morley, Uden et al. 1999). The mutant c-
fmsD802V is highly unstable and is rapidly degraded. As a result, very little of the receptor 
gets to the cell surface. It was found that this unstable mutant potently transforms FDC-P1 
Figure 4.27 A schematic representation of  the final step in the assembly of a transforming MT 
complex 
MT at the plasma membrane (light blue disc) is represented linearly in red. The cellular 
proteins bound to MT are illustrated with phosphorylation tyrosine sites represented by 
yellow circles.  Mutant (L405E MT) that blocks the assembly of a multimeric MT complex is 
represented under the arrow.  
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hematopoietic cells but not Rat-2 fibroblasts (Morley, Uden et al. 1999). Mutant MT species 
generated in this study can be useful tools to study how mitogenic signalling differs between 
fibroblasts and hematopoietic cells. For example, AKT is partially activated in fibroblasts 
expressing L405E despite the lack of a transformation phenotype (Figure 4.15 and data not 
shown). It is not known if this mutant is also unable to transform other cell types such as 
FDC-P1 cells. 
There have been various reports to suggest mitogenic signals can be initiated from 
endosomes, (Lipson, Pang et al. 1998, Wang, Pennock et al. 2002, Wang, Pennock et al. 
2004). Unlike other cell surface receptors such as EGFR1 and integrin, which are 
endocytosed upon ligand or antibody binding to their extracellular domains (see Chapter 1, 
1.13 for introduction), MT on the cell surface is not readily endocytosed (Figure 4.3 and 4.4). 
However, there is a substantial intracellular population of MT, which is associated with 
signalling molecules (Figure 4.22) and so is possibly actively signalling. However, this 
intracellular signalling is unlikely to be sufficient for fibroblast transformation, given the 
requirement for cell surface expression (Table T4.1), but it may contribute.  
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Table T4.1 
  
Final Location in 
Cells 
 
Foci 
Formation 
 
PP2A 
 
 
pp60c-src 
 
pp62c-yes 
ShcA/ 
PI3K  p85/ 
PLC-γ1 
wtMT Cell surface ++++ + + + + 
200Δ10 Cell surface - + - - - 
180Δ10 ER - - - - - 
MTKDEL ER - + + - - 
Δ402-406 Golgi - + + + + 
Δ416-419 Plasma 
membrane 
+ + + + + 
416G6 Plasma 
membrane 
+ + + + + 
Δ419-421 Cell surface ++++ + + + + 
L405E Plasma 
membrane 
- + + + + 
G406L Cell surface +++ + + + + 
neu-mutant 
MT 
Plasma 
membrane 
- + + + + 
neu-wt MT Cell surface ++++ + + + + 
 
 
 
4.3.3 Macromolecular complexes of MT on the cell surface is required for 
transformation 
We introduced a single negatively charged residue into the middle of the MT hydrophobic 
sequence, which is known to stabilise dimerisation between two adjacent helices of the 
ErbB2/neu receptor by forming additional hydrogen and to cause cell transformation 
Table T4.1 Subcellular location of MT mutants and their ability to transform as well as their 
ability to associate with MT-binding partners 
Final location of wild type MT and mutants in stable Rat-2 cell lines generated in Chapter 3 
and 4 as analysed by IF staining for total MT or surface epitope tags (cell surface). 
Transformation efficiency was assayed by the ability to induce foci formation when 
transfected into a Rat-2 fibroblast cell monolayer and results are summarised with ‘-’ being 
non-transforming and, ‘++++’ being equivalent to wild type levels of transformation. Mutants’ 
abilities to associate with known MT-binding partners were analysed by PAb762 anti-MT 
immunoprecipitation as indicated above the columns. The presence of each polypeptide is 
indicated with ‘+’.  180Δ10 lacks both PP2A and Src binding. 200Δ10 lacks Src binding only. 
See List of Mutants for detailed description of the other mutants. 
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(Sternberg and Gullick 1989, Gullick, Bottomley et al. 1992). However, the resulting MT 
mutant L405E failed to transform Rat-2 fibroblasts and to translocate its C-terminus outside 
the cell despite its localisation to the plasma membrane (Figure 4.12 and 4.13). The C-
terminus of this mutant presumably adopts a hairpin structure instead of spanning the lipid 
bilayer. Hence the inability to transform cells is due to defect in membrane insertion and 
topology of the C-terminus. The finding with L405E MT is supported by the neu-mutant MT 
(Figure 4.11) and mutant 416G6 presented in the previous chapter (Figure 3.15). Charged 
residues are tolerated in GFR transmembrane domains probably because they utilise a 
different membrane insertion mechanism compared to MT (as discussed in Chapter 3, 3.3.5).   
Rat-2 fibroblasts expressing wild type MT frequently showed a number of gold 
particles forming clusters in the plasma membrane when examined by IEM (Figure 4.19 A). 
This confirms the result seen with immunofluorescent surface labelling of MT (Figure 4.1-
4.5), and this complex was shown to contain active phospho-ShcA, so probably represents an 
active signalling complex (Figure 4.7 and 4.8). This is the first demonstration that MT exists 
in the plasma membrane as discrete, active, clusters containing a number of MT molecules. 
The gold particles that bound to L405E MT, however, were rarely seen in groups (Figure 
4.19 A and B). Therefore, perhaps as a consequence of the failure to translocate the C-
terminal tail across the membrane, L405E MT in the plasma membrane fails to assemble into 
macromolecular complexes and perhaps for this reason does not transform. Table T4.1 
summarises a range of mutant MT and how their final cell location and ability to bind to 
signalling molecules correlates with their ability to transform Rat-2 fibroblasts. Some of the 
mutants bind all of the known signalling proteins (Figure 4.16, 4.11 and Figure 3.19) but fail 
to show cell surface expression, to form clusters and to transform fibroblasts. This 
strengthens the argument that these clusters are an essential part of oncogenic signalling by 
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MT and are a final step in the establishment of a transforming MT complex (Figure 4.27 and 
6.1). 
Similarly to MT, many receptors have also been shown to cluster in the plasma 
membrane (Gillham, Golding et al. 1999). Using a GFP-85 PI3K fusion construct, Gullick 
and co-worker showed that cytoplasmic PI3K relocates to discrete patches on the PM upon 
EGF stimulation(Gillham, Golding et al. 1999). This occurs within as little as 1 min, prior to 
receptor internalisation and degradation. There is evidence that this clustering is associated 
with EGFR activation (Yang, Raymond-Stintz et al. 2007, Clayton, Orchard et al. 2008, 
Hofman, Bader et al. 2010). Dynamic clustering has been implicated in EGFR activation as a 
means to amplify activating signals locally. Ichinose and co-workers observed that only a 
small fraction of fluorescent-conjugated EGF ligand colocalises with activated EGFR at one 
time after a 30 min stimulation period. Instead the signal was found propagated through 
clustering of non-ligand associated but phosphorylated EGFR by their transient interaction 
with ligand-activated EGFR (Ichinose, Murata et al. 2004). Therefore, receptor clustering 
was proposed by many as an effect secondary to receptor dimerisation and activation as the 
initial response to ligand stimulation (Gillham, Golding et al. 1999, Nagy, Jenei et al. 1999, 
Ichinose, Murata et al. 2004).  
Our data for the first time suggests that kinase activation alone may not be sufficient 
and that in addition, the assembly of a large macromolecular complex is important for 
signalling. The demonstration that MT clusters can form in the absence of Src tyrosine kinase 
activity (Figure 4.7, 4.8 and 4.25) may suggest these two processes can be separated, and 
explain why receptor clusters are seen in the absence of growth factor stimulation (Yang, 
Raymond-Stintz et al. 2007). It has been suggested that clustering of macromolecular 
complexes is a mechanism to provide efficient and rapid spatial confinement in order to avoid 
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long-distance diffusion in the crowded environment of a cell (Cebecauer, Spitaler et al. 
2010). 
IEM analysis of the EGFR family members located to the cytoplasmic surface of the 
plasma membrane showed EGFR1, ErbB2 and ErbB3 receptors are pre-clustered in the 
absence of stimuli (Yang, Raymond-Stintz et al. 2007). In the SKBR3 breast cancer cell line, 
which is driven by ErbB2 over-activation, the sizes of ErbB2 pre-formed clusters do not 
change significantly following ligand stimulation or upon treatment with an ErbB2-specific 
kinase inhibitor but the level of receptor phosphorylation changes (Yang, Raymond-Stintz et 
al. 2007). These preformed clusters also contain signalling molecules such as ShcA, PI3K 
and STAT5. It is the distribution of these signalling molecules co-clustered with receptors 
which is changed in response to ligand stimulation. ShcA pre-associates with EGFR1 and the 
co-clusters move into distinctive ‘coated-pit’ structures in the membrane following 
stimulation, which is an indication of receptor internalisation (Yang, Raymond-Stintz et al. 
2007). PI3K p85 is only  recruited to ErbB3 after stimulation by heregulin and produces a 
distinctive membrane domain consists of ErbB3 cluster surrounded by a ring of p85, forming 
a ‘bull’s eye’ structure, which resembles a macro-complex made of signalling molecules and  
T-cell receptors often observed in immunological synapses (Bromley, Burack et al. 2001). 
STAT5 associates inherently with all EGFR family members. While ligand stimulation leads 
to rapid tyrosine phosphorylation of STAT5, the signalling molecule is re-distribution to 
separate membrane microdomains away from the receptor clusters (Yang, Raymond-Stintz et 
al. 2007).  
Similar to our observation of surface MT clusters with sizes in the range between 500 
- 1000 nm on confocal microscope, Nagy and co-workers estimated that Her2/neu clusters of 
500 nm in diameter probably contain thousands of receptors using scanning near-field optical 
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microscope which has a much higher resolution (Nagy, Jenei et al. 1999). It is likely that the 
clusters observed in our system are also made up of tens of thousands of MT molecules.  
Our data suggest that disruption of receptor cluster formation has the potential to 
inhibit receptor oncogenic signalling independently of kinase activity, so providing a wholly 
separate goal for drug development. Indeed, it has been demonstrated that cells expressing 
certain variation of neu transmembrane polypeptides, lacking ligand binding or intracellular 
kinase domains, in cells transformed by the activating neu V664E mutation reduced 
oncogenic potentials in mouse xenograft models by preventing neu receptor dimerisation 
(Lofts, Hurst et al. 1993). It is feasible that the MT transmembrane domain in isolation could 
also insert into membranes and act as a competitive inhibitor to prevent signalling by related 
complexes. In preliminary experiments (Figure 4.28 – 4.31), mutant 200∆10 when co-
expressed with wild type MT reduced the transformation potential of the wild type, probably 
by diffusing the local concentration of transforming signals via the formation of a 
heterogeneous macro-complex with wild type MT (Figure 4.28). However, foci formation 
was not completely inhibited. Despite the lack of Src binding site, all the tyrosine residues 
targeted by Src are completely intact on mutant 200∆10 so it is possible that these tyrosine 
residues on the mutant can phosphorylated in trans by wild type MT in the same cluster. A 
better dominant negative mutant may be constructed by removing all major phospho-tyrosine 
sites from 200Δ10 MT.  
Colocalisation between FLAG and HA-tagged MT complexes was also observed on 
the cell surface when a cell line expressing wild type MTFLAG was transiently expressing 
transfected with wtMTHA+ or 200∆10 MTHA+ plasmids (Figure 4.29 – 4.31). However 
MTFLAG complexes do not always colocalise perfectly with MTHA complexes, probably as 
a result of different binding affinities or because of steric hindrance between anti-HA and 
anti-FLAG antibodies. Similarly, preliminary co-immunoprecipitation experiments have not 
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successfully proven the interaction between MT molecules with the two different epitope 
tags, possibly due to the large difference in expression level between the two MT species in 
co-expressing cells (data not shown). 
 
 
 
 
 
Figure 4.28 Mutant 200∆10 reduces the foci formation induced by wild type MT plasmid 
A. Co-transfection of wild type MT and 200∆10 mutant at 1:12 wild type to mutant ratio. 
Subconfluent Rat-2 fibroblasts on 10cm tissue culture plates were transfected with 1.4 µg 
pUC19 MT (wild type) plasmid with those carrying 200∆10MT (16.8 µg) or empty plasmids 
at 1:12 ratio using calcium-phosphate method. Transfections without wtMT plasmids were 
also performed as controls (column on the left). Cells were cultured for 2 weeks before the 
foci were stained. 
B. Co-transfection of wild type MT and 200∆10 mutant at 1:8 (wild type: mutant) ratio. 
Subconfluent Rat-2 fibroblasts on 6cm tissue culture plates were transfected with 0.7 µg 
pUC19 MT (wild type) plasmid with those carrying 200∆10MT (5.6 µg) or empty plasmids at 
1:8 ratio using above methods. 
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Figure 4.29 Colocalisation between MTFLAG and 200∆10 MTHA on the cell surface 
A. Rat-2 fibroblast cell line 2.11 expressing wtMTFLAG was transfected with plasmids 
carrying 200∆10MTHA+ sequence using Attractene transfection kit for 6 hrs at 37˚C. 24 hrs 
post-transfection, cells were seeded on to glass slide and stained for surface FLAG- and HA- 
tags at the same time 48hrs post transfection. A cell with strong surface HA signals is shown 
in (a). An independent frame with weaker HA fluorescent signal is shown in (b). Each image 
represents an area of 30.60 x 30.60 µm. Scale bar = 5 µm 
B. Zoom-in images of area highlighted in A. Smaller area of 15.26 x 15.26 µm was selected for 
further analyses. Open arrows indicated colocalisation between surface MTFLAG and 
200∆10 MTHA. Scale bar = 2 µm. 
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Figure 4.30 Colocalisation between MTFLAG and MTHA complexes on the cell surface 
A. Rat-2 fibroblast cell line 2.11 expressing wtMTFLAG was transfected with plasmids 
carrying wtMTHA+ sequence using Attractene transfection kit for 6hr at 37˚C. After 24 hrs, 
cells were seeded on to glass slide and stained for surface FLAG- and HA- tags at the same 
time 48hrs post transfection. A cell with strong surface HA signals is shown in (a). An 
independent frame with weak HA fluorescent signal is shown in (b). Each image represents 
an area of 30.60 x 30.60 µm. Scale bar = 5 µm 
B. Zoom-in images of area highlighted in A. Smaller area of 15.26 x 15.26 µm was selected for 
further analyses. Open arrows indicated colocalisation between surface MTFLAG and MTHA. 
Scale bar = 2 µm. 
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The indication that a MT cluster must form to initiate oncogenic signalling by MT 
raises the question why? Clustering of molecules within cell membranes has been reported 
recently in a number of systems, notably proteins involved in signal transduction (Cebecauer, 
Spitaler et al. 2010). Ras Family of GTPases in particular have been shown to exist in nano-
clusters on the inner surface of the plasma membrane mediated by their C-terminal lipid 
modified region (Prior, Muncke et al. 2003). Accumulation of Ras in these nanoclusters is 
essential for signalling activity (Plowman, Muncke et al. 2005, Tian, Harding et al. 2007) and 
requires the actin cytoskeleton (Plowman, Muncke et al. 2005).  It is interesting to note that 
one of the few membrane targeting domains that can functionally replace the MT 
hydrophobic sequence are the C-terminal regions of both H-Ras (Elliott, Jones et al. 1998) 
and K-Ras (unpublished observations), and MT has been shown to associate with cytoskeletal 
0
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+ 200∆10HA + wtMTHA control
Fraction of Surface MTFLAG
Colocalising with HA
Figure 4.31 Colocalisation analysis between MTFLAG and MTHA complexes on the cell 
surface 
Images of surface FLAG- and HA-tags co-staining in MTFLAG cell line transfected with 
200∆10 MTHA+ or wtMTHA+ were analysed for colocalisation. The average fraction of 
surface FLAG complexes colocalising with HA signals was calculated from 5 independent 
frames. Error bar = standard deviation. 
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structures (Schaffhausen, Dorai et al. 1982, Andrews, Gupta et al. 1993, Elliott, Jones et al. 
1998, da Costa, Wang et al. 2000). Given these functional similarities between Ras and MT, 
it is tempting to speculate that the MT and Ras clusters are related and that close proximity is 
essential for transforming activity.  
How MT is organised into large clusters in the plasma membrane is not clear. 
Cholesterol containing, ordered lipid structures, or lipid rafts, in external cell membranes 
(Cebecauer, Owen et al. 2009) may possibly contribute to the clustering of MT molecules 
seen in the plasma membrane. There has been intensive speculation concerning the role of 
lipid rafts in signalling, with conflicting views about their importance. The mechanism of MT 
macro-complex formation will be explored in Chapter 5. 
A recent report has shown that there is a physical association between MT and the 
insulin receptor as well as the related IGF-I receptor and this association is required for 
transformation (Novosyadlyy, Vijayakumar et al. 2009). It will be interesting to determine 
whether this interaction occurs in the MT containing plasma membrane complexes, and if 
other receptors are also present. These results also provide an exciting potential new approach 
to drug development. It is interesting to note that the interaction of receptors within a cluster 
is probably dynamic in order to allow for rapid reversal when the initiating signal is removed 
(Cebecauer, Spitaler et al. 2010).  MT has evolved to be permanently and strongly activating, 
and consequently, a competitive inhibitor based on the MT sequence may be considerably 
more potent than one designed on a receptor sequence. It is possible that hydrophobic 
compounds could also be devised that could prevent receptor oligomerisation. TMD-
mediated signalling in GFR and the idea of artificial transmembrane polypeptide as 
competitive inhibitor for GFR signalling will be explored further in Chapter 6.  
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4.3.4 Estimating the proportion of active MT molecules 
Since we have determined that MT localisation at the plasma membrane is important for 
transformation, it is intriguing to see how much of MT expressed is located at the plasma 
membrane. It has been a long standing question as to what proportion of MT produces 
mitogenic signals (Schaffhausen 1982). Overall, the amount of MT that can be 
immunoprecipitated from the cell surface in comparison to the bulk of the viral protein 
expressed inside the cell is very small (probably 1%). However, the amount of certain 
signalling molecules that associate with this surface population of MT is relatively high. 
These include a tenth of pp60c-src, a quarter of PI3K p85 and a third of PLC-γ1 
immunoprecipitated from total MT (Figure 4.22). Therefore, the MT complexes 
immunoprecipitated from the cell surface represent a potentially more active population of 
MT. By IF, we found that only 15-20% of MT near the cell basement membrane is at the cell 
surface (Figure 4.6 C). The small proportion of active MT signalosome raises the question 
about the role of intracellular MT since they account for the bulk of the viral protein. After 
all, MT mutants localised to these cellular membrane sites have access to most of the 
signalling molecules associated with MT transformation (Table T4.1) but it is not clear 
whether MT in Golgi and microsomes are generating mitogenic signals.  
 About 30-50 % of surface MT colocalised with ShcA (Figure 4.7 B and 4.8 B). This 
raises the question as to whether MT bound to ShcA is also bound to all signalling molecules. 
The binding sites for PI3K p85 (pY215) and PLC-γ1 (pY322) are very close to each other on 
MT but it is not known whether this precludes binding of all of these signalling molecules to 
one MT protein. Cluster formation may overcome this possible limitation by increasing the 
number of available binding sites for different signalling molecules in the local region. 
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4.3.5 TMD targets MT from the Golgi to the plasma membrane 
MT seems to be ubiquitously expressed throughout the cell membranes, with the bulk of the 
molecules found in the perinuclear region and the peripheral plasma membrane (Dilworth, 
Hansson et al. 1986). However, in the previous chapter, we have demonstrated, with mutant 
MT KDEL that MT located in the ER cannot transform and lacks access to most of the 
signalling molecules required for transformation. MT migration out of the ER to other 
membrane sites requires both the MT hydrophobic sequence as well as its association with 
the PP2A core dimer. Here, with the new TMD mutant ∆402-406 MT, which was found to 
localise solely in the Golgi apparatus (Figure 4.21), we demonstrated that once in the Golgi 
membrane, MT has access to all of the direct binding proteins required for generating 
mitogenic signals (Table T4.1). These include ShcA, PI3K and PLC-γ1 and pp62c-yes. 
Despite binding to tyrosine kinases and MT-associated signalling molecules, ∆402-406 MT 
failed to transform Rat-2 fibroblasts. Therefore, transformation signals must be generated 
from the locations beyond the Golgi apparatus, most likely at the plasma membrane. 
Characterisation of ∆402-406 MT demonstrates once again that subcellular localisation plays 
an important role in MT transformation. 
Here we show that the length of MT hydrophobic sequence is important for the 
exocytic transport of this tail anchored protein out of the Golgi to the plasma membrane. 
Mutant ∆402-406 MT contains a hydrophobic sequence with deletions made to the central 
five residues. Shortening of the TMD sequence probably resulted in the retention of ∆402-
406 MT in the Golgi apparatus. Using an ER-resident TA protein, Cytb5, Pedrazzini and co-
workers showed that extension of the C-terminal hydrophobic sequence from 17 to 22-
residues relocated Cytb5 to the plasma membrane (Pedrazzini, Villa et al. 1996). The anchor 
length in itself is a factor determining the subcellular localisation of many tail-anchored 
proteins. Other examples include Protein Tyrosine Phosphatase 1B (PTP1B), which has very 
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short anchor sequence and is targeted to microsomes and Sed5, a cis-Golgi located protein 
involved in vesicular transport (Banfield, Lewis et al. 1994). It was suggested that the plasma 
membrane is thicker in comparison to intracellular membranes as it has higher levels of 
cholesterol and sphingolipids (Pedrazzini, Villa et al. 1996). The ER-/ Golgi-resident 
enzymes with their shortened tail anchors are excluded from transport vesicles to the cell 
surface (Pedrazzini, Villa et al. 1996)(Masibay, Balaji et al. 1993, Pelham and Munro 1993), 
which supports the conclusion that the length of the hydrophobic sequence of MT is 
important for targeting MT to the plasma membrane.  
 Short stretches of alanine substitutions of the MT hydrophobic sequence had no 
impact on its ability to induce foci (394A4 to 412A4, Figure 4.10), which seems to suggest 
there is little sequence specificity in the hydrophobic domain of MT. However, for some 
transmembrane proteins, the specific sequence of the hydrophobic membrane spanning can 
sometimes play a role in the final localisation of the protein. In a collection of new TMD 
mutants generated in the lab, only sequences from wild type neu and PDGFRβ but not 
FGFR3 can functionally replace MT hydrophobic sequence. Replacement with the FGFR3 
hydrophobic sequence, which is similar in length to the hydrophobic sequence of MT, 
resulted in mutants trapped in the intracellular membranes. We observed strong 
immunofluorescent-labelled signals of FGFR3 MT in the perinuclear region and cytoplasmic 
vesicles (Figure 4.20).Similar subcellular localisation pattern of FGFR3 was also observed in 
other fibroblast cell lines (Johnston, Cox et al. 1995).  The TMD of FGFR3, when expressed 
alone, failed to reach the plasma membrane, thus confirming that the hydrophobic sequence 
of FGFR3 targets compartments other than the plasma membrane (He, Shobnam et al. 2011). 
Therefore, apart from the length of the hydrophobic sequence, there must be other properties 
in the sequence that target the MT to the plasma membrane, that are common to neu receptor 
and PDGFRβ TMDs, which will require more experiments to decipher. 
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CHAPTER 5 - MECHANISM OF MPyV MT MACRO-COMPLEX 
FORMATION 
 
5.1 INTRODUCTION: 
In the previous chapter, we have demonstrated that the ability to form large macro-molecular 
complexes on the cell surface membrane is an important requirement for MT-induced 
transformation and is mediated by the membrane anchoring transmembrane domain of MT. 
How MT molecules are organised into large multimeric complexes is unknown. Although the 
hydrophobic region does not seem to target MT to one particular membrane site, this region 
must have some specificity, as replacement with membrane targeting domains of cytochrome 
b5 and pp60c-src myristoylation sequence abolish transformation without disrupting 
membrane binding whereas H-Ras CAAX box restored oncogenic function (Elliott, Jones et 
al. 1998). 
 Ras proteins have been shown to exist in nano-clusters on the inner surface of the 
plasma membrane mediated by their C-terminal lipid modified regions (Prior, Muncke et al. 
2003) (see Chapter 1, 1.14 for introduction). H-Ras can be found in cholesterol-dependent 
microdomains and its affinity for raft and non-raft microdomains is modulated by GTP-
loading or palmitoylation (Roy, Plowman et al. 2005). Since the lipid modified CAAX 
sequences at the C-terminus of H-Ras can functionally replace the C-terminus of MT (Elliott, 
Jones et al. 1998), it is possible that MT and H-Ras share similar specificity for membrane 
domains.  
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Accumulation of H-Ras in nano-clusters requires the actin cytoskeleton (Plowman, 
Muncke et al. 2005, Tian, Harding et al. 2007) (Hancock and Parton 2005, Plowman, Muncke 
et al. 2005). MT has been shown to be associated with cytoskeletal structures (Schaffhausen, 
Dorai et al. 1982, Andrews, Gupta et al. 1993, Elliott, Jones et al. 1998, da Costa, Wang et al. 
2000), but it is not clear how this association is mediated. It has been reported, amongst the 
early studies on MT, that phosphorylated MT can be immunoprecipitated by anti-serum 
raised against vinculin, an actin-binding protein that localises to focal contacts (Ballmer-
Hofer, Ziegler et al. 1988). In MT transformed fibroblasts, PI3K p85 has been shown to 
associate with focal adhesion kinase (Bachelot, Rameh et al. 1996), but direct MT and FAK 
interaction has not been reported. It has been suggested that cholesterol-rich, ordered lipid 
structures, or lipid rafts, in the cell membranes can influent cluster formation of many cell 
surface molecules and may play a role in regulating signalling events (Cebecauer, Spitaler et 
al. 2010). 
Protein-protein interaction may also be involved in cluster formation in the lipid 
bilayer. Some RTK such as the ErbB family receptor kinases are thought to hetero-dimerise, 
through part of their TMD (Gerber, Sal-Man et al. 2004). Cell surface receptors involved in 
adhesion, such as integrins have been shown to form complexes with growth factor receptors 
such as ErbB2, which enhances ligand-dependent phosphorylation of the GFR (Falcioni, 
Antonini et al. 1997). Integrin β1 was found to be required for mammary gland tumorigenesis 
in MMTV-MT mice (White, Kurpios et al. 2004).  MT association with insulin receptor β 
(IRβ) and the insulin-like Growth Factor I (IGF-I) receptor have been detected (Novosyadlyy, 
Vijayakumar et al. 2009). Here we investigate how MT macro-complexes are formed, 
whether MT macro-complexes in the plasma membrane are related to lipid rafts or may also 
contain other membrane proteins. 
  
182 
 
5.2 RESULTS: 
5.2.1 Membrane Micro-domains 
5.2.1.1 Lipid Rafts  
In order to investigate whether surface MT complexes are associated with or avoid lipid rafts, 
we used the lipid raft marker, Vybrant Alexa Fluor-conjugated cholera toxin subunit-B (CT-
B) to label the cholesterol-rich lipid rafts in the membrane. CT-B binds specifically to 
monosialotetrahexosylganglioside (GM1), which is found in high concentration in 
cholesterol-rich lipid rafts in the membrane. 
As Figure 5.1 shows, the level of colocalisation between the CT-B-labelled lipid rafts 
and surface MT complexes is relatively low. There is also no apparent difference between 
cells expressing wild type or non-transforming mutant 200Δ10 MTHA+ and lipid raft 
location (Figure 5.1). In fact, cells with more MT complexes on the cell surface showed much 
lower levels of lipid raft labelling (Figure 5.2 and 5.3). Although the fluorescent-conjugated 
CT-B does not permeate the lipid bilayer, it may be internalised with the plasma membrane 
during the incubation period at 37ºC. Therefore the experiment was repeated at 4ºC in cells 
expressing wtMTFLAG. Anti-FLAG antibody and fluorescent-conjugated CT-B were 
incubated together for 30 min to maximise lipid raft labelling. Some colocalisation between 
surface MT complexes and the lipid raft marker can be observed (arrows in Figure 5.4) but 
the majority of MT complexes do not colocalise with GM1-positive lipid rafts (Figure 5.4). 
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Figure 5.1 Little colocalisation between surface MTHA and raft marker at 37°C in cells 
expressing wild type or non-transforming mutant 
A. Fluorescent labelling of surface MT and lipid rafts. Rat-2 fibroblasts expressing wtMTHA+ 
or 200∆10 HA+ were incubated in mouse anti-HA antibody for 20 min at 37°C. 10min before 
fixing, Vybrant AlexaFluor555-conjugated cholera toxin subunit B (CT-B) was added to cells, 
to label GM1 positive lipid rafts (red). After fixing, cells were incubated in AlexaFluor488-
conjugated anti-mouse IgG to label surface HA-tags (green). Fluorescent signals on the 
basement membrane of a cell were captured using Leica SP5 confocal microscope with 
63.0x1.40 oil lens, zoom factor 6. An area of 20.5 µm x 20.5 µm was shown. Scale bar = 2 µm. 
B. Zoom-in image of highlighted area in A. Image for each cell line was representative of at 
least 6 independent frames. Scale bar = 2 µm. 
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Figure 5.2 Level of surface MT fluorescent signals inversely correlates with lipid raft staining  
Fluorescent labelling of surface MT and lipid rafts was performed as described in Figure 5.1. 
Images of a group of cells were captured with low zoom factors. Scale bar = 2 µm 
185 
 
 
 
 
Figure 5.3 Cells with stronger surface MTHA signals have lower levels of the raft marker 
A. Fluorescent labelling of surface MT and lipid rafts was performed as described in Figure 
5.1. An area of 20.5 µm x 20.5 µm is shown. 
B. Zoom-in image of highlighted areas in A. Scale bar = 2 µm for A and B. 
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Figure 5.4 Little colocalisation between surface MTFLAG and raft marker at 4°C 
A. Fluorescent labelling of surface FLAG tag and lipid rafts.Rat-2 fibroblasts expressing 
wtMTFLAG were rested at RT for 15 min before the addition of rabbit anti-FLAG antibody and 
Vybrant AlexaFluor555-conjugated CT-B in 1% FCS media supplemented with Hepes buffer 
pH 7.4. Cells were incubated at 4°C for 30 min before fixing in cold formaldehyde. 
AlexaFluor488-conjugated anti-rabbit IgG was then added to label the FLAG-tag (green). 
Fluorescent signals on the basement membrane of a cell were captured using a Leica SP5 
confocal microscope with 63.0x1.40 oil lens, zoom factor 6. An area of 30.04 µm x 30.04 µm is 
shown.  
B. Zoom-in image of highlighted area in A. Image for each cell line is representative of at least 6 
independent frames. Area shown = 20.5 µm x 20.5 µm. Scale bar = 2 µm for part A and B. 
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5.2.1.2 H-Ras G12V Non-raft Domains 
It has been demonstrated that activated H-Ras nanoclusters are localised to cholesterol-
independent microdomains in the membrane, therefore may be used as a non-raft marker in 
our study (Roy, Plowman et al. 2005). We then investigated whether MT at the plasma 
membrane colocalises with activated H-Ras microdomains. To do this, FLAG-tagged MT 
was co-expressed with a constitutively activated mutant (G12V) of human H-Ras in Rat-2 
fibroblasts, which has two consecutive Myc-tags added to the N-terminus (H-Ras-2XMyc 
G12V). Very little colocalisation were observed between MT labelled from the cell surface 
and internally labelled activated H-Ras using an antibody (mouse monoclonal 9E10) against 
Myc-tag (Figure 5.5). Most of the activated H-Ras mutants were located to large intracellular 
vesicles, with very little found at the basement membrane (Figure 5.5 A). Co-
immunoprecipitation analysis between MT and H-Ras-2XMyc G12V also failed to show 
direct interaction between the two proteins (Figure 5.6). MTFLAG expression was relatively 
low compared to the cell line expressing MTFLAG alone. Any colocalisation between the 
two proteins is likely to be obscured by the strong H-Ras-2XMyc G12V staining from 
intracellular membranes (Figure 5.5 B). 
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Figure 5.5 Very little colocalisation between surface MT complexes and intracellular H-
RasG12V-Myc 
A. Cell lines co-expressing MTFLAG and H-Ras-2XMyc G12V were established. Surface MT was 
labelled as described previously using rabbit anti-FLAG antibody. After fixing and 
permeabilisation of cell membranes, mouse monoclonal 9E10 was added to bind Myc-tags of 
H-Ras-2XMyc G12V mutant. Then fluorescent-conjugated secondary anti-rabbit or anti-mouse 
IgG was added to label MT on the cell surface (green) and H-Ras (red). The ratios of MTFLAG 
to H-Ras-2XMyc G12V plasmids transfected are indicated above the panel. Images are 
representative of at least 12 independent frames. 
B. Zoom-in images of highlighted area in A. Scale bar = 2 µm in both A and B. 
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5.2.1.3 Cholesterol Depletion by Methyl-β-cyclodextrin 
Since we have observed inversely correlated staining of surface MT complexes and lipid rafts 
(Figure 5.1, 5.2 and 5.3), we next investigated whether cholesterol-rich lipid rafts may be a 
barrier for the formation of MT macro-complex on the cell surface. Methyl-β-cyclodextrin 
(MβCD) is a hydrophobic organic polymer commonly used to remove cholesterol. 60 min 
treatment in 1% MβCD has been shown to induce ligand-independent activation of the 
EGFR1 by depleting cholesterol from the plasma membrane (Chen and Resh 2002). Figure 
5.7 shows the time-course of cell surface lipid raft staining after treatment in 1% MβCD. 
Incubation for 90 min or longer showed CT-B-labelled lipid rafts appear more diffused on the 
cell surface membrane.  
 
 
Figure 5.6 Co-immunoprecipitation between MT and H-RasG12V-Myc 
MT and H-Ras-Myc were immunoprecipitated by PAb762 (left) and 9E10 (right), 
respectively, from equal volumes of cell lysates collected from confluent cells. After SDS-
FAGE and Western blotting, the nitrocellulose membrane was probed with biotinylated 
PAb762 followed by streptavidine peroxidase to assess MT level in each cell line (i) or mouse 
monoclonal 9E10 against Myc-tags (ii). 
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Treatment of cells expressing wtMTFLAG with 1% MβCD 3 hrs before surface tag 
labelling, induced stronger overall fluorescent signals on the cell surface (Figure 5.8 A and 
B). After treatment in MβCD, MT complexes labelled from the external cell membrane 
appeared more numerous with stronger intensity for individual punctate. MβCD treatment did 
not increase background fluorescent level when non-transfected Rat-2 fibroblasts were used 
(results not shown).  However, overall MT staining was also increased (Figure 5.8 C). The 
enhanced detection of MT was surprising and prevents us from concluding whether removal 
of cholesterol from the plasma membrane promotes macro-complex formation of MT. It is 
possible that treatment with MβCD causes exocytosis of intracellular MT to the cell surface 
(Takahashi, Hatakeyama et al. 2004), which complicates the interpretation of results.   
 
Figure 5.7 Time course for MβCD treatment 
Rat-2 fibroblasts expressing wtMT were incubated in 1% MβCD prepared in serum-free 
DMEM. At 10 min before each of the indicated time points, Vybrant fluorescent-conjugated 
CT-B was added to the media at 1:500 dilutions. After 10 min incubation with the lipid raft 
marker at 37°C, cells were subsequently fixed and mounted. Images of labelled lipid rafts on 
a single cell were captured with a confocal microscope. Scale bar = 10 µm.  
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Figure 5.8 Methyl-β-cyclodextrin increases surface and overall MT staining 
A. Surface MT labelled after treatment in Methyl-β-cyclodextrin (MβCD). Cells expressing 
wtMTFLAG were incubated in 1% MβCD prepared in serum-free DMEM for 3 hrs. Media were 
removed and cells were incubated in rabbit polyclonal anti-FLAG prepared in 1% MβCD for 20 
min before fixing and were subsequently incubated in AlexaFluor488-conjugated anti-rabbit 
IgG. Images of cells were captured with confocal microscope. Scale bar = 50 µm.  
B. MT complexes on the basement membrane surface of a cell. Two independent frames are 
shown. Scale bar = 2 µm. 
C. Total MT distribution after MβCD treatment. Cells were treated with MβCD under the same 
conditions described in A before fixing and permeabilisation of cell membrane. MT was 
labelled with PAb762 mouse monoclonal anti-MT (green). Nuclei were stained by DAPI (blue). 
Scale bar = 50 µm. 
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5.2.1.4 Detergent Resistance Membrane Fractionation 
We then investigated whether MT signalling complexes are located in detergent soluble or 
insoluble membrane factions by fractionation. A similar protocol was used to show that many 
GPI-anchored proteins, such as caveolin-1, reside in the Triton-insoluble fraction while 
certain transmembrane proteins, such as EGFR1, preferentially reside in the detergent soluble 
fraction (Funatsu, Miyata et al. 1999, McKie, Vaughan et al. 2012). Cells were lysed by 
osmotic pressure and the cell membranes were collected by ultracentrifugation. The 
membrane faction was solubilised in 1% Triton-X 100. Any detergent insoluble membranes 
were then collected at the bottom of the eppendorf tube by ultracentrifugation. Caveolin-1 is 
a known lipid raft marker found exclusively in detergent-insoluble fraction of the membranes 
(Figure 5.9 A). Interestingly, non-stimulated PDGFRβ was fractionated mostly in the 
detergent soluble fraction (Figure 5.9 B and C), therefore can be used as an indicator for non-
raft proteins. Figure 5.9 A shows similar amounts of wild type MT are found in both 
detergent soluble and insoluble fractions. Ponceau S protein stain was used as an indicator of 
the amount of proteins loaded in each lane.  
Since mutant L405E seems to lack the ability to form large clusters in the membrane, 
fractionation experiment was also performed on cells expressing this mutant MT to see 
whether this non-transforming mutant partitions differently in the membrane. Figure 5.9 A 
shows L405E was also distributed almost equally between detergent-soluble and detergent-
insoluble fractions, although a small amount of the mutant MT was detected in the non-
membrane fraction, which indicates a weaker membrane association, probably as a result of 
the lack of C-terminus translocation across the lipid bilayer. However, the majority of L405E 
was still membrane bound. The non-transforming mutants 180Δ10 (lacks PP2A and Src 
binding sites) and 200Δ10 (lacks Src binding site only, see Mutant List) did not fractionate 
differently compared to wild type (Figure 5.9 C and data not shown). More importantly, 
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wtMT isolated from both detergent-soluble and detergent-insoluble fractions associates with 
signalling molecules such as PP2A core dimer, PI3K p85 subunit and p52 of Shc (Figure 5.9 
D). Immuno-labelled surface MT complexes (wild type) showed very little colocalisation 
with caveolin-1 (results not shown). Together with previous IF data, it is likely that MT does 
not have any preference between raft and non-raft microdomains in the membrane. 
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Figure 5.9 Detergent resistance fractionation of cell membrane in cell lines expressing wild 
type or non-transforming MT mutant 
A. Fractionation of wild type and L405E mutant MT. Cell lines stably expressing wtMT or 
L405E MT were fractionated as described in material & methods. Samples of whole cell lysates 
(WCL), non-membrane fraction (NMF), membrane fraction (MF), detergent-soluble faction 
(DSF) and detergent-insoluble faction (DIF) were normalised against protein concentration as 
determined by BCA assay, then analysed for MT content (i) or caveolin-1 (ii). Ponceau S protein 
stain in the migratory region of MT is show in (iii). 
B. Fractionation of PDGFRβ in normal non-transfected Rat-2 fibroblasts. Ponceau S protein 
stain of PDGFRβ migratory region was shown in (ii).  
C. Fractionation of non-transforming mutant 180∆10 MT. Fractionation samples were 
generated as described in A and analysed for the PDGFRβ.  
D. Analysis of MT-associated signalling molecules in different membrane fractions. Cell lines 
expressing non-transforming mutant 180∆10 or wtMT were fractionated in to detergent 
soluble or insoluble fractions. After pre-clearing with Protein-A Sepharose beads, MT in each 
membrane fractions were immunoprecipitated with PAb762, and then analysed for the 
presence of known MT-binding molecules, as indicated above each panel. 5 µl of wtMT whole 
cell lysate was loaded in lane e as a reference (ref.) for the migratory position of each 
polypeptide.  
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5.2.2 MT Association with the Cytoskeleton 
Various sucrose gradient fractionation studies showed that MT co-fractionates with actin, 
vimentin and tubulin (Andrews, Gupta et al. 1993, da Costa, Wang et al. 2000). However, 
direct association between MT and cytoskeletal components has not been demonstrated so 
far. Here we investigate whether MT colocalises with actin cytoskeleton on the cell surface 
and if so, whether the formation of these MT macro-complexes in the plasma membrane is 
driven by actin polymerisation. Cells expressing epitope-tagged MT were transfected with the 
LifeAct-RFP plasmid, which encodes a short peptide with an actin binding property fused to 
red fluorescent protein (Riedl, Crevenna et al. 2008). Figure 5.10 (i) shows the detection of 
an extensive actin mesh near the membrane ruffle of a cell and its colocalisation with MT 
clusters labelled from the cell surface. Colocalisation analysis of the image suggests that 
about 50% of surface wild type MT clusters colocalise with actin.  
Clusters of mutant 200Δ10, which lacks Src binding, also colocalise with actin. 
Instead of actin meshwork, 200Δ10 is located to actin cables or stress fibres running along 
the under surface of the cells (Figure 5.10 ii), These actin structures are also evident in non-
transformed control Rat-2 fibroblasts. This suggests that Src tyrosine kinase binding is not 
requirement for MT association with actin cytoskeleton. Transformation of Rat-2 fibroblasts 
by MT is accompanied by a remodelling of the actin cytoskeleton (compare panels i and ii in 
5.10 A). An additional picture of wild type MT complexes colocalising with actin 
cytoskeleton together with negative control are shown in Figure 5.11.  
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Figure 5.10 Surface MT complexes colocalise with actin cytoskeleton  
A. Dual IF labelling of surface HA tag and actin cytoskeleton. Cell lines expressing wild type or 
200∆10 MTHA+ were transfected with LifeAct-Tag RFP plasmids using the Attractene 
transfection kit. 48hrs post-transfection, cells were incubated with mouse monoclonal anti-HA 
antibody at 37oC for 20 min before fixing. AlexaFluor-488 conjugated anti-mouse secondary 
antibody was subsequently added to label surface MT (green). Images of the cell basement 
membrane were captured using a Leica SP5 confocal scanning microscope. An area of 20.5 µm x 
20.5 µm is shown for each cell line indicated above the panel.  
B. Zoom-in images of highlighted area in A. Individual and combined channels in an area of 
10.25 µm x 10.25 µm are shown. Scale bar = 2 µm for both part A and B. Images shown are 
representative of at least 6 independent frames for each cell line. 
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Figure 5.11 Additional support images for surface MT complexes co-stained with actin-
cytoskeleton 
A. Dual IF labelling of surface HA tag and actin cytoskeleton. WtMTHA+ cells and parental Rat-2 
fibroblasts were transfected with LifeAct-Tag RFP plasmids using the Attractene transfection 
kit. Staining conditions for surface HA is described in Figure 5.1. An area of 20.5 x 20.5µm is 
shown for each cell line indicated above the panel.  
B. Zoom-in images of highlighted area in A. Individual and combined channels in an area of 
10.25 x 10.25µm taken from A (white squares) are shown. Scale bar, 2 µm. 
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We then investigated whether actin disassembly affects surface MT cluster formation 
by treating cells with an inhibitor of actin polymerisation, cytochalasin D (CCD) before 
labelling surface MT. Cells were flattened and showed impaired cell division after 48hr-
treatment in 500 nM CCD (Figure 5.12 A & B), which indicates that the actin cytoskeleton 
was effectively disrupted by the treatment conditions although actin staining was not 
performed. Figure 5.12 C shows MT complexes are observed on the cell surface with little 
difference in size and numbers compared to untreated cells. Therefore disruption of actin 
polymerisation probably does not affect the formation of MT macro-complexes in the plasma 
membrane. 
Using similar methods, colocalisation between surface MT complexes and the 
intracellular micro-tubule network is demonstrated in Figure 5.13 A when α-tubulin 
(monomeric unit of microtubules) was labelled following surface FLAG-tag binding. 
Disruption of micro-tubules with nocodazole or colchicine, which bind to tubulin and inhibit 
the formation of microtubule, did not inhibit the formation of MT complexes on the cell 
surface despite inducing a lot of cell death (Figure 5.13 B and data not shown).  
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Figure 5.12 Cytochalasin D does not disrupt surface MT complex formation 
A. Surface MT labelled after treatment with cytochalasin D (CCD). Cells expressing 
wtMTFLAG were incubated in culture media containing 500 nM CCD for 48 hrs before 
surface MT was immuno-labelled using rabbit polyclonal anti-FLAG. After fixing and 
permeabilisation of the cell membrane, mouse monoclonal PAb762 was added to label 
overall MT. AlexaFluor488/ 633-conjugated anti-rabbit/-mouse IgG were then added to label 
surface and total MT, respectively. Images of cells were captured with confocal microscope. 
Scale bar = 50 µm.  
B. Total MT distribution of the images shown in A. 
C. Surface MT complexes do not change after cytochalasin D treatment. High magnification 
images of surface MT complexes shown in A. Two independent frames are shown for each 
treatment and are representative of at least 20 images generated in 3 independent 
experiments. An area of 20.5 µm x 20.5 µm on the basement membrane is shown in each 
frame. Scale bar = 2 µm. 
200 
 
 
 
Figure 5.13 Surface MT complexes colocalise with micro-tubules inside cells 
A. Surface MT complexes colocalise with tubulin. Cells expressing wtMTFLAG were incubated 
with rabbit anti-FLAG antibody for 30min before fixing and permeabilisation of the cell 
membrane. Mouse polyclonal anti-α-tubulin was added to cells, followed by AlexaFluor488 
anti-rabbit IgG and AlexaFluor633 anti-mouse IgG to label surface MT (green) and 
microtubule cytoskeleton (red). Images were captured on a confocal microscope. Areas of 
colocalisation are indicated with open arrows. Primary antibodies are indicated above the 
top panel. 
B. Tubulin destabilising agents did not affect surface MT. Cells were treated with 25 ng/ml 
nocodazole or 25 µg/ml colchicine for 4 hr before IF labelling of surface FLAG tags as  
described above. Two independent frames were shown for each treatment with the upper 
panel showing cells with weaker fluorescence and the lower panel showing stronger 
fluorescent signals. Scale bar = 2 µm for A and B. 
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5.2.3 Focal Adhesion Associated Proteins 
5.2.3.1 Vinculin 
Although we have observed colocalisation between surface MT complexes and the actin 
cytoskeleton, co-immunoprecipitation experiments did not show direct interaction between 
MT and β-actin (result not shown). It is possible that MT may interact with the cytoskeleton 
indirectly via actin binding protein such as vinculin or molecules involved in actin 
remodelling, such as FAK and integrins. It has been reported that MT can be 
immunoprecipitated using anti-vinculin serum and that MT/pp60c-src associates with focal 
adhesion sites (Ballmer-Hofer, Ziegler et al. 1988) (see Chapter 1, 1.14 for introduction).We 
therefore investigated whether the MT macro-complexes associated with cytoskeleton on the 
cell basement membrane represent sites of focal contacts. Vinculin, an actin binding protein 
which connects integrin molecules on the cell surface with intracellular actin filaments, was 
used as a marker for focal contacts. Co-staining of surface MT complexes and vinculin 
produced very little colocalisation (Figure 5.14). The lack of colocalisation between MT 
complexes and vinculin may be attributed to the transformed phenotype of the cells. 
Therefore, in order to see whether more surface MT complexes colocalise with vinculin in 
non-transformed cells, cells expressing wild type MT were treated with 50 nM dasatinib for 
48hrs before IF staining. Figure 5.14 shows that although dasatinib treatment increases the 
number of MT complexes at the edge of the cells, the majority of the surface MT complexes 
still do not colocalise with vinculin. Additional frames can be found in Figure 5.15. 
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Figure 5.14 Dual labelling surface MT complexes and intracellular vinculin 
A. Co-staining surface MT with internal vinculin. Cells expressing wtMTHA were incubated in 
culture media containing 50 nM dasatinib for 48 hrs before surface MTs were immuno-
labelled using mouse monoclonal anti-HA added to living cells. After fixing and 
permeabilisation of the cell membrane, rabbit monoclonal anti-vinculin was added. Cells 
were subsequently incubated in AlexaFluor488/ 555-conjugated anti-mouse/ rabbit IgG to 
detect surface MT or intracellular vinculin, respectively. Images of cells were captured with a 
confocal microscope. For each treatment, the image shown is representative of at least 6 
independent frames. Scale bar = 2 µm. 
B. Zoom-in images of areas highlighted in A.  The antibody detected in each channel is 
indicated above the top panel. Scale bar = 2 µm. 
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Figure 5.15 Little colocalisation between surface MT complexes and vinculin at the basement 
membrane 
A. Co-staining surface MT with internal vinculin. Cells expressing wtMTHA with or without 50 
nM dasatinib treatment were immuno-labelled for surface MT and total intracellular vinculin 
as described in Figure 5.14. Scale bar = 2 µm.  
B. Zoom-in images of area highlighted in A. Antibody detected in each channel is indicated 
above the top panel. Scale bar = 2 µm. 
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5.2.3.2 Focal adhesion kinase 
Focal adhesion kinase (FAK) is a protein tyrosine kinase often associated with focal adhesion 
plaques (see Chapter 1, 1.14.1 for introduction). It is activated by integrin clustering or by 
growth factor receptor activation and autophosphorylation on Y397, which recruits other 
signalling molecules to the integrin/FAK complex. PI3K p85and pp60c-src bind to phospho-
Y397 on FAK in fibroblasts transformed by MT but the association between MT and FAK 
was not established (Bachelot, Rameh et al. 1996). It has been reported that dasatinib 
treatment abolishes the phosphorylation on all tyrosine residues of FAK except Y397, and 
autophosphorylation site (Caccia, Micciche et al. 2010). Therefore, we investigate whether 
the MT complexes observed on the basement membrane of transformed cells contain 
activated FAK (phospho-Y397) which regulate the formation of focal adhesion sites. Figure 
5.16 shows that similar to vinculin, most of the phospho-FAK signals are located at the cell 
periphery with little colocalisation with surface MT complexes. After treatment with 
dasatinib, the number of MT complexes colocalising with phospho-Y397 increased at the cell 
periphery. However, complexes of surface MTHA and activated FAK do not always match 
perfectly in their shape and position (open circles, Figure 5.16). There are still a lot of surface 
MT complexes that do not colocalise with activated FAK. An additional frame can be found 
in Figure 5.17. 
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Figure 5.16 Surface MT complexes and activated focal adhesion kinase 
A. Co-staining surface MT with activated FAK. Cells expressing wtMTHA were incubated in 
culture media with/ without 50 nM dasatinib for 48 hrs before surface MT were immuno-
labelled using mouse monoclonal anti-HA. After fixing and permeabilisation of the cell 
membrane, rabbit monoclonal antibody specific for phospho-FAK Y397 was added. Cells 
were subsequently incubated in AlexaFluor488/ 555-conjugated anti-mouse/ rabbit IgG to 
detect surface MT or intracellular phospho-FAK, respectively. Images of cells were captured 
with a confocal microscope. For each treatment, the image shown is representative of at least 
6 independent frames. Scale bar = 5 µm. 
B. Zoom-in images of areas highlighted in A. Antibodies used are indicated above the top 
panel. Scale bar = 2 µm. Open circles highlight examples of colocalisation between surface 
MT and phospho-FAK at cell periphery. 
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5.2.3.3 Integrin αVβ5 Macro-complexes on the Cell Surface 
Phosphorylation of FAK at focal adhesion complexes coincides with the clustering of 
integrins. These are well characterised integral transmembrane hetero-dimeric protein 
complexes found on the cell surface (see Chapter 1, 1.14.3 for introduction). Since MT 
formed macro-complexes on the cell surface membrane which colocalised with actin 
network, we asked whether MT complexes co-exist in domains in the plasma membrane 
occupied by integrins. Amongst the commercially available antibodies, only the mouse 
Figure 5.17 Additional frames for surface MT complexes co-staining with activated FAK 
A. Cells expressing wtMTHA+ were immuno-labelled for HA and phospho-FAK Y397 as 
described in Figure 5.16.  Scale bar = 2 µm.  
B. Zoom-in images of areas highlighted in A. Antibodies used are indicated above the top 
panel. Scale bar = 2 µm. Open circles highlight areas of strong phospho-FAK. 
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monoclonal antibody (P1F6), which binds to the extracellular domains of αVβ5 integrin, has 
been shown to produce strong immunofluorescent staining when added to living cells. Here, 
this mouse monoclonal antibody was added in conjunction with rabbit anti-FLAG antibody to 
produce co-staining of surface MTFLAG and integrin αVβ5 complexes simultaneously 
(Figure 5.18 and 5.19). Both MT and integrin complexes are distributed throughout the under 
surface of the cell. However, at 37ºC, antibody cross-linking of integrin αVβ5 resulted in 
rapid internalisation of the cell surface receptor, whereas MT on the cell surface was not 
readily endocytosed (Figure 5.20). Therefore co-staining experiment was repeated at 4ºC. At 
both temperatures, some colocalisation between MT and integrin αVβ5 complexes was 
observed (open arrows, Figure 5.18 and 5.19).  Dasatinib treatment did not affect the level of 
colocalisation between the two surface molecules (Figure 5.18 (ii) and 5.19 (ii)). On average, 
21% of surface MTFLAG and 16% of surface integrin αVβ5 were found to colocalise with 
one another (Figure 5.18 and 5.19). However, this level of colocalisation probably occurred 
by chance, as the integrin clusters were numerous. Despite various attempts, integrin has not 
been found in MT immunoprecipitates (data not shown). It is likely that the MT macro-
complexes observed on the cell surface only passively associate with adhesion molecules.  
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Figure 5.18 Partial colocalisation between surface MT and integrin αVβ5 
A. Surface labelling MT and integrin αVβ5 at 37°C and 4°C. Rat-2 fibroblasts expressing wtMT 
FLAG were incubated live in rabbit polyclonal anti-FLAG antibody and mouse monoclonal 
[P1F6] to integrin αVβ5 extracellular domains for 30 min at 37°C or 4°C. After fixing, cells were 
incubated with AlexaFluor488-conjugated anti-rabbit IgG and AlexaFluor555-conjugated anti-
mouse IgG to label surface FLAG (green) and integrin αVβ5 (red) at the same time. The 
fluorescent signals on the basement membrane of a cell were captured using a Leica SP5 
confocal microscope with 63.0x1.40 oil lens, zoom factor 6. Each image represents an area of 
20.5 x 20.5 µm. Scale bar = 2 µm. Examples of colocalisation are indicated with open triangles. 
B. Surface labelling MT and integrin αVβ5 at 4°C. The experiment in A was repeated at 4°C. 
Images for each staining condition are representative of at least 6 independent frames. 
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Figure 5.19 Zoom-in images of Figure 5.18 
Examples of colocalisation are indicated with open triangles. Scale bar = 2 µm. 
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5.2.4 EGFR1 and PDGFRβ 
It has been reported that MT can bind to and activate the insulin receptor (IR) and the insulin-
like growth factor I receptor (IGF-IR) (Novosyadlyy, Vijayakumar et al. 2009). We found 
that the MT TMD can be functionally replaced by the hydrophobic membrane spanning 
sequence from wild type neu and PDGFRβ (see Chapter 4, Figure 4.10). EGFR1 and 
PDGFRβ are well expressed in Rat-2 fibroblasts. Therefore, initially we intended to 
investigate whether MT macro-complexes in the plasma membrane may contain these two 
abundant receptor tyrosine kinases. However, initial experiments produced negative results 
(data not shown). In cells expressing wild type MT, very little EGFR1 was internalised 
following EGF stimulation (Figure 5.21).  
Figure 5.20 Antibody-induced endocytosis of integrin αVβ5 
Surface MT (green) and integrin αVβ5 (red) were labelled at 37°C, as described in Figure 
5.16. Each image represents an area of 32 µm x 32 µm. Scale bar = 2 µm.  
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Above result was followed up by assessing the protein level of EGFR1 and PDGFRβ 
in cell lines expressing wild type and various mutants of MT. Figure 5.22 shows that only cell 
lines transformed by MT, but not by the constitutively activating mutant H-Ras G12V, 
showed reduction in EGFR1and mature PDGFRβ protein levels. Reduction of both PDGFRβ 
and EGFR1 was also observed with the non-transforming mutant L405E MT. The small 
amount of PDGFRβ in cells expressing wild type MT is not phosphorylated in the absence of 
ligand and the level of phosphorylated receptor is much lower compared to normal Rat-2 
fibroblasts in response to stimulation by ligand human PDGF-BB (hPDGF-BB) (Figure 5.23 
Figure 5.21 Slow EGFR internalisation in fibroblasts expressing wild type MT 
Rat-2 fibroblasts expressing wtMTHA+ were stimulated with 50ng EGF in normal tissue 
culture media at 37°C. At time points indicated, cells were fixed and permeabilised before they 
were immuno-labelled for total EGFR1 using rabbit polyclonal EGFR (1005) sc-03 (Santa Cruz) 
followed by AlexaFluor555-conjugated anti-rabbit IgG. Non-transfected Rat-2 was used as 
control. Cell lines are indicated on the left. 5 – 10 cells were imaged using confocal microscope. 
Scale bar = 20 µm.  
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B). Therefore in the absence of ligand, residual PDGFRβ is not activated in cells expressing 
wtMT.  
 
 
 
 
 
Figure 5.22 Analysis of EGFR1 and PDGFRβ protein levels in Rat-2 fibroblast cell lines  
Antibody used is indicated above each panel. Cell lines expressing wild type MT, non-
transforming mutants L405E, MTKDEL, 180∆10 and 200∆10, activated H-Ras-Myc only or co-
expressed with wtMTFLAG are compared to parental control Rat-2 fibroblasts. Cells were 
lysed in 1% Triton-X100 lysis buffer with scraping. Protein concentrations of lysates were 
normalised by a BCA test and analysed by 8% bis-acrylamide SDS-PAGE gel and Western 
Blotted for EGFR1 and PDGFRβ. The membrane of lower molecular weight region was blotted 
for α-tubulin as a loading control for each receptor blot. 
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Figure 5.23 Changes in expression levels of various growth factor receptors in Rat-2 
fibroblasts transformed by MT 
A. Residual PDGFRβ in MT transformed cells can be activated by ligands. Confluent control 
cells or cells expressing wtMT were cultured on 6-well plates. Ligand human PDGF-BB 
(PDGF-BB) was added to stimulate PDGFRβ activation. After normalising sample volume 
against protein concentration, lysates were analysed for PDGFRβ phospho-Y751. Ponceau S 
staining of the membrane after Western Blotting was used as a loading control (lower panel). 
Time-point of ligand stimulation (min) is indicated above each lane. 
B. Analysis of various receptor levels in response to dasatinib. Cells expressing wild type MT 
or non-transforming mutant 200Δ10 and control cells were treated with 50 nM dasatinib (+) 
or vehicle for 48hrs then lysed in 1% Triton-X 100 lysis buffer. Lysates were analysed for the 
receptor indicated above each panel.  Sample volume was normalised against lysate 
concentration determined by BCA assay. Western blot for α-tubulin was used as a loading 
control. X indicates a void sample loading. 
C. PDGFRβ levels in transformed fibroblasts after removal of dasatinib. Cells expressing 
wtMT were treated with 50 nM dasatinib for 48 hrs to induce PDGFRβ expression. The 
inhibitor was then removed and cells were lysed at various time points (c-e).  
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Figure 5.24 Level of mRNA for EGFR family receptors and PDGFRβ in cell lines expressing MT 
A. Analysis of mRNA levels of ErbB receptors and PDGFRβ in cell lines expressing wild type or 
mutant MT. Equal number of cells were seed on 6-well plates 24hrs before experiment. Cells 
were lysed in 1ml Trizol. Total RNA were purified and used as templates for cDNA conversion 
using Invitrogen Superscript cDNA conversion kit. Equal volume of each cDNA sample was 
analysed by PCR method for receptor tyrosine kinase DNA sequence using a pair of primers 
that bind to sequence specific for each receptor cDNA. PCR products were separated by PAGE 
and stained by ethidium bromide to visualise the band corresponding to the predicted PCR 
product size. A mistake was made in A (ii) Rat-2 PCR reaction mix, which resulted in an empty 
lane. 
B. The same cDNA preparation from above experiment was re-analysed for EGFR1 and 
PDGFRβ with loading control ATP5B. Control primer from was a kind gift from Dr Jocelyn 
Mora.  
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In order to assess whether the expression level of receptors are affected in MT-
transformed cells, RNA from cell lines expressing wild type or mutant MT were extracted 
and analysed for their mRNA levels of various EGFR family receptors and PDGFRβ by PCR. 
Figure 5.24 shows, that the mRNA of PDGFRβ is absent in cells expressing wild type MT 
but not in those expressing non-transforming mutants such as MTKDEL, a mutant trapped in 
the ER, and 200Δ10, a mutant lacking Src tyrosine kinase binding sequence. The reduction in 
EGFR1 mRNA level is less dramatic in cells transformed by MT. The mRNA levels of other 
EGFR family members are more variable between the cell lines expressing MT and mutant. 
Therefore, we focused on PDGFRβ expression in subsequent experiments.  
We next tested whether inhibition of Src tyrosine kinase activity, which causes the 
transformation in cells expressing MT, could rescue the expression of PDGFRβ. Figure 5.25 
A shows that 5 nM or higher concentrations of dasatinib can up-regulate PDGFRβ levels in 
cells expressing wtMT after 48hrs. Treatment with 50 nM dasatinib induced the maximum 
level of PDGFRβ expression without affecting the viability of the cells. The up-regulation of 
PDGFRβ by dasatinib was observed only in cells expressing wtMT but not 200Δ10 and 
control (Figure 5.25 B). Similar results were obtained for both confluent and growing cells 
that were transformed by MT (Figure 5.25 C). Dasatinib treatment did not affect PDGFRβ 
protein level in normal Rat-2 fibroblasts control (Figure 25 C) or those transformed by H-Ras 
G12V (data not shown). Attempts to analyse the mRNA level of the PDGFRβ after dasatinib 
treatment failed due to poor quality of the RNA extracted. After dasatinib was removed, cells 
become transformed again but the protein level of PDGFRβ was maintained for at least 4 hrs 
(Figure 5.23 C). Longer time points will be required to assess the stability of the receptor 
expression in transformed cells after the removal of dasatinib. The up-regulated PDGFRβ 
after dasatinib treatment is a fully mature polypeptide responsive to ligand stimulation (data 
not shown).  
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Dasatinib is also a potent inhibitor of many members of the PDGF receptor family, 
including c-KIT, PDGFRβ (Lombardo, Lee et al. 2004) and the FMS receptor (Brownlow, 
Mol et al. 2009). In order to confirm that the down-regulation of PDGFRβ was not due to 
constitutive activation of the receptor in MT-transformed cells, imatinib, a tyrosine kinase 
inhibitor that is specific for PDGFRβ but does not inhibit Src, was then used. The effects of 
dasatinib and imatinib on cells transformed by wild type MT are compared to their effects on 
non-transforming mutant L405E, which binds to all MT-associated protein and 180∆10, 
which lacks both PP2A and Src binding sites. Figure 5.25 D shows imatinib treatment failed 
to up-regulate PDGFRβ expression in all three cell lines. Dasatinib (at 10 or 50 nM) induced 
re-expression of PDGFRβ in cells expressing wild type MT and up-regulated the level of 
PDGFRβ in cells expressing mutant L405E, which has reduced PDGFRβ expression in 
Figure 5.22 (iii). PDGFRβ expression was not affected by either drug in cells expressing 
Figure 5.25 Dasatinib up-regulates PDGFRβ in cells expressing wild type MT 
A. PDGFRβ levels in cells treated with increasing concentration of dasatinib. Rat-2 fibroblasts 
expressing wild type MT were cultured on 6-well plates and treated with increasing 
concentrations of dasatinib in 10% FCS media. After 48 hrs, cells were lysed in lysis buffer with 
1% Triton-X 100 and scraped. Protein concentration was analysed by BCA kit. Normalised 
lysates were analysed for PDGFRβ level. Ponceau S staining of the membrane after Western 
Blotting was used as a loading control. 
B. Dasatinib induces up-regulation of PDGFRβ in cells expressing wtMT. Cells expressing wtMT 
or the non-transforming mutant 200Δ10 were treated with 50 nM dasatinib for 48hrs then 
lysed in 1% Triton-X100 lysis buffer and analysed for PDGFRβ level. 
C. Effect of dasatinib and confluency on PDGFRβ expression level. Under-confluent (left panels) 
or confluent cells (right panels) were seeded on 6-well plates 24 hrs before the addition of 50 
nM dasatinib (+) or vehicle DMSO (veh.). At 24 or 48 hrs post drug treatment, the confluency of 
cells was estimated under the microscope then lysed. The area covered by cells in each well at 
the time of lysis is indicated below each lane. Time-point of treatment period is indicated above 
each lane.  
D. Imatinib does not induce PDGFRβ up-regulation. Cells expressing wtMT, L405E MT or non-
transfected Rat-2 fibroblasts were treated with 10 or 50 nM dasatinib (dasat.), 5 µM imatinib 
(imat.) or vehicle (DMSO) for 48 hrs before lysis. Ponceau S stain of the membrane in the 
migratory region of PDGFRβ and α-tubulin blot was used as loading controls. 
See image on previous page. 
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mutant 180∆10, which lacks both PP2A and Src binding sites (lane i – l in Figure 5.25 D). 
The down-regulation of PDGFRβ, and possibly EGFR1, is therefore not a result of MT-
induced constitutive receptor activation. After dasatinib up-regulation of EGFR1 and 
PDGFRβ, immunofluorescence-labelled surface MT complexes did not show colocalisation 
with either receptor (data not shown). 
The effect of dasatinib treatment on other receptors has also been tested (Figure 5.23 
B). In cells expressing wild type MT, ErbB2 expression was up-regulated after inhibition of 
Src, while ErbB4 and IRβ was reduced, but the differences are less dramatic compared to the 
changes in PDGFRβ protein level (Figure 5.23 B).Results also confirm dasatinib does not 
affect MT expression levels.  
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5.3 DISCUSSION: 
5.3.1 Summary 
Immuno-fluorescent microscopy experiments showed that wild type MT molecules are able 
to accumulate into clusters at the plasma membrane (see Chapter 4). We found little 
correlation between these MT-containing clusters with lipid raft markers (Figure 5.1 – 5.9), 
indicating that cholesterol-dependent membrane sub-domains are probably not involved in 
MT transformation. For the first time, we have demonstrated that MT macro-complexes on 
the cell surface are associated with cytoskeletal structures (Figure 5.7 and 5.9). However, we 
did not find direct interaction between MT and actin by immunoprecipitation methods. 
Therefore MT surface complex association with intracellular actin cytoskeleton is likely to be 
indirect. MT complexes on the cell surface are likely to utilise actin cytoskeletons as a means 
to limit free-diffusion of active MT signalosomes (see 5.3.3.1). The association between MT 
surface clusters and actin cytoskeleton does not depend on MT’s ability to bind Src tyrosine 
kinase though active MT complexes may play a role in re-modelling cytoskeleton to 
influence cell morphology (Figure 5.10). Disrupting cytoskeleton polymerisation with 
various inhibitors did not affect MT complex formation (Figure 5.12 and 5.13). Surface MT 
macro-complexes are probably not related to focal adhesion complexes (Figure 5.14 and 
5.16), although partial colocalisation with cell surface integrin complexes have been observed 
(Figure 5.18 and 5.19). Despite report on MT association with the insulin receptor and 
insulin-like growth factor receptor (Novosyadlyy, Vijayakumar et al. 2009), we found very 
little colocalisation between surface MT complexes and several growth factor receptors tested 
in this study (data not shown). However we observed repression of PDGFRβ protein 
expression in Rat-2 fibroblasts transformed by MT, which complicated the study of MT 
association with cell surface receptors (Figure 5.22 – 5.25).  
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5.3.2 Lipid rafts do not play a role in MT cluster formation  
Clustering of molecules within cell membranes has been reported recently in a number of 
systems, and may play a role in signal transduction (Cebecauer, Spitaler et al. 2010). Using a 
commercial lipid raft marker, we observed very little colocalisation between surface MT 
clusters with cholesterol-rich ganglioside GM1-positive lipid rafts (labelled by cholera toxin 
subunit-B in Figure 5.1 and 5.4). Chen and Resh have demonstrated that cholesterol depletion 
with Methyl-β-cyclodextrin (MβCD) caused ligand-independent activation of EGFR1 and 
suggested that cholesterol-rich rafts may act as a spacer that minimise EGFR dimerisation in 
the absence of ligands(Chen and Resh 2002). Cholesterol depletion by Methyl-β-cyclodextrin 
(MβCD) increased the level of surface MT clusters (Figure 5.8). However, due to the 
reported side effect that the compound has on exocytosis, we cannot conclude whether MT 
complexes reside in non-raft regions of the cell membrane. MβCD was found to promote 
exocytosis and the fusion of vesicles with the plasma membrane (Takahashi, Hatakeyama et 
al. 2004, Chen, Li et al. 2010, Hissa, Duarte et al. 2012). We have observed that cells with 
strong lipid raft marker staining were often accompanied by lower amount of MT clusters on 
the cell surface, therefore suggesting that MT may reside in non-cholesterol-enriched 
domains (Figure 5.2). We tried to use activating H-Ras mutant G12V as a marker for 
cholesterol-independent microdomains, but found that H-Ras was not a good indicator for 
non-raft domains in our system as it can only be labelled internally and the fluorescent 
signals masked the signals of MT clusters labelled from the cell surface (Figure 5.5). We then 
used detergent fractionation method to show that MT does not preferentially resided in raft or 
non-raft regions of the membrane, using caveolin-1 as an indicator for cholesterol-dependent 
detergent insoluble fraction (Figure 5.9). 
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Whether a membrane protein fractionates with caveolin-positive lipid raft is highly 
influenced by the method used. Some reports suggest that the PDGFRβ resides exclusively in 
detergent insoluble, caveolin-positive lipid rafts (Liu, Ying et al. 1996, Wu and Gonias 2005), 
while others reported half of the PDGFRβ resides in detergent insoluble fraction (Coats, 
Pledger et al. 1996). In non-transformed Rat-2 fibroblasts, we found that PDGFRβ 
fractionates predominantly in the detergent soluble membrane fraction (Figure 5.9), similar to 
the observation made with EGFR1 using the same fractionation protocol (McKie, Vaughan et 
al. 2012). 
 
5.3.3 MT and Cytoskeleton 
5.3.3.1 MT macro-complexes on the cell surface associate with actin cytoskeleton 
Accumulation of Ras in nano-clusters is essential for signalling activity (Plowman, Muncke 
et al. 2005, Tian, Harding et al. 2007) and requires the actin cytoskeleton (Plowman, Muncke 
et al. 2005).We have also observed localisation of MT complexes to the intricate actin mesh 
near the membrane ruffles of transformed cells (Figure 5.7 i), and along the actin cables in 
non-transformed fibroblasts expressing mutant 200Δ10, which lacks Src-binding site (Figure 
5.7 ii). In non-transformed cell type, cortical actin bundles are very prominent and surface 
200Δ10 clusters seem to follow the track of these actin cables (Figure 5.6 ii). MT associated 
kinase activity has been shown to co-fractionate with cytoskeletal elements (Schaffhausen, 
Dorai et al. 1982). Cytoskeletons such as actin, tubulin and vimentin have all been detected in 
MT-enriched fractions using sucrose gradient fractionation methods (Andrews, Gupta et al. 
1993, Krauzewicz, Elliott et al. 1994, da Costa, Wang et al. 2000). Here, for the first time, we 
have demonstrated MT complexes on the cell surface membrane are associated with networks 
of cytoskeleton (Figure 5.7 and 5.9). 
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Single-particle tracking have shown that a number of transmembrane proteins and 
lipids are restricted in their movement to ‘confinement zones’ that vary in size from 30 – 700 
nm (Sako and Kusumi 1994, Simson, Sheets et al. 1995, Lillemeier, Pfeiffer et al. 2006). This 
favours our model that cell surface receptor clusters are pre-formed and are independent of 
extracellular stimuli-induced kinase domain activation. In the ‘picket-fence’ model proposed 
by Kusumi and co-workers, ‘Membrane proteins, like pickets, are anchored to and line up 
along a fence of cytoskeletal proteins surrounding the confinement zones’ – Kusumi, et al. 
Semin. Immunol. 2005, (Kusumi, Ike et al. 2005). This is then developed further into a 
recently described ‘active’ model of receptor clustering that is driven by the cortical actin 
meshwork just under the lipid bilayer of cell surface membrane (Sbalzarini 2012). This is 
supported by recent report that GPI-anchored folate receptors on the outer leaflet of the 
plasma membrane form clusters which are sensitive to inhibitors of myosin function, which 
are cellular motors that interacts with actin to form actomyosin and regulates contractility, but 
are not sensitive to inhibitors of actin polymerisation (Plowman and Hancock 2005, 
Gowrishankar, Ghosh et al. 2012, Sbalzarini 2012).  
The new model suggests that the actin snippets held together by myosin, form actin-
rich domains under the inner membrane leaflet of cells. The movement of these actin-rich 
domains is influenced by myosin motors, which are actively regulated by receptors and 
signalling molecules in the local area. Membrane proteins localised to these actin-rich 
domains or rafts are dragged along by actomyosin movement. Therefore it is possible that the 
clustering of MT as reported in this study and GFRs reported by others are not formed by 
equilibrium, but instead, are driven by actin mesh on the cytosolic surface. The movement of 
such complexes in the plasma membrane is dependent on myosin motor activity instead of 
actin polymerisation. This model may also explain why cytochalasin D (CCD) did not affect 
complex formation on the cell surface in our system and others such as the nicotinic 
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acetylcholine receptor (Wenz, Borroni et al. 2010), since clustering is largely driven by 
myosin activity instead of actin polymer stability (Gowrishankar, Ghosh et al. 2012, 
Sbalzarini 2012). 
 
5.3.3.2 MT macro-complexes may be involved in cytoskeleton re-modelling 
It has been suggested that MT C-terminal region plays a role in targeting MT to the 
cytoskeleton. Elliott and co-workers demonstrated that the Arginine clusters or R-rich region 
(385-393: QRHLRRLGR) which precede the MT hydrophobic sequence, when fused to GFP, 
can target the normally cytosolic protein to cytoskeletal fractionation of the cell lysate 
(Elliott, Jones et al. 1998). Therefore, it is possible that the C-terminus of mutant L405E and 
neu-mutant MT which fail to translocate across the membrane completely, may interfere with 
the Arginine-rich, cytoskeleton-targeting region. This explanation was proposed for the lack 
of transformation in MT mutant, NT-1d, which has a mutation of positively charged Arginine 
to a negatively changed Glutamate at the cytoplasm-membrane interface (Dahl, 
Thathamangalam et al. 1992). This non-transforming mutant is capable of binding and 
activating pp60c-src and PI3K but showed weaker membrane association, a property similar 
to L405E (Figure 5.9 A) (Dahl, Thathamangalam et al. 1992). Many transmembrane proteins, 
such as glycophorin A, a heavily glycosylated protein on the red blood cell surface 
membrane, have been shown to rely on the basic amino acids in the cytoplasmic 
juxtamembrane region to mediate interaction with cytoskeleton (Dahl, Thathamangalam et al. 
1992)(Anderson and Marchesi. 1985). 
MT complexes in the plasma membrane may also play a role in remodelling of the 
cytoskeleton. In MT-transformed fibroblasts, actin cytoskeleton and microtubules appear 
disorganised (Figure 5.10 and 5.13 A). Many of the proteins involved in regulating actin 
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dynamics are known effectors of Src tyrosine kinases including vinculin (El Sayegh, Arora et 
al. 2004) (reviewed by Reynolds and Roczniak-Ferguson 2004). Although some reports 
suggest that MT associates with actin-binding protein, vinculin, and MT/pp60c-src 
complexes localise at the focal adhesion sites (Ballmer-Hofer, Ziegler et al. 1988, Bachelot, 
Rameh et al. 1996), we found little colocalisation between surface MT clusters and vinculin 
or FAK (Figure 5.14 and 5.16). Due to the complexity of actin associated proteins, we have 
not been able to identify the mechanism by which MT is anchored to the cytoskeleton.  
The microtubule associated protein tau, which plays a role in stabilising microtubules, 
was found to be a target of PP2A therefore PP2A regulates tubulin dynamics (Sontag, 
Nunbhakdi-Craig et al. 1996, Gong, Lidsky et al. 2000). In fact, there is an increased 
association between microtubules and PP2A in cells transformed by MT (da Costa, Wang et 
al. 2000). In addition, MT activates Rac-1 and the Cdc42 Rho family GTPase by both PI3K 
and Shc – Ras pathways (Urich, Senften et al. 1997). These GTPases play important roles in 
regulating filamentous actin organisation. Activated Rac induces rapid actin polymerisation 
in membrane ruffles (Ridley, Paterson et al. 1992)(Machesky and Hall 1997). Indeed, the 
disorganised nature of actin at the membrane ruffles of cells transformed by MT resembles 
that of PDGF-stimulated fibroblasts (Figure 5.10 and Machesky and Hall 1997). Therefore, a 
higher local concentration of Src tyrosine kinases and other signalling molecules in MT 
macro-complexes may influence cytoskeletal structures to favour cellular transformation 
(Krauzewicz, Elliott et al. 1994). 
 
5.3.3.3 MT and Integrin 
Hetero-dimeric integrin molecules have been known to form large clusters on the cell surface 
membrane, which mediates adhesion and migration by interacting with actin-binding 
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proteins. We have observed partial colocalisation between MT and integrin complexes on the 
cell (Figure 5.18 and 5.19).The antibody P1F6 targets only the αVβ5 integrin. We cannot rule 
out that whether MT colocalisation with other integrin subunit combinations may also occur. 
Although only about 20% of surface MT complexes colocalise with integrin clusters (Figure 
5.18 and 5.19), this is not so low considering colocalisation between surface MTFLAG 
clusters and MTHA is only 30-40% on average (Figure 4.31).We did not find direct 
association between MT and integrin αVβ5 by immunoprecipitation (results not shown). This 
could be due to the small fraction of MT in complex with integrin or because the complex 
interaction was sensitive to detergent. Overall, we cannot conclude whether MT and integrin 
can co-exist in the same macro-clusters.  
Integrin may be implicated in both tumorigenesis and metastasis in vivo. Integrin 
αVβ5 is expressed in most primary breast cancers, renal cancer, melanoma and its expression 
is particularly high in brain tumours metastasised from lung cancer and melanoma 
(Vogetseder, Thies et al. 2013). In the MMTV-MT mouse model for mammary gland 
carcinoma, β1 integrin-mediated phosphorylation of FAK, especially on Y576, is required for 
MT-induced tumorigenesis (White, Kurpios et al. 2004). However, Rac-induced actin 
reorganisation at membrane ruffles and lamellipodia was found to be independent of integrin 
and focal complex assembly (Machesky and Hall 1997). Therefore, integrin or FAK may not 
be absolutely required to mediate cell transformation.  
 
5.3.4 Lack of PDGFRβ and reduced EGFR expression in MT-transformed cells 
It has been reported that MT interacts with the insulin receptor and the closely related IGF-I 
receptor in a cell line derived from MMTV-MT mammary gland tumours. This association is 
required for the cells to initiate new tumours in animals (Novosyadlyy, Vijayakumar et al. 
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2009). Association between MT and IRβ was not observed in our system (data not shown). 
This discrepancy of results may be attributed to the difference in MT antibody and the cell 
type used in our study. Since replacement of the hydrophobic region of MT with sequence 
from wild type PDGFRβ did not affect MT transformation potential (Chapter 4, Figure 4.10), 
we then investigated the possible interaction between MT and this growth factor receptor by 
immunofluorescent labelling. However, instead of finding definitive answers, we observed 
significantly reduced PDGFRβ expression in MT-transformed Rat-2 fibroblasts at both 
protein and mRNA levels (Figure 5.22 and 5.24). The PDGFRβ expression is inversely 
correlated with the transformation potential of the MT expressed (Figure 5.22). PDGFRβ is 
re-expressed after inhibiting Src with dasatinib (Figure 5.25). Therefore the suppression of 
PDGFRβ is a specific consequence of MT activated mitogenic signalling. Reduced 
expression of PDGFRβ is also observed in cells expressing the mutant L405E, which was 
found to partially activate AKT signalling pathway (Figure 4.15). EGFR1 and ErbB2 protein 
levels are also reduced to a lesser extent in MT-transformed cells and the effect of MT 
signalling on their transcriptional levels are not very clear (Figure 5.22 - 5.24).  Although 
dasatinib up-regulates EGFR1 and PDGFRβ expression in MT-expressing fibroblasts, we did 
not observe association between MT and GFRs by both immunofluorescent labelling and co-
immunoprecipitation methods (data not shown).  
 Figure 5.24 indicates that MT transformation signals cause inhibition of the 
transcription of the PDGFRβ gene. The fact that dasatinib but not imatinib could suppress the 
down-regulation of the PDGFR shows that inhibition is caused by the activation of signalling 
pathways by MT and not by the PDGFR in response to MT (Figure 5.25 C). MT and normal 
mitogenic PDGF signalling share a lot of common effectors, so it is possible that the 
enhanced activation of a shared signalling pathway(s) may contribute to the down-regulation 
of PDGFRβ transcription. Activation of PI3K/AKT/mTORC signalling pathway has been 
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shown to down-regulate PDGFRβ expression by a negative feedback loop in mesenchymal 
stem cells stimulated with PDGF-BB ligands (Gharibi, Ghuman et al. 2012). Many of the 
PDGF early response genes such as fos, jun, and myc constitutively activated in cells 
expressing MT (Rameh and Armelin 1991, Armelin and Oliveira 1996). The PDGFRβ 
promoter contains a number of transcription factors binding sites for GATA-1, AP-1, AP-2 
and NF-1 (Ballagi, Ishizaki et al. 1995). Some of these, such as AP-1, are known to be 
activated by MT oncogenic signalling. The implication of PDGFRβ down-regulation in MT-
transformed cells will be discussed further in the next chapter. 
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CHAPTER 6 – GENERAL DISCUSSION 
 
6.1 Overall Summery 
In summary our data illustrates that MT associates with signalling proteins at different sites in 
its maturation pathway. MT binds to PP2A core dimer in the cytoplasm, to pp60c-src at the 
ER, and to pp62c-yes, ShcA, PI3K, and PLC-γ1 at subsequent locations en route to the 
plasma membrane (Chapter 3). However, MT association with activated Src and other 
signalling molecules is not enough to transform fibroblasts and there appear to be a least two 
other requirements.  One, MT needs to reach the cell surface in order to transform fibroblasts, 
as apparently do other cell surface signalling molecules (Chapter 3). Two, MT may also need 
to form a large macromolecular complex in order to transform fibroblasts (Chapter 4).  These 
complexes are probably not associated with lipid rafts but there is interaction with the actin 
cytoskeleton, which may contribute to transformation (Chapter 5).  Figure 6.1 summarises 
our current understanding of the requirement for fibroblast transformation by MT. We did not 
observe MT colocalisation with cell surface receptors such as PDGFRβ and EGFR1. 
However, we have observed that MT-induced transformation caused a dramatic down-
regulation of PDGFRβ protein expression (Chapter 5). 
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Figure 6.1 A schematic representation of the maturation of a transforming MT complex 
Stages of the MT signalosome assembly are shown. Starting in the bottom right hand corner: MT 
is synthesised in the cytoplasm on free poly-ribosomes; MT maturation through the ER, exocytic 
membranes; the MT signalling complex eventually reaches the plasma membrane. At each stage, 
the cellular proteins added to the MT complex are illustrated. A representative mutant that blocks 
each individual step is also indicated. Adapted and extended from (Zhou, Ichaso et al. 2011). 
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6.2 Macro-complex Formation in GFR Activation 
6.2.1 Receptor Clusters  
Activation of growth factor receptor kinase activity by dimerisation of the receptor (reviewed 
by Lemmon and Schlessinger 2010), is an essential first regulatory step in signalling. 
However, recent evidence suggests receptor dimerisation probably takes place in the context 
of a higher order macromolecular complex structure (Yang, Raymond-Stintz et al. 2007, 
Arkhipov, Shan et al. 2013, Kozer, Barua et al. 2013). Cluster formation has been observed in 
many systems of Growth Factor Receptor (GFR) activation (Gillham, Golding et al. 1999, 
Ichinose, Murata et al. 2004, Yang, Raymond-Stintz et al. 2007, Kaufmann, Muller et al. 
2011) (see Chapter 4 discussion). Our data supports the view that large signalling complexes 
can form on the cell surface without kinase involvement as observed with a MT mutant 
200Δ10, which is unable to activate Src, and also in cells expressing wild type MT after 
treatment with the Src tyrosine kinase inhibitor, dasatinib (Figure 4.7, 4.8 and 4.25). In 
addition, mutants that failed to cluster efficiently cannot transform despite binding to Src 
tyrosine kinase and other signalling molecules (Figure 4.12 - 4.16). Together our results 
suggest that the assembly of a large macromolecular complex is important for transformation 
and that signalling by GFRs is dependent upon both kinase activation and upon preformed 
clusters.  Large cluster formation may be necessary to achieve a sufficient threshold of 
signalling. This is supported by preliminary observation that AKT activation is much weaker 
in mutant L405E, which cannot cluster (Figure 4.15).  
 The significance of large complex formation is better established for a different class 
of GFR. EphA receptors are receptor tyrosine kinases that transduce signals mediated by cell-
cell contact via their binding to ephrins on the surface of neighbouring cells. EphA receptor 
binding to corresponding ephrin ligands leads to activation of the kinase activity on the 
intracellular domain of the receptor, which results in the activation of signalling pathways 
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involved in growth, differentiation and pattern formation during development (Bocharov, 
Mayzel et al. 2008). It has been established that cluster formation is essential for EphA3 
signalling. Cluster formation of EphA3 does not require a functional cytoplasmic signalling 
domain, therefore is independent of kinase activity (Wimmer-Kleikamp, Janes et al. 2004). 
Eph are highly promiscuous receptors that are known to form clusters (Surawska, Ma et al. 
2004). Depending on the ephrin ligand densities and therefore the size of the clusters, Eph 
receptors can mediate kinase-dependent or kinase-independent signalling with different 
outcomes, with higher-order Eph receptor/ephrin clusters over-riding kinase-dependent 
signalling mechanism (Vearing and Lackmann 2005). Kinase-dead EphA8, when clustered 
with high density ephrin coated beads, is capable of binding to PI3K and promoting cell 
adhesion (Gu and Park 2001). Therefore, oligomerisation and dimerisation in the sense of 
ligand-induce conformational change in the cytoplasmic domain are likely to be two separate 
requirements for signal initiation, which are subjected to independent regulations. Since MT 
is strongly activating, it probably has a higher tendency to form large clusters and therefore, 
can be a useful model for studying the mechanism regulating macro-complex formation, 
which is likely to be required for normal GFR activation. 
 
6.2.2 Inhibiting GFR oligomerisation 
It has been demonstrated previously that expression of the transmembrane domain of neu-
mutant V664E can inhibit transformation by prevention of receptor dimerisation (Lofts, Hurst 
et al. 1993). It is feasible that the MT transmembrane domain in isolation could also insert 
into membranes and act as a competitive inhibitor to prevent signalling by related complexes. 
Indeed, mutant 200Δ10 MT had an inhibitory effect on foci formation induced by wild type 
MT in preliminary experiments (Figures 4.28 - 4.30).  
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A similar approach has been used in the studies of transmembrane domain interaction 
between bovine papilloma virus (BPV) membrane oncoprotein E5 and PDGFRβ (see Chapter 
1.13). It is thought that the transmembrane protein E5 dimer forms hydrogen bonds with 
PDGFRβ membrane spanning helix in the lipid bilayer in such way that it promotes the 
conformational change required for PDGFRβ cytoplasmic kinase domain activation 
independent of ligand binding (Lai, Henningson et al. 1998, DiMaio and Mattoon 2001, 
Talbert-Slagle and DiMaio 2009). Recently, screening of an artificial transmembrane peptide 
library derived from E5 sequence has identified a polypeptide (pTM36-4 T21N) that binds to 
PDGFRβ but does not transform cells. The artificial protein successfully blocked PDGFRβ 
activation and PDGF-BB induced mitogenic signalling (Petti, Talbert-Slagle et al. 2013). 
Similar hydrophobic peptide screens can be translated to identify hydrophobic sequence that 
inhibits GFR activation. It is worth noting that the most effective artificial activator and 
inhibitor of PDGFRβ signalling derived from the screen by Petti et al., has little resemblance 
of the original E5 amino acid sequence (Talbert-Slagle and DiMaio 2009, Petti, Talbert-
Slagle et al. 2013). It is evident that our understanding of the mechanism behind TMD 
interaction in relation to GFR activation is still rather limited. 
 
6.2.3 Mixed clusters: do they exist? 
It is not clear whether MT has any ability to associate with other GFRs in the cell surface 
membrane and promote their activation in the same way as BPV E5. It has been recently 
reported that MT physically associates with the insulin and IGF-I receptors and that such an 
interaction is required for transformation in cell lines derived from MMTV-MT mouse model 
(Novosyadlyy, Vijayakumar et al. 2009). We did not find association between MT and GFRs 
such as EGFR1, PDGFRβ and insulin receptor by both immunofluorescent labelling and co-
immunoprecipitation methods. Although some partial colocalisation between surface MT and 
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integrin αVβ5 have been observed (Figure 5.18 and 5.19), we cannot exclude the possibility 
that such a colocalisation occurred by chance. It has been reported that activated PDGFRβ 
co-immunoprecipitates with integrin αVβ3 (Schneller 2001). However, it only accounts for a 
very small fraction of the total integrin (Schneller 2001). It is likely that most of the MT 
surface complexes are not associated with other GFRs. 
ErbB2/HER2/neu and ErbB3 have been widely studied for their propensity to hetero-
dimerise. Since ErbB2 does not have a putative ligand and ErbB3 lack an active kinase 
function, it was thought that their signalling would have to involve hetero-oligomerisation 
with other members of the ErbB receptor family (Kashles, Yarden et al. 1991) (reviewed 
by(Cymer and Schneider 2010)). EGFR family receptor dimerisation is thought to be 
mediated by two GXXXG motifs, except ErbB3, which has only one of such motif. It has 
been proposed that the GXXXG motif near the membrane-cytosol interface is required for 
homodimer formation while the motif near the membrane-extracellular interface plays a role 
in heterodimerisation (Gerber and Shai 2001, Cymer and Schneider 2010).  However, recent 
visualisation of ErbB2/neu and ErbB3 distribution in the plasma membrane failed to show 
conclusive evidence of mixed clusters between EGFR family members (Yang, Raymond-
Stintz et al. 2007). Using a highly sensitive fluorescent microscopy method, Kaufmann and 
co-workers reconstructed Her2/neu and Her3 clusters in 3D and showed that most of the two 
types of receptors are found mostly in separate clusters (Kaufmann, Muller et al. 2011). Such 
segregation of ErbB family members provides a potential limitation to heterodimerisation to 
levels much lower than previously predicted, probably to allow specific signal propagation 
(Yang, Raymond-Stintz et al. 2007). This is favourable for rational drug design because short 
peptides or compounds that inhibit the oligomerisation of a receptor are more likely to be 
specific. Indeed, high throughput selection of a peptide library based on the TMD domain of 
ErbB2/neu found only a very few of the ~ 4000 peptides can dimerise with ErbB2/neu 
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receptor with a higher affinity than native sequence (He, Hoffmann et al. 2011). This seems 
to suggest that oligomerisation is mediated by highly specific sequence of the membrane 
spanning region of the transmembrane receptor, which also argues against mixed cluster 
formation.  
  
6.2.4 Mechanism of Macro-complex Formation 
Ichinose et al., have summarised in their study of EGFR1 clustering, the various mechanisms 
that have been proposed for cluster formation of GFRs in the plasma membrane (Ichinose, 
Murata et al. 2004). These including interaction between neighbouring transmembrane α-
helices (Moriki, Maruyama et al. 2001), interaction between regions in the extracellular and 
cytoplasmic domains (Yu, Sharma et al. 2002), binding to the cytoskeleton (van Bergen en 
Henegouwen, den Hartigh et al. 1992), and accumulation into membrane domains (Mineo, 
Gill et al. 1999, Ichinose, Murata et al. 2004). We have found colocalisation between surface 
MT complexes and the cytoskeleton, especially actin network on the inner leaflet of the 
plasma membrane near the membrane ruffles of transformed cells (Figure 5.10). However, 
association between surface complexes and actin probably does not require binding to Src 
tyrosine kinase as mutant 200Δ10, which lacks Src binding, also localises to actin cables 
typical in non-transformed cells.  
 
6.2.5 Additional components in MT clusters require further investigation 
The exact mechanism behind macro-complex formation in MT is still not clear. Lipid rafts 
does not seem to play a role in the formation of these large clusters in the plasma membrane 
(Figure 5.4 - 5.8). Some reports suggest complex formation is supported by protein-protein 
interaction. Knock-down of galectin-1 reduces the clustering of H-Ras G12V and it has been 
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proposed that galectin-1 stabilises the interaction of activated H-Ras in non-raft 
microdomains (Paz, Haklai et al. 2001, Prior, Muncke et al. 2003, Rotblat, Belanis et al. 
2010). It is worth noting that clusters of gold-particle labelled MT clusters are only found at 
the plasma membrane whereas the gold particles in microsomes or vesicles in the cytoplasm 
are mostly found in singlet (communication with Dr Jitka Forstova). It is possible that there 
are factors required for macro-complex formation of MT, which are only available at the cell 
surface membrane. It may be possible that there are not yet identified MT binding partners in 
plasma membrane. However, interaction in the plasma membrane can be easily disrupted by 
detergent-containing lysis buffers. Identification of potential MT binding partners on the cell 
surface will likely to require chemical cross-linking (see below in Future projects).  
 
6.3 Changes in PDGFRβ in cells transformed by MT 
During the investigation of MT and GFR complex formation, we observed diminished 
PDGFRβ expression in MT-transformed cell lines, which could be up-regulated by the Src/ 
Bcr-Abl tyrosine kinase inhibitor, dasatinib (Figure 5.22 – 5.25). PDGFRβ down-regulation 
has been reported in other fibroblast cell lines transformed by SV40 or v-Src (Cook, Wang et 
al. 1993, Zhang and Baldwin 1994, Zhang, Walker et al. 1995). It was reported recently that 
‘de-repression’ of PDGFRβ transcription confers resistance to targeted tyrosine kinase 
inhibitor therapy in human brain tumour driven by activated EGFR (Akhavan, Pourzia et al. 
2013). It is not clear whether PDGFRβ re-expression confers any pro-survival signals in MT-
transformed Rat-2 fibroblasts treated with dasatinib, which will be one area of future 
investigation.  
PDGF-BB ligands stimulate mesenchymal stem cell (MSC) differentiation. However, 
persistent PDGFRβ activation can down-regulate expression of the receptor via a PI3K/AKT 
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negative feedback mechanism and this down-regulation of PDGFRβ promotes cell 
proliferation in the long term (Gharibi, Ghuman et al. 2012). It has been shown that activation 
of mTORC suppresses the transcription of PDGFRβ in mouse embryonic fibroblast (MEF) 
and also in some human brain tumours (Zhang, Bajraszewski et al. 2007). Fibroblasts 
expressing wild type MT are highly proliferative, with reduced cell-cell contact and other 
features associated with mesenchymal stem cells. Many of the PDGF early response genes 
such as fos, jun, myc are constitutively activated in cells expressing MT (Rameh and Armelin 
1991, Armelin and Oliveira 1996). It is possible that the expression of genes including 
PDGFRβ may be switched off as cells return to a more stem-cell-like state. The observation 
of PDGFRβ down-regulation in MT-transformed fibroblasts raises interesting questions about 
the gene expression controlled by MT on a global scale in order to transform cells.  
The changes in gene expression required to overcome contact inhibition in tumour 
initiation is poorly understood. We have generated mutants (L405E or neu-mutant MT) that 
bind to all major MT-binding partners known to induce transformation (Chapter 4, Figure 
4.11 – 4.15) but still failed to transform Rat-2 fibroblasts. These new mutants of MT are 
likely to help elucidating the set of genes responsible for producing transformed cell 
morphology.  Our system of MT and its mutants that block defined steps in oncogenic 
signalling initiation provides a simplified model for deciphering the signalling pathways and 
the associated transcription changes required for cell transformation. 
 
6.4 A Story Unfinished 
It is still unknown to us why mutant dl1015 does not transform. This mutant carries a deletion 
of a Proline-rich region immediately downstream of PI3K binding site (see List of Mutants). 
It seems to bind to known signalling proteins and forms clusters on the cell surface 
membrane. Mass-spectrometry analysis of proteins bound to dl1015 did not find significant 
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differences compared to those bound to wild type (unpublished data). Unlike L405E, dl1015 
does not activate AKT or MAPK pathway (data not shown) therefore the defect in dl1015 
appears more severe. Further characterisation of this mutant will likely to yield new 
knowledge on the requirement for tumorigenesis.  
 
6.5 Future Projects: 
i) Detailed investigation into the downstream signalling molecules including AKT, MAPKs 
and STATs in fibroblasts expressing various MT species in order to see how location to 
different subcellular compartments alters cell signalling. Similar analysis in other cell types, 
particularly haematopoietic cell lines where the signalling requirements for transformation 
may be different (Morley, Uden et al. 1999).  
 
ii) Construct a potential dominant negative mutant of MT (Δ185-381) lacking intrinsic 
binding sites for Src, ShcA, p85 PI3K and PLC-γ1. Co-transfection of this mutant with wild 
type MT plasmid should inhibit foci formation (Figure 4.28). The mutant should retain the 
PP2A binding site in the N-terminal region, which is required for migration out of the ER to 
higher membrane sites; the hydrophobic sequence with juxtamembrane region on both sides, 
which contain positively charged residues; HA+ or FLAG-tag at the C-terminus, which allow 
dual immunofluorescent labelling of surface complexes with wild type MT, similar to those 
shown in Figure 4.29 - 4.30. 
 
 iii) Chemically cross-link MT and associated membrane proteins on the cell surface. N-
hydroxysulfosuccinimide (NHS) ester forms covalent bonds between the amine groups of 
Lysine residues. Since the extracellular region of MT C-terminus is very short and contains 
only one Lysine residue right at the membrane interface, cross-linking experiment should be 
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performed on cell line expressing MTFLAG, which contain two additional Lysines. Cross-
linking experiment should be performed on live cells before lysis in detergent. However, 
cross-linker derivatives that cross the plasma membrane may be considered when comparing 
proteins associated with L405E mutant as the C-terminus is facing the cytosol. Cross-linking 
experiment like this may also help to identify key components affected in the non-
transforming mutant dl1015. The MT-immunoprecipitates will be treated with β-
mercaptoethanol or dithiothreitol, releasing proteins from MT complexes, which can be 
separated by 2D-gel SDS-PAGE and analysed by MALDI-TOF mass spectrometry after in-
gel tryptic digest. 
 
iv) Construction of an expression vector of PDGFRβ under a strong promoter, in order to 
investigate whether strong PDGFRβ expression has any inhibitory effect upon cell growth in 
fibroblasts transformed by MT. Use inhibitors targeting AKT or MAPK pathway to identify 
the driver behind PDGFRβ down-regulation in fibroblasts transformed by wild type MT. 
These can include mTORC-specific inhibitor rapamycin and MEK inhibitor PD325901. Past 
mutants of MT lacking the binding of individual signalling proteins are also useful tools to 
decipher the pathways responsible for PDGFRβ. It is still not clear whether re-expression of 
PDGFRβ after Src-inhibition by dasatinib confers any advantages for survival. Further 
experiments with combined treatment of dasatinib and imatinib in cells expressing MT will 
be required to investigate possible caspase-3 activation at various drug concentrations, 
combinations and time-points.  
 
v) Analysis the difference in gene expression before and after dasatinib treatment in 
fibroblasts transformed by MT using microarrays. This will allow identification of genes 
regulating transformation.  
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SUPPLEMENTARY MATERIAL 
 
Amino Acid Sequence of MPyV MT 
        1 MDRVLSRADK ERLLELLKLP RQLWGDFGRM QQAYKQQSLL LHPDKGGSHA LMQELNSLWG 
       61 TFKTEVYNLR MNLGGTGFQV RRLHADGWNL STKDTFGDRY YQRFCRMPLT CLVNVKYSSC 
      121 SCILCLLRKQ HRELKDKCDA RCLVLGECFC LECYMQWFGT PTRDVLNLYA DFIASMPIDW 
      181 LDLDVHSVYN PKRRSEELRR AATVHYTMTT GHSAMEASTS QGNGMISSES GTPATSRRLR 
      241 LPSLLSNPTY SVMRSHSYPP TRVLQQIHPH ILLEEDEILV LLSPMTAYPR TPPELLYPES 
      301 DQDQLEPLEE EEEEYMPMED LYLDILPGEQ VPQLIPPPII PRAGLSPWEG LILRDLQRAH 
      361 FDPILDASQR MRATHRAALR AHSMQRHLRR LGRTLLLVTF LAALLGICLM LFILIKRSRH 
      421 F 
 
  
Supplementary Figure S2.1 Complete amino acid sequence of MPyV MT 
TMD region is highlighted in grey. NCBI Reference Sequence: NP_041265.1   
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Supplementary Table ST2.1 Primers for MT Mutagenesis 
 Oligonucleotide Sequence 5’ – 3’ 
MT forward CCGCACATACTGCTGGAAGAAGACG 
∆416-421 MTHA+ 
reverse 
GCGAATTCCTAAAGAGAAGCGTAATCTGGAACATCGTATGGGTAAG
CTATTAGAATAAATAGCATGAGACAAATACCCAG 
∆419-421MTHA+ 
reverse 
GCGAATTCCTAAAGAGAAGCGTAATCTGGAACATCGTATGGGTAAG
CGGAACGTTTTATTAGAATAAATAGCATGAGAC 
∆416-421 MT 
reverse 
GCGGAATTCTATCATATTAGAATAAATAGCATGAGACAAATACC  
416G6 MTHA+ 
reverse 
GCGGAATTCTATCAAAGAGAAGCATAATCAGGAACATCATAAGGAT
AAGCGCCACCCCCGCCACCTCCTATTAGAATAAATAGCATGAGACA
AATACCCAG 
MT FLAG reverse GCGGAATTCTATCATTTATCATCATCATCTTTATAATCGAAATGCC
GGGAACGTTTTATTAG 
MTGGDV reverse CGCGAATTCTTAAACGTCTCCTCCGAAATGCCGGGAACGTTTTATT
AG 
MTKDEL reverse CGCGAATTCTTACAACTCGTCCTTGAAATGCCGGGAACGTTTTATT
AG 
MTSec61β reverse GCGAGATCTTTTGCCCCAAATGTGCAGCATAAATACAGCAGCGATG
AACAGAAGACTCATCACCAGCACTGGGACAGGGCCCACCCGGCCGG
CG 
wtMTHA+ reverse CGCGAATTCCTAAAGAGAAGCGTAATCTGGAACATCGTATGGGTAA
GCGAAATGCCGGGAACGTTTTATTAG 
 
Supplementary Table ST2.2 Primers for Receptor Transcription Detection 
 Oligonucleotide Sequence 5’ – 3’ 
EGFR1 forward GCGAGAACCAAGCTACTGCT 
EGFR1 reverse TCCAAGTTTCCAAGGACCAC 
PDGFRβ forward TGTGCTGTCCGTTTTGAGTC 
PDGFRβ reverse TTCTTCTCATGCAGCGTCAC 
ErbB2 forward GTTCCTCCTCGCCCTCCT 
ErbB2 reverse GCAGGCACGTAGGTAAGCTC 
ErbB3 forward AGGTGCTGTGCTTCCTTCTC 
ErbB3 reverse GGTCAGCATTGTGTCCTGTG 
 
Supplementary Table ST2.3 Oligonucleotides for Sequencing MT Plasmids 
 Oligonucleotide Sequence 5’ – 3’ 
MT-ApaI forward CCCCACCTTTGTAAGATCCGGAC 
pUC reverse TAGGCACCCCAGGCTTTACAC 
pEMBL reverse GCGGGCCTCTTCGCTATTAC 
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Supplementary Table ST2.4 Inhibitor and Compound List 
Reagents Stock concentration Working 
concentration 
Vehicle 
Nocodazole 100 µg/ml 25 ng/ml DMSO 
Colchicine 100 mg/ml 25 µg/ml 100% 
Ethanol 
Cytochalasin D 
(potassium salt) 
2 mM 500 nM 100% 
Ethanol 
Okadaic acid 20 µM 5 – 100 nM 100% 
Ethanol 
dasatinib 200 µM 1 – 100 nM DMSO 
imatinib 20 mM 5 – 10 µM DMSO 
cyclohexamide 50 mg/ml 100 ng/ml 100% 
Ethanol 
Methyl-β-
cyclodextrin 
2% w/w 1% w/w DMEM 
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